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ABSTRACT 
The immunophilin enzymes cyclophilin A (CypA), the target of the 
immunosuppressive drug cyclosporin A and hFKBP12, the target of the 
immunosuppressive drugs FK506 and rapamycin, have recently become the subjects 
of renewed scientific research. The identification of hCypA as playing a major role 
in the infectivity and progression of HIV-1, and of hFKBP12 as a potential target in 
the treatment of various neurological disorders, has led to a large global effort to 
further characterise these enzymes and design potential inhibitors, with a view to 
obtaining chemotherapeutic drugs. The work in this thesis describes the cloning, 
expression purification and characterisation of human CypA and FKBP12 proteins. 
Various biophysical techniques were then used to study and characterise the 
interactions of different ligands with these target proteins. 
Vectors containing the genes for expression of both wild-type protein and 
protein with a hexa-histidine tag, have been cloned for both hCypA and hFKBPI2. 
Crystals of hCypA have been grown, and the structures, in complex with a range of 
small molecules including dipeptides, and dimedone derived ligands, have been 
solved. hCypA crystal complexes were also used to further explore the nature of the 
'crystal dissociation constant, using the depetide ligand Val-Pro. Crystals were 
soaked in various ligand concentrations and by solving the X-ray structures of these 
complexes, ligand occupancies could be determined providing an experimental value 
for the equilibrium binding constant, Kc rys t = 23mM. This compares well with a K 1 
value 19mM measured using an enzyme inhibition assay. Protein—ligand binding 
data measured using a range of methods is also presented, including fluorescence 
spectroscopy, mass spectrometry and surface plasmon resonance. It has also been 
demonstrated how the technique of surface plasmon resonance may be optimised to 
provide a sensitive ligand-binding assay. By tethering protein to a Ni 2 chip via an 
N-terminal hexa-his tag followed by covalent linking via primary amines, a stable 
and active surface was obtained. This allowed a competition binding assay to be 
developed, which allows the binding of ligands of 250-500Da to be measured. 
The work done here should help further the design of potential inhibitors of 
hCypA, and in the measurement of their binding affinities; and possibly aid in the 
future design of anti HIV- I therapies. 
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Amp 100:- ampicillin at a concentration of iOOtgmF' 
APS:- ammonium persuiphate 
ATP:- adenosine triphosphate 
BCIP:- 5-bromo-4-chloro-indolylphosphate 
BSA:- bovine serum albumin 
CCD:- charge coupled detector 
CypA (hCypA):- human cyclophilin A 
Cyp3 ((-Cyp3):- cyclophilin 3 from caenorhabclitis elegans 
Da:- dalton 
DMSO:- dimethyl sulphoxide 
DNA:- deoxyribonucleic acid 
DW:- distilled water 
EDC:- I -ethyl-3-(3-diaminopropyl) carbodiimide hydrochloride 
EDTA:- di ami noethanetetra-acetic acid 
EtOH:- ethanol 
FKBP:- FK506 - binding protein 
Hepes:- N - [ 2-hydroxyethyl]piperazine -N' - [2-ethane-sulphonic acid] 
HCI:-hydrochloric acid 
I PTG:- isopropyith iogalactoside 
ITC: - isothermal titration calorimetry 
LB:- Luria Bertoli 
LiCI:- lithium chloride 
Mr:- molecular weight, relative molecular mass. 
MS:- mass spectroscopy 
NaOH:- sodium hydroxide 
[NH4 ] 2 SO4 :- ammonium sulphate 
NHS:- N-hydroxysuccinimide 
NTA:- nitrilotriacetic acid 
O.D. :- optical density. At 600nrn used to measure amount of cells in a culture. 
PAGE:- polyacrylamide gel electrophoresis 
PBS:- phosphate buffered saline 
PEG:- polyethyleneglycol 
PCR:- polymerase chain reaction 
PROP:- 3-acetyl- I -propanol 
R-factor:- reliability factor 
SDS:- sodium dodecyl sulphate 
SOC:- glucose supplemented growth media 
SPR:- surface plasmon resonance 
TBE:- tris borate/EDTA buffer 
TE:- tris-HCl/EDTA buffer 
TEMED:- N,N,N' ,N'- tetramethyl-ethylenediamine 
TFE:- trifluoroethanol 
TMSO:- tetramethylene sulphoxide 
Tris:- tris(hydroxyrnethyl)arninomethane.hydrochloride 
TWEEN:- Po lyoxyethylenesorbitan monooleate. A non-ionic detergent 
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Ch 1: Introduction 
1:1:- The Immunophilins 
The immunosuppressant drug cyclosporin, first isolated from the fungus 
To!vpocladium inflatum in the early 1970s, was the subject of much research by 
workers at the Sandoz company (now Novartis) in Basel, and by the early 1980s was 
in clinical use, with applications in the treatment of autoimmune disorders such as 
rheumatoid arthritis, and for the prevention of graft rejection following tissue 
transplant surgery. It was not until 1984, however, that an 18kDa cyclosporin binding 
protein was identified and isolated from bovine thymocytes (1), around the same 
time as an l8kDa protein with PPIase activity was isolated from porcine kidney 
cortex by Fischer et al. (2,3). The amino acid sequence of the cyclosporin binding 
protein was first published by Harding et al. (4), but it was not until 1989 that the 
cyclosporin binding protein and the enzyme responsible for accelerating the rates of 
cis-trans isomerisation at peptidyl-prolyl bonds were identified as one and the same 
(5,6). 
Another cytosolic PPlase, the l2kDa FKBP (FK506 Binding Protein), purified from 
human T-cells, was identified in 1989 as the target protein for the 
immunosuppressant drugs FK506, (also known as tacrolimus, isolated from the soil 
fungus Streptornyces tsukuhaenis (7)) and rapamycin (isolated from Streptornyces 
hvgroscopicus (8)) and shown to possess different amino acid sequence, molecular 
weight, and substrate specificity to cyclophilin (9,10). FKBP has been shown to be 
present in a wide variety of cells and tissues, including human and murine T-cells, 
human B-cells, human lung tissue and umbilical cord endothelial cells, as well as 
hamster kidney cells, insect cells and yeast cells (11). More recently it has been 
shown that immunophilins are also present in nervous tissue, where concentrations of 
FKBP are up to 40% higher than in immune tissues (12,13). 
A large protein family of PPIase enzymes includes the cyclophilins, the FK506-
binding proteins and the parvulins (14), and trigger factor (15,16), which was found 
to be associated with the SOS subunit of the ribosome in Escherischia co/i, but shared 
only 18.2% sequence identity with cyclophilin, and 28.3% sequence identity with 
FKBP (17). Other members of both the FKBP and the cyclophilin family of 
immunophilins have also been identified, such as the 33kDa hCyp33, which 
possesses both an RNA-binding domain, and a PPlase domain (18), and the 51.8kDa 
FKBP52, a multi-domain FK506 binding protein (19). The immunophilin family 
itself is ubiquitous in a great many species; genes encoding smaller (-16kDa) 
cyclophilins have been found in cyanobacteria (20) and Bacillus subtilis (21), for a 
l7kDa cyclophilin in Salmonella tvphimurium (22) for 18kDa cyclophilins in 
Arahidopsis thaliana (23), Toxoplasma gondii (24), as well as in plants such as 
maize, tomato, rape and bean (25) and in the chloroplasts of spinach (26). 
Cyclophilin activity has been shown to be necessary for the growth of B. subtilis 
under starvation conditions (27), for functional expression of homo-oligomeric a7-
neuronal nicotinic and type 3 serotonin receptors in oocytes of Xenopus laeL'is (28), 
and has been shown to be part of the mitochondrial protein folding machinery in 
Neurospora crassa (29). A l6kDa cyclophilin from the human parasite Onchocerca 
volvulus has recently been isolated and characterised (30). In 1996, eleven 
cyclophilin genes from Caenorhahditis elegans were cloned and characterised, and 
highlighted the similarity between cyclophilins from different species; cyclosporin 
had been shown to have an detrimental effect on helminth worms, causing a 
reduction in growth related to a cuticle shedding defect, likely due to inhibition of 
cyclophilin thus preventing the correct folding of proteins thereby leading to their 
resultant accumulation (3 1). 
The X-ray structure of human cyclophilin A (hCypA) was first published in 1991 
(32), since then many other structures have become available, such as the X-ray 
structure of a 20.1kDa cyclophilin, with low affinity for cyclosporin, from Brugia 
nalavi, a mosquito borne parasite which causes filarial disease and elephantiasis (33), 
and a cyclophilin from the free living nematode C. elegans (34). There are now 
approximately 80 other cyclophilin structures available on the protein data base in 
either the apo- or holo- enzyme form. Perhaps the most striking example of similarity 
between cyclophilin from different species is that of hCypA and C. elegans 
Cyclophilin 3 (cCyp3). The tertiary structure of both enzymes consists of an anti-
parallel eight stranded 13-barrel capped by two a-helices, and the binding sites both 
possess 13 conserved residues important in cyclosporin binding. The amino acid 
sequences of the two enzymes are 67% identical, a sequence alignment performed 
using ClustaiW (35) is shown in figure Fl-I. Indeed, a comparison of the two 
2 
structures shown in figure Fl-2 shows the only obvious difference being the 
divergent loop from residues 45-54 present on cCyp3 but absent on hCypA, as 
described by Doman et al. (34). 
The FK-506 binding proteins are just as prevalent across a wide range of organisms 
as the cyclophilins, with l2kDa (36,37), l3kDa (38) and 45kDa (39) forms having 
been isolated from Saccharoinvces cerevisiae, a 1 2kDa form from Neurospora 
crassa (40), a 25kDa form from Legionella micdadei (41), and are present in many 
other microorganisms (42,43). The structure of an archaeal FKBP has also been 
solved by NMR (44). A 39kDa protein with a C-terminal FKBP domain has been 
isolated from Drosophila melanogaster (45), as has a larger 45.8 kDa protein with a 
C-terminal FKBP domain from Spodopterafrugiperda (46). 
It was shown in 1992 that PPIase activity detected in the mitochondrial fraction from 
pea plants could be inhibited by high concentrations of the FKBP-specific 
immunosuppressant rapamycin, and that a 25kDa protein within this fraction reacted 
with antibodies against FKBP12 (47). It was not until 1996, however, that that first 
FKBP was isolated from higher plants, with the characterisation of a 15kDa protein 
homologous to the l2kDa and l3kDa proteins previously isolated from yeast (48). 
More recently, a I3kDa FKBPI2 from the chloroplast of arabidopsis thaliana was 
described in the literature (49). 
The immunophilins FKBP12 and Cyp are essentially unrelated in both sequence and 
structure. An alignment of the sequences of hFKBP12 and hCypA shows little 
similarity. The tertiary structure of FKBPI2, consisting of antiparallel five-stranded 
13-sheet packing against a small u-helix (shown in figure Fl-3) bears scant 
resemblance to the structure of Cyp. 
:7PAWJ!AN 	"I'M PT-  .: :AvD .EPL • VSF.FA_ K' 	. E .......s: 	K-F -------- -- --- - C 	53 
CYP3_CAEZL MSRSK'.' 	 ... K 60 
* • 	*222*: : 2 :. *2: .2*. * *22*2 2*22*2*2:2:2 	 : 22 * * 
CYPAHUIIAN 	!'I I i G,-!'C 	.rTP1TI K :',Etr:EJFILiT;PGrL.:ANA' IT -:FF 113 
C'YP3_CAEEL }I IPNFMI :TPGT E 	 F  120 
CYPA_HUMAN 	I ITAFft;LL 	' ' WK. ?NI'E,JtRF ;RN TSiKITtAL:.E- 165 
CYP3CAEEL L:TVTEliL[ :;-iF'.',GR"V LDVK,V5N ;05 PVDCNJ' :..KA 173 
:*t.**t*t 2 t* 2 * 22 *:* 2*: : : 2 : 2:2 	*t: •**• 	2 * 222 * 2 : 
Figure Fl - I: Sequence alignment performed using ClustaiW (35) shows 77% 
similarity. 67% sequence identity between hCypA and cCyp3. 
9-1 
Figure FI-2: Cartoon representations of hCypA (top) and cCyp3 (bottom). 




Figure FI-3 Cartoon representation showing hFKBPI2. Structure 
shows antiparallel 5-stranded 13-sheet packing against small a-helix 
5 
1:2:- PPIase activity 
Whilst in most proteins whose structure has been solved, the torsion angle at a 
peptide (w) bond may be either cis or trans, the trans conformation is generally the 
more energetically favourable, due to steric hindrance in cis, and that the probability 
of an X-X (where X = any amino acid) peptide bond adopting the cis conformation is 
0.1%. In the case of proline, however, the probability of the X-Pro peptide bond 
adopting the cis conformation is estimated to be from 10-30% (50), depending on the 
character and properties of flanking residues (51). The activation energy barrier for 
cis X-Pro peptide bonds has been reported to be 13 K caj mof', whereas for XX 
peptide bonds this barrier is higher, at 20 Kcal rnol 1 (52), which may account for the 
higher proportion of X-Pro imide bonds in the cis conformation compared with other 







Figure F I -4. cis and trans conformations of proline residues 
Whilst an enzyme which was responsible for catalysing the cis-trans isomerisation 
at proline residues was identified by Fischer and coworkers in 1984 (2,3), their later 
hypothesis that the reaction proceeded by nucleophilic addition of an active site thiol 
to the carbonyl carbon of the X-Pro bond, forming a tetrahedral intermediate (6,53) 
was disputed a year later when Harrison and Stein presented evidence for catalysis 
by distortion, involving partial rotation about the imide bond, stabilised by the 
PPIase (54). It was later suggested that the intermediate was stabilised by hydrogen 
bonding between a solvent water molecule and the nitrogen lone pair (55), or by an 
amino acid at the binding site of the PPIase (56). In cyclophilin A, the arginine 
residue at position 55 is well placed to form hydrogen bonds with substrate (indeed, 
substitution of this arginine with a glycine has been shown to cause PPiase activity to 
fall to less than 1% of the native enzyme (57)), as is the histidine residue at position 
126, although on the whole, the binding pocket is largely hydrophobic. 
It therefore appears to be the case that the PPIase enzymes bind to proline containing 
peptides lowering the energy barrier required for this intermediate 'twisted aniide' 
conformation, possibly due to a loss in amide resonance. Figure Fl-5 shows the 
















Figure F1-5 The cis to trans isomerisation at proline residue. showing possible 
twisted amide' intermediate conformation (55) 
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1:3:- The Suppression of T-cell Activation 
1:3:1:- Calcineurin and Calmodulin 
Whilst it can be seen that the PPIase activity of cyclophilin and FKBP is important in 
ensuring the correct folding of proteins at proline residues, it is through their ability 
to bind immunosuppressant drugs such as CsA and FK506 that T-cell activation and 
the immune system response is inhibited. It is this property which is utilised in the 
treatment of various immune disorders, T-cell leukaemia, and for the prevention of 
rejection following transplant surgery. 
In 1991 Liu et al. (58) identified the target of immunophilin/drug complexes as 
calcineurin, a Ca 2+ dependent protein phosphatase (59), and calmodulin (60). 
Calcineurin is a heterodimer, comprising a 57-59kDa catalytic subunit and a 19-
20kDa regulatory subunit (59). The activity of calcineurin is regulated within the cell 
by Ca 2, concentration. An intracellular increase in Ca 2+ concentration induces a 
conformational change in both calcineurin (61) and in the B (regulatory) subunit of 
calmodulin (62,63). These conformational changes cause calcineurin and calmodulin 
to associate, thereby activating the phosphatase activity of calcineurin. The 
downstream target of the activated calcineurin in T-cell activation has been shown to 
be the transcription factor NFAT (nuclear factor of activated T-cells) (64-67). 
Dephosphorylation of NFAT effects its translocation to the nucleus, and the 
subsequent transcription of cytokines involved in the immune response (68-71). 
Antigen recognition by cell surface receptors therefore activates an intracellular 
second messenger, stimulating a response within the cell involving a burst in Ca 2+  
ion concentration. Ca 2 binding to calmodulin and calcineurin B-subunit results in 
their association; this activated calcineurin-calmodulin complex then 
dephosphorylates the transcription factor NFAT, resulting in its translocation to the 
nucleus and the subsequent expression of cytokines and the activation of the immune 
response. A schematic diagram illustrating this is shown in figure F 1-6. 
In the presence of cyclosporin (K -20nM) (72) or FK506 (Kd -0.4nM), this 
response is inhibited. Binding of these immunosuppressant drugs to their target 
proteins causes them to bind to calcineurin, thereby inhibiting its phosphatase action. 
The structures of CsA and FK506 are shown in figures F1-7 and Fl-8. Figure F1-9 
shows CsA at the binding site of hCypA. A cartoon representation of the hCypA- 
CsA-Calcineurin complex is shown in figure F 1-10, and figure F 1-11 shows FK506 
bound to hFKBP12. 
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Figure Fl -6 General schematic illustrating postulated pathway by which 
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Figure FI-7 Cyclosporin A (CsA). Residues 1.2.9 and 1() form hydrogen bonds with 










Figure Fl-S FK506. Oxygen atoms 2 and 3. which form hydrogen bonds with 
FKBPI2 residues 1le56 and Tyr82 respectively have been numbered for clarity. 
re 
Figure Fl-9 Two images showing CsA hound at the active site of cyclophilin A. Top image 
shows hydrogen bonded interactions contacts, described in table TI - I. Bottom (cartoon) 
image shows buried CsA residue II circled in red for clarity (72). 
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Calcineunn A, catalytic 
Figure Fl -b The Cycbophibin A-Cyclosporin A complex bound to calcineurin 
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Figure Fl-I I FK506 bound to FKBPI2. Top image shows FK506 at binding site with direct 
hydrogen bonded contacts labelled. Bottom figure shows cartoon representation of complex in the 
same orientation for clarity. 
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Another immunosuppressive drug, isolated from Streptoinvces sp. has recently been 
reported, Sanglifehrin A, which is shown to bind cyclophilin with an affinity of 
-7nM, and is described as having potent immunosuppressive activity. As yet, 
however, a downstream target for the CypA-SfA complex has to be identified (73) 
1:3:2:- Rapamycin and TOR 
The protein kinase TOR (Target of Rapamycin), also known as FRAP (FKBP-
Rapamycin Associated Protein) and RAFT (Rapamycin Activated Factor of activated 
T-cells), has been shown to exert control over the progression of the cell cycle 
(74,75). TOR has a similar active site to that of the phosphatidylinositol kinases, 
although no lipid kinase activity has been reported, it appears to be a serine/threonine 
kinase which acts upon the protein kinase p7os6k  and the eIF4E-binding protein (76). 
TOR was also recently reported to also phosphorylate the motor tubule associated 
protein CLIP-170 (4), which is overexpressed in Hodgkins disease (77,78). 
The protein kinase p70,6k,  in its phosphorylated state, phosphorylates and activates 
the 40S ribosomal protein S6, implicated in the production of ribosomal proteins, 
insulin growth factor and elongation factors (79). 
In its non-phosphorylated form, the eIF4E binding protein 4E-BPI, binds the 
initiation factor eIF4E, thereby inhibiting its activity (80). Phosphorylation of 4E-
BPI by TOR causes dissociation of the 4E-BPI-eIF4E complex, increasing 
availability of eIF4E. The free eIF4E then associates with elF-4G, eIF4B, and eIF4A, 
forming the multi subunit eIF4F complex. This leads to an increase in the translation 
of mRNA and a rise in the intracellular concentration of cyclin Dl, which is required 
for progression of the cell cycle from G I through S phase (8 1). 
The effect of the FKBP-rapamycin complex has been shown to be different from that 
exerted by the FKBP-FK506 complex. It has been shown that FK-506 and rapamycin 
act as antagonists, each one inhibiting the effect of the other (82,83). Both 
immunosuppressants have been reported to bind FKBP with similar Kd values, 
(Rapamycin Kd = 0.2nM, FK506 Kd = 0.4nM) (84). The FKBP-rapamycin complex 
has been shown to inhibit the kinase activity of TOR, thereby preventing cell cycle 
progression through GUS phase (82,85,86). Recently, a soluble ester analogue of 
rapamycin, CCI-779, with similar affinity as rapamycin for FKBP has been reported, 
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and is currently being tested as a potential anti-cancer therapy (87). A schematic 
comparing the effect of rapamycin with that of FK506 and cyclosporin is shown in 
figure F1-12, and the structure of rapamycin is shown in figure Fl-13. Figure F 1-14 
shows rapamycin bound at the active site of hFKBP12 and figure F 1-15 shows the 
hFKBP 1 2-Rapamycin-FRAP complex. 
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Figure Fl-13. Rapamycin. Oxygen atoms 2 and 3, which form 
direct hydrogen bonded contacts with FKBPI2 are labelled. 
Figure FI-14 Cartoon showing rapamycin bound to FKBPI2. Direct 
hydrogen bonds are labelled. 
FE'1 
Figure F1-15 Cartoon showing FRAP bound to the FKBP I 2-rapamycin complex 
1:4: - Neuroprotection and Neuroregeneration 
The immunophilins have been shown to be abundant in nervous tissue, with 
concentrations of FKBP as much as 50-fold higher in nervous tissue than that 
observed in immune tissues (88). It has further been shown that treatment with FK-
506 and rapamycin have a neuroprotective effect following ischaemia in rats (89), 
that in vitro treatment with FK506 and rapamycin encourages neurite growth in 
PCI2 cells and sensory ganglia, with FK-506 increasing sensitivity to nerve growth 
factor (13). Using animal models, FK506 has been demonstrated to promote nerve 
regeneration following nerve crush (90,91), and spinal cord injury (92-94). This has 
led to much focus on the identification of potential small molecule inhibitors for 
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FKBP which may be developed into potential lead compounds, without the 
immunosuppressive properties of FK506 or rapamycin (95). Whilst there has been 
many potential candidates described in the literature (96-99), one in particular, GPI-
1046, which inhibits the PPiase activity of FKBP12 with a K 1 of 7.5nM (100) has 
been shown to be a particularly promising candidate for the treatment of 
neurodegenerative disorders such as parkinsons disease and alzheimers (101,102). 




Figure F I - I 6 The neuroprotective ligand GPI-1046 
Whilst the precise mechanism by which neuroregeneration and protection occurs as a 
result of immunophilin/drug complexes is as yet unclear, there are several potential 
mechanisms suggested in the literature. It has been reported that inhibition of 
calcineurin by the cyclophilin/cyclosporin complex results in reduced activity of the 
enzyme nitric oxide synthase, resulting in decreased nitric oxide concentration within 
the cell, thereby moderating its toxic effects. Calcineurin inhibition by FKBP/FK506 
is also likely to have the same effect (103-105). It has also been suggested that 
neuroprotection by FK506 analogues, which do not inhibit calcineurin, is brought 
about by the rapid synthesis of mRNA molecules and the expression of anti-
apoptotic proteins (99), although the means by which this might he induced by non- 
immunosuppressive FKBP ligands is not clear. Another suggestion is that it is 
related to ryanodine regulation of Ca 2 ion concentration (106). FKBP has been 
shown to be associated with ryanodine channels in cardiac tissue (107,108). Much 
work is being carried out in order to further elucidate the pathways involved in the 
regeneration of nervous tissue, and the contribution made by immunophilin-drug 
complexes. 
1:5:-The Role of Cyclophilin in HIV Progression 
Where cyclosporin was administered to patients following transplant surgery in the 
1980s, it was reported that in those patients who were HIV positive the progression 
into AIDS was less precipitous (109). Whilst at this time, the precise action of 
cyclophilin was still unclear (it was not until 1989 that the target protein for 
cyclosporin was identified as a PPIase (4)) much work has since been done in order 
to elucidate the mechanism of cyclophilin in HIV progression. It was reported in 
1994 that intracellular hCypA is incorporated into assembling HIV virions and 
interacts with the HIV-GAO polyprotein, and was required for virion infectivity 
(110, 111). It was later shown that approximately 10% of the capsid coat is comprised 
of cyclophilin A, and that inhibition of CypA using cyclosporine A (CsA) and its 
analogues prevents its incorporation into the HIV protein coat thus markedly 
reducing viral proliferation (112). 
Viral entry into host cells is understood to proceed via recognition of viral membrane 
glycoprotein gpl20 and cell surface receptor CD4, and the recruitment of chemokine 
receptors CXCR4 and CCR5 (113). This leads to a change in the conformation of 
envelope glycoprotein, which allows viral glycoprotein gp41 to insert into the cell 
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membrane and the fusion of viral and cell membranes, permitting virus to enter the 
cytoplasm (114). Evidence suggests that hCypA also plays a role. A cell surface 
receptor for hCypA has been reported as being present on T-cells (115,116), and it 
was suggested that hCypA on the viral membrane was recognised by these T-cell 
receptors facilitating cell entry (117). It was later demonstrated that a small portion 
of hCypA extended beyond the viral membrane and was accessible to protease 
cleavage (118). It has further been shown that the membrane receptor protein CD 147, 
expressed on a wide variety of cells, including 1-cells, binds with hCypA, and it has 
been suggested that complexing of hCypA and CD 147 during virus- host interactions 
may facilitate an intermediate step between virus attachment and cell-virus fusion. It 
has also been suggested that signalling by CD 147 may induce cytoskeletal 
rearrangements, facilitating virus entry (119). 
Another explanation for the uptake of hCypA into the capsid may be to escape 
recognition by the human intra-cell defence mechanisms; it has been shown that 
formation of a CypA complex with capsid protein prevents recognition of virions by 
human restriction factor Ref-I (120), related to TRIM5a , a restriction factor shown 
to confer resistance to HIV-1 infection in rhesus macaque cells (121). 
One role of cyclophilin in HIV replication and progression has been reported to 
involve viral protein Vpr, implicated in the cell cycle arrest or delay in G2 of 
proliferating T-cells (122,123), and may also be involved in shuttling the viral 
preintegration complex from the cytoplasm of the host cell to the nucleus (124,125). 
The reason for arresting the cell cycle is unclear, possibly because viral gene 
expression is optimal in G2, and by delaying the cell cycle here virus production can 
be maximised (126). A requirement for intracellular cyclophilin has been 
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demonstrated in order to regulate folding of Vpr in vivo (127). It has also been shown 
that in the absence of CypA. Vpr-mediated cell cycle arrest in G2 does not occur 
(128). 
The binding of hCypA to the HIV GAG polyprotein, which is cleaved to produce the 
matrix, capsid and nucleocapsid proteins, has been studied. It has been shown that 
hCypA binds at a portion of GAG, numbered 119-124, sequence HAGPIA, with 
lC50 value -1mM (129). This sequence corresponds to 87-92 of the capsid protein, a 
region of flexible loop near the N-terminus of the capsid, and a likely suggestion is 
that hCypA may be necessary to catalyse a cis-trans isomerisation at proline 90 so 
that the disassembly of the viral core may ensue (130). This may be the case, 
although the understanding just now is that hCypA plays a chaperone role as regards 
HIV infectivity, but its PPIase activity is necessary for viral replication (131). The 
affinity of hCypA for capsid protein has been reported as having a Kd of -16-I8jiM, 
measured by isothermal titration calorometry and by surface plasmon resonance 
(132). 
The published data clearly suggest a crucial role is played by hCypA in the 
progression of HIV, although the exact nature of the involvement of hCypA is still 
poorly understood. It has been observed that inhibition of hCypA with cyclosporin 
during the early stages of infection has a marked effect on HIV progression, likely 
due to a reduction in sequesterable hCypA within the host cell thereby inhibiting the 
production of new virions. This is perhaps due to the incorrect folding of the GAG 
polyprotein prior to cleavage, or possibly as a result of the loss of association 
between Vpr and hCypA. The immunosuppressive qualities and inhibition of 
calcineurin directed T-cell activation have, however, not been ruled out. 
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Cyclophilin therefore is an ideal target for the development of anti-HIV therapies. 
Where much work has been done in order to design drugs which bind and inhibit 
viral proteins such as HIV protease and HIV reverse transcriptase (133), and HIV-
protease inhibitors such as amprenavir are current treatments, the rapid evolution of 
HIV into drug resistant forms reduces the potential effectiveness of these compounds 
(134). Although the immunosuppressive qualities of cyclosporin are an obvious 
handicap in treating HIV during the latter stages of infection (135), much work is 
being done in order to find non-immunosuppressive cyclophilin ligands which may 
be developed into anti-HIV therapies. 
The crystal structure of hCypA bound to the short peptide HAGPIA is shown in 
figure F 1-17, and the structure of the capsid protein dimer bound to two molecules of 
hCypA is shown in figure F 1-18. 
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Figure FI-17 HAUPIA. shown in blue. at binding site of hCypA. 










Figure Fl - I 8 Capsid dimer (green), shown in cartoon format, 
bound to two molecules of hCypA. 
1:6:-Previous Work at Edinburgh 
1:6:1:- Cyclophilin/Cyclosporin 
Previous work has been done in order to more fully characterise the cyclophilin-
cyclosporin (hCypA-CsA) interactions involved in enzyme ligand binding, involving 
crystallographic studies of hCypA complexes with CsA and with a CsA analogue. 
These studies identified direct hydrogen bond contacts (table TI-1), as well as five 
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water molecules which also contribute to hydrogen bonded interactions. It was also 
observed that the hydrophobic residue 11, methylvaline (MVA) is directed in 
towards protein residue Phel 13, at the hydrophobic binding pocket (the ABU pocket, 
named after CsA residue 2, L-a-aminobutyric acid). Conformation shifts in hCypA 
residues Arg55 and Met6l to accommodate ligand have also been observed 
(58,59,72). 
CYCLOSPORIN CYCLOPHILIN  
Residue number Atom Residue Atom 
0 G1n63 NE2 
2 N AsnlO2 0 
9 0 Trpl2l NE1 
10 0 ArgSS NH2 
10 0 Arg55 NI-Il 
Table TI -I The hydrogen bonded contacts made on Cyclophilin-Cyclosporin (hCypA-
05A) binding. These are illustrated in figure Fl-9. 
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1:6:2:- Development of Ligand Libraries 
Further studies carried out using the database mining program DOCK (136) 
identified the small molecule, 5,5-dimethylcyclohexane- 1 ,3-dione (dimedone, DCH), 
shown in figure Fl-19. Dimedone was shown to bind to cyclophilin with a Kd - 
22mM, and the crystal structure of dimedone hound to cyclophilin was solved, figure 
Fl-20 (137). 
0 	0 
Figure Fl -19 the small molecule Dimedone, identified using 
the database mining program DOCK. 
Arg5 	Trp121 
%4061 
• 	 - 
Figure F 1-20 Diniedone bound at the active site of cyclophilin A, showing 
residues Trp 12 I. Met6 I and Arg55. 
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Comparison of the conformation of dimedone at the active site of cyclophilin with 
known structures of cyclosporin and cyclosporin analogues bound to cyclophilin 
indicated a common binding mode, ie, hydrogen bonding contacts between ligand 
and Trpl2l and Arg55 (which adopt a slightly altered conformation to accommodate 
ligand), movement of Met6l to accommodate ligand. The position of the dimethyl 
group was also interesting, directed in towards the hydrophobic pocket, close to 
Phel 13, in a similar conformation to the methyl valine residue at position 11 on 
cyclosporin, but without a neighbouring hydrogen bonding contact directed towards 
Asn 102. Dimedone, available commercially, was therefore used as a starting point in 
the synthesis of a ligand library 'in-house' using combinatorial chemistry techniques, 
where a range of ligands were synthesised incorporating the dimedone moiety bound 
to a valine residue via an ester bond. One such example from this initial range of 
ligands is shown in figure Fl-21. This example, EM234, was shown to bind 
cyclophilin with a Kd of —20tM. 
0 
0 N 0-,-&o 
Figure Fl-21.Ligand EM234. with the dimedone 
moiety incorporated via an ester bond 
Another two ligand libraries based around dimedone have since been developed. One 
of these involves the incorporation of dimedone via an amide bond, rather than as 
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previously via the ester. Examples from this range are shown in figures Fl-22 and 
F 1-23. 
cL°  H 	II OH 
o H  2 N 	
0 
Figure Fl-22. Example from dimedone based ligand library where dimedone is incorporated 
via an amide bond. The green box shows dimedone analogue where the 0 atom has been 
replaced with NH. The yellow box shows the valine analogue forming the central core' of 
this range of ligands, and the blue box shows a benzene moeity. incorporated as an ether. 














~L- 0--~,N:e"_ 	. 0 
Figure F 1-23 A selection from the range of ligands based around dimedone incorporated 
via an amide bond, synthesised using combinatorial chemistry techniques. 
The other range of ligands developed has involved the formation of cyclised 
structures, again based around the dimedone moiety, such as that shown in figure Fl-
24 which has then been further developed into a range of ligands with the addition of 
various side chains at 'R'. 
R N
0 
Figure Fl-24 Example showing cyclised structure around dimedone, 
the basis for ligand library 2. 
1:6:3:- Cyclophilin 3 
Other work at Edinburgh involved the crystallisation and structural characterisation 
of cCyp3, from Caenorhabd iris elegans, the free living nematode, and its comparison 
with hCypA (34), which, owing to its close identity to hCypA, has made it a 
compelling model system for in vivo studies, in collaboration with Dr. T. Page, at 
Glasgow University. Crystallographic studies involving cCyp3 and the dipeptide 
Ala-Pro have also been done in order to determine the crystallographic binding 
constant, (138), which is described in more detail in chapter seven. 
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1:6:4:- FKBP12 
Previous studies have also been carried out in order to more fully characterise the 
binding of small molecules to human FKBPI2. Crystal structures of FKBPI2 bound 
to the dimethylsuiphoxide (DMSO), 4-hydroxy-2-butanone (BUT), methyl sulphinyl-
methyl sulphoxide (DSS), 3-acetyl- I -propanol (PROP), and 5-diethylarnino-2-
pentanone (DAP) have been published (139). 
1:7:- SUMMARY 
To summarise then, it is clear that the immunophilins present an extremely topical 
and intensive area of research. Whereas previously they were the known binding 
partners of immunosuppressive drugs cyclosporin, FK-506 and rapamycin, and hence 
the cellular target for the treatment of immune disorders, T-cell leukaemia, and in the 
prevention of rejection following organ transplant, their potential as the target for 
chemotherapeutic drugs in the fight against other debilitating and life-threatening 
conditions continues to grow. In particular, the recent evidence implicating hCypA in 
the progression of HIV has led to an explosion of interest in this area, and many 
groups are working towards a greater understanding of the role played by cyclophilin 
in HIV infectivity. This is especially important given the prevalence of HIV infection 
in particular populations and the rapid evolution of the virus into drug resistant 
strains, rendering the current treatments targeted against viral protein ineffective. 
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1:8:- Aims 
The aims of this project were: 
To clone, express and purify recombinant human cyclophilin A and FKBP12, 
in both the native form and with a hexa-his tag. Previous studies at Edinburgh 
utilised a vector carrying the gene for native CypA, kindly supplied by 
Novartis. To avoid any potential conflict of interests the expression of protein 
using vectors synthesised 'in-house' was necessary. No vector for expression 
of hFKBPI2 was available. 
• To examine the binding of dimedone based ligands to cyclophilin as they 
became available, using biophysical techniques, in order to determine their 
relative affinities. 
To obtain well diffracting crystals of recombinant protein. To obtain novel 
complex crystal structures with examples from the library of dimedone based 
derivatives synthesised 'in-house', and develop a dynamic, iterative screening 
process. The feedback of information to the combinatorial chemistry allowing 
the development of these ligand libraries and the establishment of a lead 
compound. 
• To further investigate the possibilities of calculating Kcr,st using crystals of 
cyclophilin and dipeptides of the form X-Pro. 
• To examine the binding of small molecules, previously characterised in 
complex with hFKBP12, with crystals of hCypA. 
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Ch 2: Materials and Methods 
A description is given of some of the more general techniques which were used during 
the course of this project, and of the necessary components used to facilitate their 
execution. More specific approaches are described in the relevant sections. 
2:1 SDS PAGE 
2:1:1 Brief Outline 
Sodium Dodecyl Sulphate Polyacrylarnide Gel Electrophoresis is a technique used to 
separate proteins according to their relative molecular mass (Mr). Samples are treated 
with SDS, a negatively charged detergent molecule which binds and denatures protein 
molecules, giving all proteins in solution a constant charge/mass ratio. On application of 
an electric current, proteins of low Mr are able travel further through the mesh of the 
acrylarnide gel than larger Mr proteins, which are retarded. By staining gels with 
coomassie blue dye, protein bands can be visualized, and by comparison with a marker 
protein ladder, identified according to their mass. 
All protein gels run were 15% acrylamide. Had the proteins of interest been of 
particularly low Mr, the percentage of acrylamide would have been increased in order to 
slow down their rate of travel through the gel, likewise, had they been of high Mr, the 
amount of acrylamide would have been decreased, allowing the molecules to travel 
further through the gel, giving increased resolution. 
Samples were also treated with the reducing agent -mercaptoethanol, to break 
disulphide bonds. 
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2:1 :2Preparation of Gels 
7.50% 10% 12% 15% 18% 200/ 
DW 4.85ml 4.05m1 3.35ml 2.35m] 1.35ml 0,75ml 
1.5M Tris, pH 8.8 2.5ml 2.5m1 2.5m1 2.5m1 2.5m1 2.5ml 
10% SDS 100il l00.tl l0O,il 100tl 100il IOOpI 
30%acrylamide 2.5m1 3.3m1 14.0ml 5.0mI 6.Oml 6.6m1 
10%APS 50p1 50j.il 5OjiI 50.jl 50pi 501.11 
rEMED 	- 5pI 5pI 5pI 5j.il 5pI 51.11 
Separating Gel. Highlighted in blue is the I 54 mixture, which was used here. 
Higher molecular weight proteins would possibly require a lower percentage 
acrylamide, and lower molecular weight proteins may require a higher 
percentage acrylarnide. 
DW 305ML 
0.5M Iris, pH 6.8 I .25ml 
10% SIDS 50j.il 
'30% acrytamide 650pI 
10%APS 25111 
EMED 5 11 1 
Stacking gel (4% acrylamide) 
Tables T2-1 and T2-2. Mixtures prepared for separating and stacking gels 
Separating gel was prepared by mixing Distilled Water (DW), TRIS, SDS, and 
acrylamide, followed by addition of APS and TEMED to instigate polymerization. Once 
poured, gel was layered with 70% EtOH or DW to give a clean interface. Once set, 
EtOH was poured off, stacking gel prepared and poured. Air bubbles were removed and 
plastic a comb (either 10 or 15 tooth) was placed in top of well to mould sample wells. 
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2:1:3 Preparation of samples 
Buffers/solutions prepared: 
lox Running buffer:- 30gTRIS, 144g glycine, lOg SDS, DW to IL pH 8.3 
5X Sample buffer (reducing):- 4m1 DW, I ml 0.5M Tns, p1-I 6.8, I ml glycerol, 1.6m] 
10% SDS, 0.4ml 2-mercaptoethanol, 0.2m1 1% brornophenol blue. 
Staining solution:- lOOml glacial acetic acid, lOOmI methanol, 2.5g coomassie R250. 
DWto IL 
Destaining solution:- lOOmI glacial acetic acid, lOOmI methanol, DW to IL 
Samples for gels were prepared by taking 20111 sample and adding 5111  sample buffer, 
vortexing, then boiling for 1-2 minutes on heating block before pipetting the 25tl 
sample to the well of the stacking gel. In the case of samples of bacterial culture, 250pi 
culture was taken and spun for 10 mins at 1300rpm using the benchtop microfuge. 
Supernatant was poured off and the pellet resuspended in 80p! DW and 20111 5X sample 
buffer and boiled for 5 minutes. 25tl was pipetted into well of stacking gel. 
Gels were run for about 45minutes at a fixed voltage of 200V, variable current, max 
400mA, followed by staining for lOminutes, and 40minutes destaining. 
Marker protein used was Prestained Protein Marker, Broad Range, from New England 
Biolabs, Cat No P7708S 
2:2 Western Blot 
2:2:1 Brief Outline 
In a process analogous to southern blotting (named after Ed Southern), where DNA 
molecules may be transferred onto a membrane and treated with a labeled DNA probe to 
identify specific DNA molecules, and northern blotting which treats mRNA molecules 
in much the same way, so western blotting involves the transfer of protein molecules 
onto a membrane, which is then treated with antibodies and substrate allowing the 
identification of particular macromolecules. More specifically, an SDS-Page gel is 
blotted onto nitrocellulose membrane, which is then incubated with a primary antibody, 
directed against the protein of interest. This is followed by incubation against secondary 
antibody, which in turn is directed against the primary antibody. Generally, the 
secondary antibody will be conjugated with an enzyme, which converts a colourless 
substrate into one which may be visualized. The enzyme conjugate used is often 
horseradish peroxidase. Here we use the enzyme conjugate alkaline phosphatase, and the 
substrate BCIP which is converted into a blue product when incubated with enzyme. 
2:2:2 Buffers Prepared 
Towbin transfer buffer:- 25mM TRIS, 192mM Glycine 20% MeOH pH 8.3 
0.0IM Phosphate buffered saline (PBS):- PBS tablet (SIGMA) dissolved in 200m1 DW, 
as per manufacturers instructions. 
PBSTTWEEN (Polyoxyethylenesorbitan monooleate) stock:- 50ml 0.0IM PBS, 50pJ 
TWEEN 20 
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Blocking buffer:- 30m1 PBS1TWEEN stock, 1.5g non-milk fat 
Primary antibody/secondary antibody solutions prepared as per manufacturers/suppliers 
instructions, from 1/1000 in PBS/TWEEN for primary Ab to 1/3000 in PBS/TWEEN for 
secondary Ab. 
Substrate solution:- BCIP/NBT (sigma) mixed 1:5 with DW as per manufacturers 
instructions. 
2:2:3 Procedure 
SDS-Page was run as described above, omitting the stain/destain step as the gel was 
equilibrated against transfer buffer for lOminutes. Filters & nitrocellulose membrane 
were cut to gel size and soaked in transfer buffer. Filters, gel and nitrocellulose 
membrane were then placed in a 12V semi-dry transblot, as shown in figure F2-1, 
ensuring they were all sufficiently wet and that no air bubbles were present. After 
30minutes, the membrane was removed, placed in blocking buffer for 1 hour, then 
washed in DW. Membrane was then incubated at room temperature against primary Ab 
solution for 2hours, then against secondary Ab solution for 2hours, again at room 






Fig F2-1. Arrangement of filters, gel and membrane in semidry transblot 
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2:3 Protein Expression and Cell Transformation 
2:3:1 Brief Outline 
Expression of hCypA, His-hCypA, hFKBPI2 and His-hFKBPI2 all followed the same 
protocol. Constructs containing the inserts were stored either in QIAGEN miniprep 
buffer at 4°C, and could be used to transform expression cells directly; or were stored in 
DI-15a cells (Invitrogen) as 20% glycerol stocks at —80 °C, which required plating, 
growing and miniprepping before transformation of expression cells could be performed. 
Extraction of plasmid was performed using a Qiagen miniprep kit, as per manufacturers 
protocol, followed by transformation of BL2I DE3 cells (Novagen). Cells were grown 
in LB broth at 37 °C, with induction of expression at 0.13. 6() = 0.6 by addition of IPTG 
to a concentration of 0.4mM. Cells were harvested after a further 4 hours growth by 
centrifugation at 3000 x g for 30 minutes. In all cases, it was necessary to first prepare 
plates of the growth media LB with ampicillin for selection. 
Ampicillin was provided in 500mg vials, these were made up to a stock solution of 
50mgrn[ 1 by addition of lOmI sterile water. Ampicillin stocks were stored at 4 °C for 
maximum 7 days. 
LB agar was supplied. Plates were prepared by slowly melting 250ml LB-agar in a 
microwave, followed by addition of 50041 stock ampicillin once it was sufficiently 
cooled. Plates were poured immediately and allowed to set. Prepared plates were stored 
at 4C for maximum 7 days. 
All cells used for expression and storage were supplied as competent cells by invitrogen, 
and stored at —80°C, in 20jil vials. 
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2:3:2 Transformation of BL21 DE3 Expression Cells and DH5a storage cells 
Competent cells were removed from freezer and allowed to thaw slowly on ice. Once 
thawed, ltl of plasmid solution (from miniprep) was added and mixed gently. Cells 
were then placed on ice for 2 minutes, followed by heat shocking in a 42 °C water bath 
for 30 seconds, then back on ice for 5 minutes. 80tl room temperature SOC or LB 
media (sterile) was then added to the mixture and cells were placed in 37 °C incubator for 
60 minutes with gentle shaking. Transformed cells were plated out and placed at 37 °C 
for overnight growth. Colonies were selected and used to inoculate lOmi LB Amp 100, 
which was then grown for a further 12 hours or overnight. Where DH5a cells had been 
used, these were then used to prepare 20% glycerol stocks and frozen at —80 °C, for 
future plasmid extraction. 131-2 I DE3 cell cultures were used for protein expression. 
2:3:3 Protein Expression 
The prepared lOmI cultures of BL2I DE3 cells which had been grown overnight were 
centrifuged at 4200rpm for 15minutes, the supernatant was discarded and the cells 
resuspended in fresh antibiotic containing media. A test expression was performed by 
taking 500tl from each resuspension and inoculating a further lOmI LB ArnplOO, and 
growing at 37 °C. shaking. Once the cultures had reached O.D.000 = 0.6, samples were 
taken for SDS-Page, and protein expression in the cultures was induced by addition of 
IPTG to a concentration of 0.4mM. A brief description of the lac-operon and the effect 
of IPTG is given in figure 172-2. After 4 hours, SDS-Page was run using all the samples 
before and after induction. The stored culture(s) corresponding to samples showing 
IN 
highest protein yield were used to inoculate 2X lOOmI flasks of LB AmplOO for 
overnight growth at 37 °C. Full scale protein expression was then performed by taking 
8X 2L flasks, each containing 500m1 LB Amp 100 and inoculating each using 25m1 of 
the overnight cultures, inducing expression at O.D 600 = 0.6 by addition of IPTG to 
0.4mM (antibiotic was usually refreshed at this point too). After a further 4 hours growth 
at 37°C, cells were harvested by centrifugation at 8000rpm for 30minutes. Cell pellets 
were stored at —18 °C. 
2:3:4 The lac-operon 
lactose 	IPTG 
FRNAPOL I repressor) 
I Lad 	 EAU operator 	 LacY 	I LacA 	I 
psSsSOr 1 
1 Thiogactoside -gaIactosidase 	 transatetv1e 
Lactose perntease 
Fig F2-2. The lactose operon. The lad gene (yellow) codes for the lac repressor (purple), which hinds 
to the lactose operator (green) thereby preventing transcription of genes downstream by RNA 
polymerase (green) which is hound to the promoter section of the gene (red). In the presence of 
lactose, or the lactose analogue IPTG (isopropyl-thio43-galactoside). which hinds to the repressor 
altering its conformation and reducing its affinity for the operator, the repressor becomes unbound. 
The genes of the lac-operon can then be transcribed by RNA polymerase and their respective proteins 
expressed. 
An adaptation of this system has been developed for use in vectors, such as the pET 
vectors used here, described in chapter 3, for the expression of recombinant proteins. 
The lad (repressor), the lac operator and the lacZ genes, together with the bacteriophage 
WE 
T7 promoter (140) are incorporated into the plasmids, and the gene for the protein of 
interest is inserted into the lacZ section of the gene, and expression may he induced by 
addition of IPTG to the growth media. 
This system also allows the selection of cells which contain the vector bearing the insert. 
By plating cells onto growth media containing the substrate X-gal (5-bromo-4-chloro-3-
indolyl--galactopyranoside), where the LacZ gene is intact, the -galactosidase enzyme 
cleaves this into galactose and a blue insoluble product and blue colonies can be seen. 
Where the gene has been disrupted, such as when it contains recombinant DNA, the 
cells remain white. This method of selection was exploited here, during the cloning of 
the genes for hCypA and /iFKBPI2 into expression vectors (chapter 3). 
2:4 Blue - White Colony Selection 
As mentioned, once a gene has been ligated into a plasmid, and the plasmid has been 
used to transform cells, then the technique of blue-white selection can be used as a 
relatively fast and efficient means of examining the quality of the ligation reaction. By 
utilizing 13-galactosidase, which is coded for by lacZ, and cleaves lactose sugar into 
glucose and galactose, as a reporter gene, colonies can be screened to identify those 
which contain plasmid bearing insert DNA. 
LB-agar plates (with ampicillin) were prepared by adding 40pJ of 20mg.mr' stock X-gal 
and lOOjil of 100mM IPTG, once the plates had dried, the transformed cells were plated 
out. After overnight incubation at 37 °C, colonies which had the vector bearing the insert 
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were white, whereas those which carried the vector, but the vector did not bear the 
insert, were blue. 
2:5 Determination of Protein Concentration 
2:5:1 Brief Outline 
There are many techniques described in the literature for calculating the concentration of 
protein in a sample, such as the Lowry method (141), the Sedmark-Grossberg method 
(142) and the Bradford assay (143). The techniques used here are either the Bradford 
assay, where protein concentration is determined against a standard curve of protein 
(BSA) at known concentrations; or the extinction coefficient method, where the 
absorbance of a molecule at a specific wavelength is related to its molar extinction 
coefficient at that wavelength, the concentration of the molecule in solution and the 
pathlength through the solution. The molar extinction coefficent method is described by 
the Beer-Lambert Law, le: A = Ecl, where A is absorbance, F, is the extinction 
coefficient at X (wavelength), c is concentration (in mol/L) and I is the pathlength (in 
centimeters). It was found that when assaying protein concentration, the Bradford assay 
and the extinction coefficient technique could give very different results, generally the 
protein concentration from the Bradford assay could be as much as four times that from 
the extinction coefficient method (this was also noted by Siekerka eral. in 1989) (9). For 
consistency, the Bradford assay was used when assaying protein concentration in order 
to prepare crystallisation trays, whereas the extinction coefficient method was used to 
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assay protein concentration in samples prior to performing activity assays and 
undertaking kinetic studies. 
2:5:2 Bradford Assay 
Protein standards (Pierce) were prepared with coomassie as per manufacturers 
instructions to concentrations of 0.125, 0.25, 0.5, 0.75, 1.0, 1.5 and 2.0 mg/mF', in ImI 
volumes. Absorbance readings were taken from each at 595nm, and a standard curve 
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Figure F2-3 Bradford assay standard curve 
Samples whose protein concentration were to be assayed were then prepared. A small 
amount was taken from the protein sample (generally around 20-50j.il, depending on the 
expected concentration of protein in the sample), and series of dilutions were made, ie; 
1/10, 1/20, 1/40 etc. These were then prepared in the same manner as the standards and 
absorbance readings taken. By reference to the standard curve, protein concentration in 
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each sample could be estimated. After allowing for the dilution factors, the protein 
concentration in the stock was assumed to be the average of all readings taken. 
2:5:3 Extinction Coefficient Method 
The molar extinction coefficient for hCypA and /IFKBPI2 was obtained from the 
Expasy website, using the protpararn facility (http://au.expasy.org/tools/protparam) . By 
inputting the amino acid sequence of the protein in question, including 6X His tags and 
linker sequences where appropriate, information such as the molecular weight, atomic 
composition, (theoretical) isoelectric point, and the extinction coefficient may be 
obtained. Also given are the absorbance readings for a sample concentration of lmgmF'. 
A series of dilutions using DW were made from a small sample of the protein stock, and 
the absorbance at 280nm (after first zeroing the spectrophotometer against buffer only) 
was recorded using a quartz cuvette. Using the information from expasy, and allowing 
for dilution factors, the concentration of protein was calculated. 
eg, for His tagged /ZFKBPI2 the E2 80 = 0.9530 (from Expasy). With a pathlength of I, 
and an absorbance at 280nrn of 0.2, from the beer-lambert equation: 
A = Ec1 
therefore:- A/F_ X = ci 
=> 0.2/9530 = c => 20.9 jiM 
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2:6 Polymerase Chain Reaction (PCR) 
2:6:1 Brief Overview 
The Polymerase Chain Reaction allows the extension and duplication of specific 
sequences of DNA. By designing primers to flank the DNA sequence from 5' to 3' on 
both the sense and antisense strand, and heating the reaction mixture to an appropriate 
temperature (generally around 94 ('C) to denature the DNA, then rapidly cooling (to 
around 50°C) these primers can anneal to their complementary strand from 3' to 5'. This 
leaves the 3' hydroxyl end free for addition of free nucleotides by DNA polymerase, 
after a further temperature change to 72 °C, the optimum temperature for DNA 
polymerase. The reaction is generally run for 20 to 30 cycles, recognized as the optimum 
as mutations start creeping into the system. The polymerase chain reaction is illustrated 
in figure F2-4. 
Choice of polymerase is usually dictated by cost, and taq polymerase, from thermus 
aquaticus is often the first option. Taq is relatively stable, efficient and adds a 3' A 
overhang. Alternative polymerases include Pfu, from pyrococcus furiosus, or vent (also 
known as Tli), from thermococcus litordilis. Whilst these may be slightly more 
expensive, possibly less efficient and do not add a 3' A, they have 3'-5' exonuclease 
activity, therefore PCR product has fewer mismatches. In 1991, vent polymerase was 
shown, by Cariello etal. (144), to have an error rate of 2.4 X 10 -5 per base pair, whereas 
taq had an error rate of 8.9 X 10 per base pair, whilst the efficiency of both was 
comparable, at 55-58%. There are now, however, a wide range of polymerases available, 
such as taq precision, which is a taq/Pfu mix in a 10: 1 ratio, and was tried here. 
The optimum amount of PCR cycles which may he performed is generally taken to be 
thirty. This is a consequence of the half life of the polymerase being used. Taq 
polymerase has a half life of 30 minutes at 94 °C, therefore after 30 cycles with one 
minute each cycle at 94°C and the polymerase efficiency is markedly reduced, although 
it has been reported that for synthesis of short DNA products, the denaturation 
temperature and/or time may be reduced allowing a greater amount of PCR cycles to be 
performed (145). 
The mixture in the PCR reaction vessel therefore consists of sense and antisense primers 
specific to the gene being amplified; a DNA template, which may be plasmid DNA or 
come from a gene library; a supply of deoxynucleotides, and DNA potymerase. 
2:6:2 Procedure 
The deoxynucleotides dATP, dCTP, dGTP and dTTP in the reaction vessel were 
previously prepared in II. IX PCR buffer, all the components of this buffer are shown in 
table T2-3. Reactions were run with a volume of 50tl in the reaction vessel, consisting 
of 4.5.il I l.IX PCR buffer, 3.tl cDNA template (Stratagene), lj.il DNA polymerase, 2.tl 
forward primer, 2.tI reverse primer (giving a total concentration of -4.0ngi1_' of each 
primer in the reaction vessel). The solution was made up to 50.tl by addition of 37.5il 
sterile water. 
The DNA polymerases came from different sources (table T2-4) with stock 
concentrations from 2-5units/lJ.l. Primers were designed to incorporate the appropriate 
restriction sites for cloning into vectors and are shown in chapters 3 and 4. Primer length 
was around 20 bases per primer, plus the restriction site. This is around the optimal 
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length of primer in order to avoid mis-match or non specific binding. With four possible 
bases, a 20 nucleotide sequence has 420  possible arrangements. Too long a primer, 
however, and the chances of non-specific binding increases, as does the melting 
temperature of the primers. Primers were supplied in powdered form by Sigma, in 
quantities of —45-90jig. These were prepared to a concentration of —l1gmF' in TE 
buffer, then further diluted with sterile water to give stock concentrations of lOOngml* 











Tris HCl pH 8.8 2M 334 490mM 45mM 
[NH4 1SO4 IM 166 122mM llmM 
MgCl' IM 67 50mM 4.5mM 
EDTA pH 8.0 10mM 6.8 50jiM 4.511M 
13- 100% (13.9M) 
mercaptoethanol  
7.2 74.4mM 6.7mM 
dATP 100mM 150 11.1mM 1.0mM 
dCTP 100mM 150 11.1mM 1.0mM 
dGTP I 00mM 150 I I .1 mM I .0mM 
dTTP 100mM 150 1 11.1mM 1.0mM 
BSA lOmgmi' 170 1.25mgmF' I 	I 13p.gmi' 
Table T2-3: Components and their corresponding volumes in I lix PCR buffer Total volume: I351tl 
POLYMERASE SUPPLIER STOCK CONC. (UNITS/j.IL) 
taq Abgene 5 
vent NEB 2 
Pfu stratagene 2.5 
Taq precision stratagene 5 
Table T2-4.: DNA polymerases tested. Further PCR work was performed using 
vent. 
TEMPERATURE 92°C 56°C 727 
Time 1 minute I minute 1 minute 
Table T2-5: Thermal cycler program. 27 cycles were run. 
The polymerase chain reaction was used here in order to synthesise cloned DNA for the 
proteins hCypA and hFKBPI2, for ligation into expression vectors, and to prepare 
samples for sequencing reactions. 
Primers designed to bind both sense & antisense strands. Primers shown in red. (sequence shown is hCypA) 
5'- 	 GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAAG 	 5' (antisense) 
Reaction mixture containing template DNA, 
primers, DNA polymerase, deoxynucleotides. 
5' -ATGGTCAACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
Heat to 96°C. Strands denature and separate 
5' -ATGGTCACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAAG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
Ii Cool rapidly to 50°C. Primers anneal to 
complementary strands. 
5' -ATGGTCAACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAAG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
fi Heat to 72°C. DNA polymerase attaches 
II appropriate deoxynucleotides to free 3' 
V hydroxyl, extending strands 
5' -ATGGTCAACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAPG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
Duplicate DNA synthesised 
5' -ATGGTCAACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAAG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
5' -ATGGTCAACCCCACCGTGTTC------GACTGTGGACAACTCGAATAA-3' (sense) 
3' -TACCAGTTGGGGTGGCACAG------CTGACACCTGTTGAGCTTATT-5' (antisense) 
Repeat 
for up to 
30 cycles 
Fig F24: Schematic showing cycle of events during the polymerase chain reaction 
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2:7 DNA Gel Electrophoresis 
2:7:1 Brief Description 
In a similar technique to that involving separating proteins by gel electrophoresis, DNA 
gels can also be used to separate DNA according to size by applying samples to a gel 
and applying an electric current. DNA has an overall negative charge, therefore travels 
from negative to positive through the gel. Ladders of DNA fragments of known size can 
be used as a comparison if run alongside, in the same way marker proteins are used in 
protein gels. Once run, DNA gels are examined by first bathing in ethidium bromide and 
visualizing under UV light. 
2:7:2 Procedure 
DNA ladder used: I Kb DNA ladder (Invitrogen) 
DNA gel: I X TBE buffer + 1% w/v agarose 
6X Loading buffer: 0.25% bromophenol blue. 0.25% xylene cyanol FF, 30% glycerol 
lOOrnI TBE buffer was mixed with Ig agarose and heated to encourage dissolving of the 
agarose. Gel was poured immediately, and a comb used to form sample wells. DNA 
samples were prepared by mixing 5.tl sample with Ipi loading buffer, once gel had set, 
DNA samples and ladder was placed in sample wells, and gels were run at 150V. Gels 
were then bathed in a 0.5j.ig.ml 1 solution of ethidium bromide for —15minutes and 
visualised under UV light. 
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2:8 DNA Sequencing 
2:8:1 Brief Outline 
All sequencing reactions were carried out by the sequencing facility at Edinburgh 
University, using an ABI PRISM 310 Genetic Analyser (Applied Biosystems). Samples 
were prepared for sequencing according to the following protocol, involving 
amplification of the DNA sample by PCR followed by precipitation of the PCR product 
in ethanol. Sequencing reactions were performed in both directions, ie, both the sense 
and the antisense strands had their sequences analysed. PCR reactions were performed 
as described previously. The PCR reaction mixture is shown in table T2-6.Ethanol 
precipitation of PCR product is described. 
2:8:2 Ethanol Precipitation of PCR product 
Following PCR amplification the samples, DNA was precipitated by adding 50pJ of 
95% ethanol and 2p1 3M sodium acetate pH 4.6 to the reaction vessel. The samples were 
then incubated at room temperature for 20minutes, then spun at full speed on the 
benchtop microfuge for 20minutes and the ethanol removed. Samples were then washed 
with 250j.il 70% ethanol and spun as before for lOminutes, ethanol was removed and 
samples were spun for a further lOminutes. Residual ethanol was removed and samples 
were air dried at 37 °C for 30minutes. Samples were then submitted to the sequencing lab 
for analysis. 
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COMPONENT VOLUME (iL) 
ABI PRISM BigDye v3 Terminator Cycle Sequencing Ready 
Reaction Mix. 
8 
Plamid DNA (from miniprep) 8 
Primer _(lOOng1l_stock) 
DW 3 
Table T2-6: PCR reaction mixture for amplification of samples prior to sequencing 
2:9 Protein Purification 
2:9:1 Ion exchange chromatography 
Untagged, or native protein was purified by ion exchange chromatography, or more 
precisely, by cation exchange chromatography. This involves passing positively charged 
protein across a matrix bound negatively charged group. The protein binds to the matrix 
and may then be eluted by competition for the negatively charged binding sites on the 
matrix using positive ions (cations. ie Na). In the case of native hCypA, the isoelectric 
point (from Expasy) was 8. 1. This is the pH at which the protein carries an overall 
neutral charge. Protein was suspended in 50mM Hepes, 5mM EDTA, 5mM 13-
mercaptoethanol pH 6.8, thereby giving the protein a positive charge. The solution was 
then passed across an sp-sepharose column (Amersham), where sp- is sulphopropyl 
(-CH,CH 2CH2S03), the functional group attached to the sepharose matrix. Protein was 
eluted by passing a salt gradient across the column (buffer used:- 50mM Hepes, 5mM 
EDTA, 5mM 13-mercaptoethanol, I.OM NaCl pH 6.8). from 0-100% salt. Na ions 
Ij 
compete with the protein for binding to the matrix. For completeness, the full protocol 
which was followed for the purification of hCypA is shown, as is the gradifrac program 
used (figure T2-8). 
2:9:2 Purification of Native hCypA 
Buffers prepared:- 
Resuspension buffer:- 50mM 1-lepes, 5mM benzamidine, 5mM EDTA, 5mM - 
mercaptoethanol pH 7.5 
Buffer A:- 50mM Hepes, 5mM EDTA, 5mM 13-mercaptoethanol pH 6.8 
Buffer B:- 50mM Hepes, 5mM EDTA, 5mM 3-mercaptoethanol, I .0M NaCl pH 6.8 
Cell pellet was resuspended in resuspension buffer, sonicated for 10-15 minutes 
on ice, then centrifuged at 50,000 x g for 60minutes at 4"C. Supernatant was kept, 
filtered, then dialysed for 4 hours against 5L buffer A. 
Dialysed protein supernatant was loaded onto SP -sepharose column, gradifrac 
(Amersham) for ion exchange chromatography with NaCl gradient from 0 to 
0.5M. Gradifrac program shown (table T2-7) 
Chromatogram trace was examined to identify fractions thought to contain 
hCypA. These were run on SDS-Page. 
If protein was not pure, samples were pooled and dialysed for 4hours against 5L 
buffer A. Dialysate was then loaded onto Resource S column, using gradifrac, for 
ion exchange chromatography as before. 
52 
5) Chromatogram was examined and SDS-Page run to determine fractions 
containing hCypA. If these were not homogenous, then they were pooled and 
loaded onto G75 column, FPLC (Amersham Pharmacia), for size exclusion 
chromatography to remove any remaining impurities. 
TIME 
(MINUTES) 
% BUFFER B FLOW (MLMIN 1 ) FRACTION VOLUME 
 (ML) 
0 0 I 10 
100 0 1 5 
ISO 20 1 5 
220 20 1 5 
270 50 I 5 
320 50 1 5 
320.1 100 1 10 
380 100 I 10 
380.1 0 I 10 
450 0 I 10 
END 
Table T2-7 showing program run for ion exchange chromatography of hCypA 
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2:9:3 Metal Affinity Chromatography 
Another means of purifying protein used was that of affinity chromatography. The genes 
for both hCypA and hFKBPI2 were cloned into vectors allowing the proteins to be 
expressed with a hexa histidine tag at the N-terminus. Cloning strategies are described in 
chapter 3. 
The cell lysate containing the expressed protein was suspended in 50mM Tris, 300mM 
NaCl, 10mM Imidazole, pH 8.0, and passed across a Nickel- NTA -Agarose column 
(Amersham). The Ni 2 ions, bound to the agarose column via the nitriloacetic acid 
(NTA), bound to the imidazole groups on the histidine residues, and protein was eluted 
by passing a 1-100% gradient of 50mM Tris, 300mM NaCl, 250mM Imidazole. pH 8.0 
across the column. The imidazole in the elution buffer competes for with the histidine 
residues for binding with the N i2l  ions, thereby eluting protein. 
2:9:4 Purification of 6X His-tagged hCypA and 6X His-tagged hFKBPI2 
Buffers Prepared:- 
Buffer A (lysis buffer):-50mM Tris, 300mM NaCl, 10mM Imidazole, pH 8.0 
Buffer B:- 50mM Tris, 300mM NaCl, 250mM Imidazole, pH 8.0 
I) Cell pellet was resuspended in lysis buffer A, sonicated for 10-15 minutes on ice, 
then centrifuged at 50, 000 x g for 60 minutes. Supernatant was kept and filtered. 
Supernatant was then loaded onto Ni-NTA column, on gradifrac, for purification 
against imidazole gradient. Gradifrac program is shown (table T2-8) 
Chromatogram was examined to identify fractions thought to contain pure His-




% BUFFER B FLOW (MLMIN') FRACTION VOLUME 
 (ML) 
0 0 1 10 
30 0 1 5 
60 50 1 5 
90 50 1 5 
120 100 I 10 
150 100 1 10 
150.1 0 I 10 
180 10 1 10 
END 
Table T2-8. Gradifrac program run for purification of hexa-his tagged hCypA and hexa-his 
tagged hFKBPI2 using immobilized metal ion affinity chromatography. 
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Ch 3 Protein Cloning, Purification and Characterisation 
3:1 Introduction 
As described in chapter 1, previous studies at Edinburgh involving hCypA were 
performed using protein which had been expressed using a vector which had been 
supplied by Novartis. No information regarding the vector was available. Problems 
were incurred when trying to express protein from this vector, ranging from 
overexpression of apparently truncated target protein prior to induction, to no protein 
expression, or no growth of plated cell stocks. Whilst there had been no previous 
difficulties, it is likely that long term storage of plasmid in cells unsuitable for this 
purpose had caused plasmid to become damaged or mutated, or lost completely. It 
was therefore decided that fresh clones for this protein should be synthesised, in 
order to maintain a reliable source of recombinant protein, and to avoid any potential 
conflict of interest. 
Further, it was decided that two expression systems would be made. One, for 
expression of native protein, and the other in order to express protein with a 
cleavable N-terminal hexa-histidine tag, for ease of purification by metal affinity 
chromatography. 
3:2 hCypA Cloning 
3:2:1 Brief Overview of Strategy :- 
The expression vectors pET5a and pET15b (Novagen) were selected as the final 
destination for the hCypA gene, as these would allow the expression of protein both 
with a cleavable 6X His tag (pET l5b) and in the native form (pET5a). The DNA 
sequence of the gene for hCypA, and its corresponding peptide sequence is shown in 
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figures 173-1 and F3-2. Vector maps and multiple cloning sites of the pET5a and 
pET 15b plasmids are shown in figures 173-3/173-4 and F3-5/F3-6 respectively. 
Primers were designed and ordered from Sigma. The cDNA template for the 
hCypA gene was taken from a library of human lung tissue cDNA (Stratagene). A 
polymerase chain reaction was set up and the products run on a gel to identify 
samples containing DNA corresponding to the hCypA gene. These were then cloned 
into an intermediate vector, PCR-script (Novagen). After transformation and 
screening of XLIO gold (Stratagene) cells , the intermediate vector was purified then 
digested with restriction enzymes and a DNA gel was run to identify the !zCypA 
DNA. This was then purified and ligated into the expression vectors, and XLIO cells 
transformed. Positive transformants were grown up and used for plasmid extraction 







Figure F3- I .The DNA sequence of the gene encoding hCypA, including 
STOP signal TAA 
GLY GLIJ PRO LEU GLY ARG VAL SER PHE GLU LEU PHE ALA 
ASP LYS VP.L PRO LYS THR ALA GLU ASH PHE ARG ALA LEI) 
SER Ti-IR GLY GLU LYS GLY PHE GLY TYR LYS GLY SER CYS 
PHE HIS ARG ILE IL.E PRO GLY PIlE MET CYS GLN GLY GLY 
ASP PHE THR ARG HIS ASH GLY THR GLY GLY LYS SER ILE 
TYR GLY GLU LYS PIlE GLIJ ASP GLU ASH PIlE ILE LEU LYS 
HIS THR GLY PRO GLY ILE LEU SER MET ALA ASN ALA GLY 
PRO ASN THR ASN GLY SER GLN PIlE PIlE ILE CYS THR ALA 
LYS THR GLU TRP LEU ASP GLY LYS HIS VAL VAL PIlE GLY 
LYS VAL LYS GLU GLY MET ASH ILE VAL GLU ALA MET GLU 
L: ER FTPN GL 'f I Tt-F FI IY S !.Y THP 
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Figure F3-3.Vector map showing the pET5a plasmid. From the Novagen website. 
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Figure F3-4 The multiple cloning site on vector pET5a. The gene for hCypA was 
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Figure F3-5 Vector map showing the pETI5h plasmid. From the 
novagen website. 
17 promoter primer #693483 
._LiI 	
- 	
17 promoter 	 lac operator 	 rbs - 	 ,  
NCO His-Tag 	 Nde I XhoI Ban-H 
AIA::A oGAccAc•:.'' 	•'. 	 .. -. 	 , 
1 	" .AIaAg 
Soul 1 -02 1 	 thrombin 	17 terminator 
AAcA4trGA: 
Lysi.. IGI. 	l-' I 	I 	I 
4 
T7 'e'noncl' primer e69337-3 
Figure F3-6The multiple cloning site on vector pET15h. The gene for 
/iCypA was inserted between restriction sites NdeI and BamH I. 
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3:2:2 Primer Design and Isolation of hCypA Gene 
The gene for hCypA was examined for any inherent restriction sites, a restriction 
map for the gene is shown in figure F3-7. Primers were then designed to anneal 
upstream on the gene to the antisense strand, incorporating the site for the Ndel 
restriction enzyme; and downstream on the gene to anneal to the sense strand, 
incorporating the site for the BamHl restriction enzyme. The primers are shown in 
figure F3-8. 
I •. 	 495  
I 	I 	III 	 1111.1 	 .1 
Ti 	Hp8I 	 TSpUTI 	 To1 	 Ilsel CvIJI 	Hp98I 
MseI ToL Cvt.iI Hp91 	IspOTI 
Ben I 	 Owl 	 CviJI 





Fig F3-7. Restriction map for the gene for hCypA. From the 
New England Biolahs internet service, NEBcutter. 
5 1 - 	GCGCCATATG..::c.:.: -, :;.: 	 i;: -:: -3' (sense) 
3 1 - 	 ?ACCAGTTJ- 	 J..i -5' (antisense) 
5 1 - 	ACTGTGGACAACTCGAATA: 	 -3' (sense) 
3 1- TACACCTGTTGAGCTTATCCTAGGGCGC -5' (ant isense) 
Figure F3-8. Primers designed for ligation of the gene for hCypA into the vectors pET5a 
and pETl5h. A) shows the primer designed to hind upstream of the gene, to the antisense 
strand. The restriction site for NdeI is shown in blue. B) shows the primer designed to 
hind downstream of the gene. to the sense strand. The restriction site for BamH I is shown 
in blue. 
Stock solutions of primer were then prepared using sterile water, with a 
concentration of 40-100.tg.mF' 
Me 
Initial PCR experiments were run to test the four polymerases available:- taq, vent, 
Pfu, and taq precision plus. These are described in materials and methods, as are the 
50i! PCR mixture and thermal cycler program used. 
The PCR products were then run on a DNA gel to examine the results. The gel is 
shown in figure F3-G 1. Sample 2 (vent) was selected for further cloning. 
3:2:3 Cloning into PCR-script vector 
The cloned DNA was then ligated into a cloning vector (PCR-script, Stratagene), 
pre-digested at the Srf I restriction site. The ligation of the gene into the PCR-script 
vector (shown, fig F3-9) gives increased efficiency of gene cloning and subsequent 
ligation into the expression vector. As the DNA had been amplified using vent 
polymerase, the DNA product was 'blunt-ended'. Had the DNA been amplified using 
'taq', it would have been necessary to polish it (remove the 3'-A overhang) prior to 
ligation into the vector. The ligation reaction was incubated at room temperature for 
1 hour, followed by heating at 65°C for 10 minutes. The ligation reaction mixture is 
shown in table T3-1. This was then used to transform XLIO gold ultracompetent 
cells (Stratagene), as per manufacturers protocol, which were plated out overnight on 
agar, AmplOO, which had first been prepared with lOOi.il of 10mM IPTG and 100il 
2% XGAL, for overnight growth at 37 °C followed by blue/white colony selection. 
The gel run with the PCR-script vector containing the hCypA gene is shown in figure 
F3-G2. 
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f  (+) on 
ampicillin 







Fig F3-9. PCR-script vector. The PCR product was ligated into the Srf I 
restriction site within the multiple cloning site. From the Stratagene 
website. 
COMPONENT VOLUME (.tL) 
pPCR-script Amp SK(+) cloning vector 1 
PCR-script lox reaction buffer 
10mM rATP 0.5 
PCR product 4 
Srfl restriction enzyme 
14 DNA ligase 
DW 1.5 
Table T3-1. Reaction mixture for ligation into PCR-script. As per 
manufacturers protocol. 
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3:2:4 Screening of Colonies 
An agar, amp 100 (replicate) plate was prepared and a numbered grid of 20 squares 
drawn on the underside, 20 sterile eppendorfs corresponding to the grid were also 
prepared with 50il sterile water in each. Colonies picked from the overnight plate 
were streaked onto a square on the grid, and then placed in the corresponding 
eppendorf. The numbered plate was then placed in the incubator and the 20 
eppendorfs heated at 100°C for 5 minutes. The eppendorf samples were then 
amplified by PCR , as described previously, except with 30 cycles using the T3 and 
T7 primers, to amplify only the DNA within the multiple cloning site, and a DNA 
gel run to identify samples with the intact gene. The gel can be seen in figure F3-G2. 
After selecting the samples (in this case, samples 2,3,5,13,14,15, were selected), 
overnight cultures were prepared from corresponding samples on replicant plate. The 
overnight cultures were then used to prepare 20% glycerol stocks, and the plasmid 
was extracted using QIAGEN miniprep kit. 
3:2:5 Digest of Cloned Gene from PCR-script 
It was the necessary to cut the gene from the PCR-script intermediate cloning vector. 
This was done by digestion of the vector using the Barn HI and the Nde 1 restriction 
enzymes (supplied by NEB), which are specific for the Bam HI and Ndel restriction 
sites included in the primers, and therefore incorporated into the cloned gene. The 
expression vectors, the final destination for the cloned genes, were as yet undigested, 
and these were also cut at the Barn HI and Ndel restriction sites within the multiple 
cloning sites on the plasmids, so that the excised gene may be ligated. The PCR- 
script vector containing the gene for hCypA and the pET expression vectors which 
were the final destination for the hCypA gene were digested at the Ndel and the 
BarnH 1 restriction sites. Barn H 1 buffer was used (NEB), as it was known that Nde 1 
restriction enzyme was also stable in this buffer. Reaction mixtures are shown in 
table T3-2 and T3-3. Reactions were incubated at 37 °C for 2 hours. A DNA gel was 
run (F3-G3) with the digested sample, those showing good digestion were cut out, 
and DNA extracted using a QIAGEN gel extraction kit, as per manufacturers 
protocol. 
COMPONENT VOLUME (itL) 
Barn 1-Il buffer 10 
Miniprep plasmid DNA 25 
Restriction enzyme Barn Hi 2 
Restriction enzyme Nde 1 2 
DW 61 
Table 3-2 Reaction mixture for digestion of cloned gene 
from PCR script 
COMPONENT VOLUME (pt) 
Barn H! buffer 10 
pET expression vector (500ngiL' STOCK) 2 
Restriction enzyme Barn Hi 2 
Restriction enzyme Nde 1 2 
DW 84 
Table 3-3 Reaction mixture for digestion of pET expression vectors 
3:2:6 Ligation of DNA into Expression Vectors 
Ligation reactions were prepared and incubated at 16 °C for 1 hour. Reaction 
mixtures are shown (table T3-4) The molar ratio of vector to insert was -.1:3. XL1O 
gold ultracompetent cells were then transformed and plated out on agar, amp 100, for 
overnight growth at 37 °C. 
COMPONENT VOLUME (J.LL) lox T4 ligase buffer 2 
T4 DNA ligase 1 
Digested hCypA gene 4 
vector (pET 15b vector) 
.[
n 	DW 2(l) 1 	11 	(12) 
Table T34. Ligation reaction mixtures. 
Replicate plates were then prepared as before, with PCR screening of the 
corresponding 20 eppendorf samples. A 1 ml batch of reaction mixture was prepared 
for each vector (table T3-5). In each case 45j..tl of this premix was added to 5l.tl  of 
lysate, and 30 cycles of PCR run as before. Primers used for the pET5a PCR were 
those used previously, the primers used for the pET15b PCR were specific to the 
vector, amplifying not only the hCypA gene, but the lac operator (upstream), and the 
T7 terminator (downstream). 
COMPONENT VOLUME (p.L) 
1 1.IX PCR buffer 90 
Tag polymerase 4 
Forward primer 22 (6) 
Reverse Primer 26 (7) 
DW 770 (800) 
Table T3-5 PCR reaction mixtures for selection of positive 
transformants. pET 15h shown in brackets 
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DNA gels were run with the PCR products (figures F3-G4 and F3-G5), positives 
selected for overnight growth and preparation of glycerol cell stocks. 
3:2:7 Results 
Sequencing of the pET5a and pET l5b constructs after ligation of the hCypA gene 
was carried out as described in materials and methods, and showed that the gene was 
intact, in frame and bore no mutations. 
The figures show the DNA gels from each stage of the cloning procedure. 
Fig F3-GI: gel showing isolated hCypA 
	
Fig F3-G2. gel showing PCR-script 
gene. Lane l-taq polyrnerase, Lane2-vent, 	 vector containing insert. 
Lane3-Pfu, Lane4-taq precision+. The PCR 
product from Lane2 (vent) was selected. 
Fig F3-G3. gel showing digested PCR- 
	 Fig F3-G4: pET5a vector after ligation 
script and hCypA gene. 	 of hCypA gene. 100% positive. 
Fig F3-G5. pETI5b vector after ligation of 
hCypA gene. 90% positive 
67 
3:3 Expression and Purification of Untagged hCypA 
3:3:1 Expression of Untagged hCypA 
Approximately 5mg of hCypA was obtained per litre of cell culture. Occasionally 
protein expression could be somewhat leaky (a small amount of target protein was 
expressed prior to induction), but this was not considered to be particularly 
problematic as there was no apparent affect on cell growth. Some attempts were 
made to increase protein yield, and are outlined in the discussion, but no effect could 
be detected. Figure F3-10 shows samples taken from cultures before and 4 hours 
after induction of expression of hCypA. 






Fig F3-I0. Gel showing expression of native hCypA. Lanes 
1,4.6.9.1 1-uninduced cultures. Lanes 2,53.10.12 —cultures 4 hours 
after induction of protein expression. Lanes 3 & 8 are marker protein. 
The faint hands in lanes 4 and 9 alongside the hands marked hCypA 
show the'leaky' expression of some protein prior to induction. 
W. 
3:3:2 Purification of Untagged hCypA 
As described in materials and methods, the native form of hCypA generally purified 
in one step of cation exchange chromatography, across an sp-sepharose column. A 
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ctions (pink line indicates concentration of NaCl) 
Figure F3- I I: chromatogram showing peak corresponding to 





M 	- Fractions across peak 
Figure F3-12: SDS-PAGE showing purified hCypA after one run on  sp- 
sepharose column 
3:3:3 Expression of His-hCypA 
The 6X his-tagged protein expressed rather better that the non-tagged version under 
the conditions described, yielding approximately 10mg of protein per litre of cell 
culture. The SDS gel shown in figure F3-13 shows samples taken from cultures 
before and 4 hours after induction of protein expression. 
1 	2 	3 	4 	5 	S 	7 	I 
47.5kDa 	-. - 
. 325k0a 
25kDa 
40 hCypA 	 40 
1 6.5kDa 
e,. 	 WOO* 
• 
Fig F3-13. Gel showing expression of His hCypA. Lanes 1.4 &7- 
uninduced cultures. Lanes 2.5 &8- cultures 4 hours after induction of 
protein expression. Lanes 3 & 6 are marker protein. 
we 
3:3:4 Purification of 6X His-hCypA 
The 6X His tagged form of hCypA purified cleanly and in one step across a Nickel-
NTA column. Protein eluted at around 50mM - 60mM Imidazole ( 20% buffer B ). 
A chromatogram is shown in figure F3-14. A gel showing the purified samples is 
shown in figure F3-15. 
I 	 4- 
Column Fi1acti4ns (pink Inctes iinidaLefltration) 
Fig F3-14. Chrornatogram showing His-hCypA eluting at 5OmM Imidazole 
32 .5 kDa 
-- 	Fractions across peak 	- 
Fig F3-15. SDS Page showing purified His_hCypA 
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3:4 Characterisation 
3:4:1 Western Blot 
Both hCypA and 6X his-tagged hCypA were subjected to western blot analysis, as 
described in materials and methods. Both proteins showed positive on western blot 
analysis. 
3:4:2 Mass Spectroscopy 
Mass spectroscopic analysis was carried out by the proteomics facility at Edinburgh 
University. Bands corresponding to hCypA and 6X his-tagged hCypA were cut from 
SDS gels and submitted for tryptic digest and mass spectroscopic analysis of the 
peptide sequences. Results confirmed that proteins were hCypA. Shown in figure 
F3-16 is the mass spectrometric result for the untagged hCypA. 
Considered modifications: I Peptide N.termivai Gin to ptro(1u I Oxidation of M I Protein tc-tcrininus Acetvlated I 
Mm. It 	Peptide Mass 	Peptide 	 Max. It 	 Input It 
Digest 	
MSC1 
Cysteines 	 Peptide 	Peptidc 
Peptides Tolerance Masses 
Used Modified by N terminus C terminus 	
Peptide 
to Match 	(t II 	 Irc 	Trypsin Cleas ages carbamidomethylation Hydrogen (II) Free Acid (0 H) 	
Masses 
4 	50.000 ppm monoisotopk 	 2 	 70 
Result Summary 
Protein 	, 	, SwissProt.i6()e103 MOWSE 
Rank 	 Masses 	 Protein Name 
Matched \1W (Da)/pI SpeCies 
	
Accession It Score 
I 1.78e+004 14/70(20%) 18012.6 / 7.68 HUMAN 	111151142 	
Pcptidylprolyi cis-trans isomerase A (PPtase) (Rotantase) 
Cyciophilin A) Cyciosporin A-binding protein) 
Figure F3-16: Section from the mass spectrometric search output for native, or untagged. hCyPA gel 
bands following tryptic digest and mass spectrometric analysis. Results confirmed protein as being 
hCyPA, as the top 'hit'. 
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3:5 Discussion 
All the cloning, expression and purification of human cyclophilin A was carried out 
successfully. Whilst the leaky expression of the untagged hCypA was not considered 
to be particularly problematic as there was no apparent effect on cell growth time, 
attempts were made to increase protein yield. The effect of altering the 
concentrations of IPTG from 0.1mM to 1mM was examined, but no difference in 
protein yield was detected, except for a slight drop in protein yield at lower (<4mM) 
IPTG concentrations. Likewise, there was no noticeable difference either when the 
IPTG was added (in different concentrations), at 0D600 = 0.4, 0.6, 0.8 or 1.0, or 
when the time after induction was increased from 4 to 6 hours. A different cell line 
was also tested, competent BL2 1 DE3 pLysS cells (from Invitrogen) were available, 
and transformed with the pET5a/hCypA vector, but the cells grew poorly, with time 
taken to reach mid log growth markedly increased, and a noticeable decrease in 
protein yield. The same expression protocols for both the tagged and untagged 
protein was therefore used. As full scale protein expression cultures were 4 litres, an 
average yield of 20mg untagged protein and of 40mg 6X his-tagged protein was 
obtained, and considered as the optimal for both systems. 
Protein purification was also relatively straightforward. Initially, purification of the 
untagged hCypA involved two applications to a cation exchange column followed by 
one to a gel filtration column. This was, however, refined. By extending the length of 
time across the salt gradient the protein could be purified in one step of cation 
exchange chromatography using an sp-sepharose column. This therefore minimised 
the time taken, the sample handling, and the potential loss of protein product. The 6X 
his-tagged protein purified quickly and easily across the Ni-NTA agarose column. 
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4WJO 	 16.5 kDa vp 
Figure F3-17: Gel run with pooled samples of purified hCypA. 
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3:6 Cloning Purification and Characterisation of hFKBP12 
It was anticipated that many of the potential hCypA ligands being tested may also 
have some affinity for hFKBP12. The intention was therefore to clone, purify and 
hopefully crystallise hFKBP12 in order to compare and contrast the binding of these 
ligands with the two enzymes. This section therefore describes the steps taken in 
order to produce purified recombinant hFKBP for testing. 
3:7 Materials and Methods 
3:7:1 Brief Overview of Strategy 
The techniques employed in order to clone the gene for hFKBPI2 and ligate this into 
expression vectors were essentially the same as those which are described for hCypA, 
and therefore are described in the previous section. Specific changes which were 
made to that strategy are described. 
The expression vectors pET5a and pET15 (Novagen, described in section 3:2:1) and 
pQE30 (Qiagen, for expression of protein with a non-cleavable N-terminal hexa-his 
tag) were selected as the final destination for the gene for hFKBPI2. A map of the 
pQE30 vector is shown in figure 173-18. The cDNA template was taken from a 
library of human lung tissue cDNA (Stratagene). After running a polymerase chain 
reaction and identifying products corresponding to hFKBP DNA, these were then 
ligated into an intermediate vector, PCR-script, as before. These were then used to 
transform XLIO gold (Stratagene) cells, which were screened to identify those 
containing the vector. After overnight growth and miniprepping, these intermediate 
vectors were digested with the appropriate restriction enzymes. These hFKBPI2 
DNA sequences with restriction sites were then ligated into the relevant expression 
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vectors, which were used to transform XL1O gold cells and cell stocks prepared and 
stored at -80°C. The sequence of the gene encoding hFKBPI2 and its corresponding 
peptide sequence is shown in figures F3-19 and F3-20 respectively. In all cases, the 
DNA polymerase used was vent, as used in the cloning of hCypA. The thermal 
cycler program was adjusted however. Where previously the strand extension 
temperature of 72 °C was maintained for 1 minute, as the gene for hFKBPI2 was 
—300bp as opposed to —500bp for the hCypA gene, the time was reduced to 30 
seconds. 
I 	-- 
PT5 	bc 0- bc 0 RBS 	]-- MCS 
• pQE-30 - - 
pQE-31 AC 
pQE32 - G 
.c. 




Figure F3-18. Vector map showing pQE30 vector. The gene for hFKBP 12 was inserted into the 







Figure F3-19. The genetic sequence for human FKBPI2 
: 'JAL GLN VAL G L U TMP I LE SEP ?P.0 GLV AiP G L Y APG 
T!. PHE PP.0 LYS ARG GLY GLN THR CYS VAL VAL HIS TYR 
THR CLY MET LEU GLU ASP CLV LYS LYS PHE ASP SER SER 
ARC ASP ARC ASN LYS PRO PHE LYS PHE MET LEU GLY LYS 
GLN GLU VAL ILE ARG GLY TRP GLU GUT GLY S/AL ALA GLN 
MET SER VAL GLY GLN ARC ALA LYS LEU THR ILE SER PRO 
ASP TYR ALA TYR GLY ALA THR CLV HIS PRO CL? ILE ILE 
PRO PRO HI A LA TtP LFU 'AL Pr-rE ASP AL UT LET1 LELT 
LYS IFTI f' 
Figure F3-20. The amino acid sequence of human FKBPI2. excluding initiating Met 
3:7:2 Primer Design and Isolation of hFKBP12 Gene 
The DNA sequence of the gene for hFKBPI2 was studied in order to identify any 
intrinsic restriction sites. A restriction map of the hFKBPI2 gene is shown in figure 
F3-21. Two sets of primers were designed and ordered from Sigma, one had the 
Ndel restriction site upstream and Bain HI downstream, designed for the pET 5a 
and pET 15b vectors (as described in section 3-2-2), the other set had Barn Hi 
upstream and Hind III downstream, designed for the pQE30 vector. Primers are 























Figure F3-21. Restriction map showing the gene for IIFKBPI 2 and potential restriction sites. 




5' - GCGCCATATGATGGGAGTCCAGGTGGAA/ -3' (sense) 
3 1- 	 TACCCTCAGGTCCACTTT -5' (antisense) 
I. 
	 5' - 	1CTTCTAAAACTGGATGA 	 -3' (sense) 
3' - CTCGAAGATTTTGACCTTACTCCTAGGCGCG -5' (antisense) 
5' - GCGCGGATCCATGGGAGTCCAGTGGAAC -3' (sense) 
3' - 	 TACCCTCAGGTCC:ACCTTTG - S' (antisense) 
5' - 	CTTCTAAAACTGGAATIJA 	 -3 '(sense) 
3' - GAAGATTTTGA(-'CTTTTTCGAACGCG -5' (antisense) 
Figure F3-22.Primers ordered for hFKBPI2 cloning. A) Primer designed to hind antisense 
strand. at 5' end of gene, with restriction site for Ndel shown in blue. B) Primer designed 
to bind sense strand, at 3' end of gene. with restriction site for BamHl shown in blue. C) 
Primer designed to hind antisense strand at 5' end of gene, with restriction site for BamHl 
shown in blue. D) Primer designed to hind sense strand, at 3' end of gene. with restriction 
site for Hindlil shown in blue. Primers A & B for ligation of gene into pET5a and 
pET15b vectors. Primers C & D for ligation of gene into pQE30 vector. 
3:8 Results 
Following the ligation of cloned hFKBP12 gene into the three expression vectors and 
the transformation of XLIO gold ultracompetent cells, replicate plates were prepared 
and PCR reactions performed as described previously (Ch.2:6). The DNA gels 
showing PCR product are shown in figures F3-G6 and F3-G7. Lanes 1-20 show 
pET5a vector, lanes 21-40 show pQE30 vector, and lanes 41-60 show pETl5b vector. 
Positives were visible in lanes 2, 3, 4, 6, 7, 8, 9, 10, 12, 13, 16 (pET5a); 23, 29, 30, 
31, 35 (pQE30); 50, 51, 52, 53, 54, 55 (pET l5b). Sequencing analysis (described in 
chapter 2:8) confirmed that the gene was intact and no mutations were present. 
1PIPV 	PLM ., 
KSPI 
El 17449bO5112i M6 5657109I0 
L 
Figure F3-G6: DNA gel showing positives 
from cloning into pET5a/pQE3() vectors 
Figure F3-G7: DNA gel showing positives 
from cloning into pQE30/pETl5b vector 
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3:9 Expression and Purification of hFKBP12 
The protocols for the expression of hCypA, described in chapter 3, were also 
followed for hFKBP12, and were the same for both the tagged and the untagged form 
of the protein. Some attempts were made to increase yield, and are described in the 
discussion, but no benefit was gained. Likewise, the purification of the 6X His-
hFKBPI2 was also the same as that for 6X His-hCypA. 
3:9:1 Expression of Untagged hFKBP12 
Protein expressed well under the conditions described, with a yield of between 10 
and 15mg of protein per litre of culture. Figure F3-23 shows an SDS gel run with 
samples of cell culture taken before and 4 hours after induction. 
1 	2 	 4 	 5 	1 




Figure 173-23 Gel showing expression of native FKBPI2. Lane I shows marker protein. 
Lanes 2,4 & 6 show samples taken before induction of expression uI1iFKBPI2. Lanes 3. 5 
& 7 show samples taken 4 hours after induction of expression of hFKBPI2. 
3:9:2 Purification of Untagged hFKBP12 
Attempts were made to purify the native form of hFKBPI2. These involved both 
cation and ion exchange chromatography. The calculated isoelectric point of 
FKBPI2 (from Expasy) is 8.2. Cation exchange chromatography across an sp- 
sepharose column was carried out at a pH of 7.2, 6.8 and at 6.0, but was unsuccessful, 
as protein would not stick to the column. Anion exchange chromatography across a 
DEAE-cellulose column was carried out at a pH of 9.0, and at 9.5, with similar 
results. No more attempts were made to purify native hFKBPI2. 
3:9:3 Expression of His-hFKBPI2 
Protein from both the pET 15b construct and the pQE30 construct expressed well 
under the described conditions, yielding around 15mg of protein (pET 15h construct) 
and 20mg of protein (pQE30 construct) per litre of culture. Figure F3-24 shows an 
SDS gel run with samples taken before and 4 hours after induction from a cell culture 
transformed with the pQE30 construct. 







Figure F3-24. Gel showing samples taken before and after induction of 
expression of His-FKBPI2 from a cell culture transformed with the 
pQE30 vector. Lane 3 - marker protein. Some basal protein expression 
can he seen in uninduced samples (lanes 1. 3 and 6) 
3:9:4 Purification of 6X His-hFKBP12 
Both forms of hFKBPI2 purified quickly and easily across a Ni-NTA agarose 
column, following the same protocol as that for 6X His.-hCypA. Protein eluted at 
around 20% imidazole (50-60mM), with a similar peak to that seen for hCypA. This 












Column fractions. ti . Pink line indicates imidazole concentration 
Figure F3-25: Chromatograrn output showing peak corresponding to hexa-his tagged 




Figure F3-26: SDS-PAGE showing purified hexa-his tagged hFKBPI 2 after 
running across nickel column. 
3:9:5 Characterisation 
Protein was subjected to western blot and mass spectroscopic analysis as described 
previously, and results were positive for hFKBPI2. The western blot is shown in 
figure F3-27. 
* 	 .-- 
Figure F3-27: Western blot from gel run with FKBPI2 (gel not shown) 
3:10 Discussion 
Three constructs for the expression of hFKBPI2 have been synthesised. Whilst all 
forms of the protein showed reasonable yield, some basal, or leaky expression of the 
product from cells carrying the pQE30 vector (for the small, non-cleavable his-
tagged form) could be seen (this is visible in figure F3-24) attempts to minimise this 
were made by transforming and expressing protein using BL21 DE3 pLysS cells 
(Invitrogen). Unfortunately, these were ineffective, and only served to extend the 
time taken to reach a cell density of 0.6 at A600, by around 50%; and overall protein 
yield fell by about 30%, even after leaving cultures for up to 6 hours prior to 
harvesting cells. As this was the vector which gave the greatest protein yield when in 
BL21 DE3 cells, no further attempts were made to minimise this. 
Whilst the 6X his-tagged forms of the protein expressed quickly and easily by metal 
affinity chromatography, problems occurred in attempting to purify the native, or 
wild type form. Several attempts were made to purify the protein by anion exchange 
chromatography. Efforts were made to purify the protein by cation exchange as 
described for native hCypA, but were unsuccessful at the different pHs tried. It was 
then attempted to purify the protein by anion exchange. By suspending the protein in 
buffer at pH values greater than the isoelectric point of the protein, it was hoped that 
the protein would carry an overall negative charge and bind to the positively charged 
DEAE-cellulose column (Pharmacia). This did not occur, however, and protein was 
present in the flow through. As the main focus of the project was hCypA, and 
purified 6X his-tagged versions of hFKBPI2 were readily available, no more 
attempts were made to purify the native form of the enzyme. 
M. 
CH 4: Biophysical Analysis of Protein Ligand Complexes 
4:1 Introduction 
The study of biological role of a particular protein involves not only the study of the 
structure of the macromolecule, but also an appreciation of its affinity for other 
molecules such as substrates and inhibitors. This is particularly important where the 
protein is being studied with a view to designing potential new ligands specific to the 
protein. Values considered when studying enzyme ligand binding include K1 (the 
Michaelis constant), Kd (the dissociation constant), K (the inhibition constant) and the 
1050 (the ligand concentration at which 50% enzyme activity is inhibited). These 
values are briefly described in the following paragraphs, the constants given hereafter 
are K, K 111 and 1050. Another binding constant, Kcl.) S t , the binding constant in crystals, 
is described in chapter six. 
4:1:2 The Dissociation Constant (Kd) 
The dissociation constant describes the affinity of a particular ligand, substrate or 
effector molecule for an enzyme, and is the inverse of the Association Constant (Ka). 
Where protein and ligand are in solution, and assuming that no further reaction 
beyond EL takes place, then the following equation describes the formation of 
protein ligand complex, where k +1 is the rate of the forward reaction, and k 1 is the 




Where Ka can be described by the following equation: 
Ka = [EL]/[E][L] 
Then Kd can be described as: 
Wl 
Kd = [E][L]/[EL] = 1/Ka 
The lower the Kd value (and therefore the higher the Ka value), the greater the affinity 
of a ligand for a particular enzyme. Where the concentration of ligand in solution is 
equal to the Kd value, then 50% of the binding sites will be filled, ie, 50% occupancy. 
An occupancy of 90% requires a ligand concentration of nine times the Kd value; an 
occupancy of 99% requires a ligand concentration of 90 times the Kd value. Generally, 
when identifying potential ligands for an enzyme in order to develop into drug 
candidates, a Kd value in the micromolar range is a useful starting point. 
4:1:3 The Inhibition Constant (K1) 
Another value which is often referred to in the study of enzyme kinetics and ligand 
binding is the inhibition constant, or K1. Where an inhibitor (ligand) competes with 
substrate in protein binding, then K1 may be taken to be equal to Kd, as K i is the value 
where 50% binding sites on the protein molecule are occupied by ligand. This can be 
seen in the following equation. 
Ki = [E][L]/[EL] 
It should be stated that this only applies where ligand competes with substrate for 
binding sites, not where ligand hinds non-competitively (where ligand may bind to 
both free enzyme, to an enzyme substrate complex, or in allosteric binding) or where 
ligand binds uncompetitively (where ligand binds to enzyme-substrate complex, but 
not to free enzyme). 
4:1:4 The 1050 Value 
This term, the Inhibition Concentration (also termed EC50, the effective 
concentration) at which 50% of maximum enzyme activity is inhibited, is also used. 
The 1050 value can be determined from a graph such as that in figure F4-1, where 
the log of the ligand concentration (in order to obtain a linear portion in the area 
between 25-75% maximum rate) is plotted against reaction rate, or ligand occupancy. 
Often the 1050 (or EC50) value is quoted rather than Kd, K 1 or K 1 . 
Cr: 
Figure F4-l. Sigmoidal plot showing how 1050 value may 	obtained from plotting 
the log of the ligand concentration against the reaction rate 
The 1050 for a particular ligand or inhibitor can be related to K1 from the following 
equation, assuming a knowledge of K 11 for the substrate. 
Ki = 1050 I 1+([Substrate]/Km) 
Therefore: 
1050 = Ki (1i-([Substrate]/Km)) 
4:1:6 The Michaelis Constant (K m ) 
The Michaelis constant describes the substrate concentration at which the rate of a 
reaction is half the maximum, or limiting rate. Where a reaction follows the route: 
li 	k.2 
E+L4 ' EL 	E+P 
then the Michaelis Constant may be described by the equation: 
Km = k 2 + k. 1 I k 1 = [E+P][E][L]/[EL] 
Where a ligand being examined is not a substrate, no product is formed, therefore 
K 11=K1. Indeed, even where a ligand is a substrate and product is formed, then 
provided K 1 ~! K+2 then this is still the case. 
4:1:7 Techniques 
There are many possible techniques for studying the binding of ligands (or potential 
ligands) to proteins, allowing the calculation of the affinities of these compounds for 
the protein. In some cases, there may be a well documented, reliable assay specific to 
a particular protein, allowing the accurate measurement of binding constants, 
inhibition constants and 1050 values. Other methods for examining enzyme - ligand 
binding include fluorescence spectroscopy (146), isothermal titration calorimetry 
(147), differential scanning calorimetry (148), mass spectrometry (149), or the 
relatively new technique of surface plasmon resonance (150,151). Experimental 
techniques described here include fluorescence spectroscopy, surface plasmon 
resonance, isothermal titration calorimetry, and mass spectrometry. Some proved 
more successful than others. All are described. 
4:2 PPIase Assay 
The basis for this assay is the function of Cyclophilin A as a petidyl-prolyl isomerase 
(53,56), and has been described in the literature (152). By utilising a 
chemi luminescent substrate, covalently linked to a polypetide, of the form Suc-Ala-
Ala-Pro-Phe-pNA, and cleavable by chymotrypsin only whilst in the trans 
conformation, the activity of cyclophilin may be measured by the optical intensity of 
the cleaved pNA at 400nm (figure F4-1). A modification of the original assay, where 
the substrate is dissolved in buffer consisting of LiCI and trifluoroethanol, has been 
described as increasing the conformational equilibrium of cis/trans isomers in 
solution from --12% cis to -40% cis, thus slowing down the initial 'burst' phase of 
the reaction by reducing the amount of cleavable trans isomers present (55). 









0 	 cis 
Fig F4-l. Schematic showing the conversion from cis to trans and the 
cleavage of cheniiluminescent p-nitroalanine 
IM 
Ideally, as the reaction proceeds very rapidly, the initial 'burst' phase lasting for only 
a few seconds, the spectrophotometer should have built in stirring mechanism. This 
allows the reaction cell to be placed in the ultraviolet beam before addition of 
substrate, dispensing of the need for prior mixing and enabling the reaction to be 
monitored from the start. Reactions should be allowed to progress at a constant 
temperature of 4 °C. 
At the time of undertaking the analysis of potential dimedone-based ligands 
(described in chapter 1), owing to problems with the peltier thermostat on the 
spectrophotometer, causing large fluctuations in temperature (often climbing from 
4°C to above 20°C in the space of a few minutes), and the absence of a built-in 
stirring mechanism, meaning that prior mixing was necessary and the initial burst 
phase was missed; any results obtained were not only irreproducible and unreliable. 
For completeness, however, the following sections describe the preparation of 
buffers and solutions for performing the described PPIase assay to test ligand KM 19. 
Data was collected later for the dipeptide Val-Pro binding to hCypA, by Dr M. Wear. 
The binding curve is shown in figure F4-2, Ki values are shown in figure, together 
with the curve obtained for Val-Pro. The Ki value obtained (18.6 ± 8.7mM) 
compares favourably with the crystallographic binding constant obtained later, 
described in chapter 6. 
4:2:1 Materials and Methods 
Solutions prepared:- 
Assay buffer - 50mM Hepes, 100mM NaCl, pH 8.0 
Chymotrypsin solution - 6mg.mF 1 chymotrypsin in 10mM HCI 
Substrate buffer - 470mM LiCI in TFE 
KE 
The Hepes, NaC1, TFE and LiCI were from Sigma, the substrate was supplied by 
Bachern. 
4:2:2 Experimental Procedure 
A stock solution of protein, at a concentration of 2iM, was prepared in assay buffer 
and its concentration checked by Bradford assay. The final concentration of protein 
in assay vessel was 20nM. The SAAPFpNA substrate stock was prepared in 
LiCl/TFE to a final concentration of 4mM. The final concentration of substrate in 
assay vessel was l20nM. 
860pJ of assay buffer was pipetted into a ImI cuvette, and to this lOpi of protein 
solution was added, this was then incubated at 4 °C for 1 hour. 10Oil of chymotrypsin 
solution was added, followed by addition and rapid mixing of 30pi of substrate 
solution to start the reaction. The reaction proceeded at 4 °C, the release of p-
nitroalanine was measured at 400nm, over a period of 120 seconds, using a 
spectrophotometer fitted with a peltier mechanism. 
Ligands were tested by dissolving in ethanol to a final concentration of 1mM, and 
adding quantities ranging from 5 to 50p1 to the reaction vessel. The amount of assay 
butler present was adjusted accordingly to compensate, keeping the total reaction 
volume at lml. 
The table T4-1 shows the volumes of the different solutions added to the reaction 















865 5 0 30 lOC 
860 5 5 30 1 0 
855 5 10 30 lOC 
if 850 5 15 30 lOC 
20 845 5 20 30 1 0 
25 840 5 25 30 10C 
30 835 5 30 30 1 0 
35 830 5 35 30 1 0 
40  825 5 40 30 10C 
4f 820 5 45 30 lOC 
5( 815 5 50 30 lOC 
Table T4-1. The volumes of solution added to reaction vessel for PPIase assay of 
compound KM 19. All volumes are in microlitres 
4:2:3 Binding Constant for Dipeptide Val-Pro 
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Figure F4-2. The dipeptide Vat-Pro binding hCypA. Data obtained by PPlase 
assay, by Dr. M. Wear. K, for Val-Pro binding hCypA 18.6 ± 8.7mM. 
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4:3 Isothermal Titration Calorimetry ( ITC) 
4:3:1 Brief Description 
Where a chemical reaction is accompanied by a change in enthalpy, according to the 
energy associated with the reaction, ie, whether the reaction is exothermic or 
endothermic, measuring enthalpy changes allows the progress of a reaction to he 
followed. This property can be utilised to study the dynamics of protein - ligand 
binding, and is finding increasing application in the field of enzyme kinetics and 
drug discovery (147,153 -156). 
Isothermal titration calorimetry is a technique which is used to measure the change in 
temperature when different solutions are mixed. More specifically, it involves 
measuring the change in temperature in a reaction cell, on addition of some other 
solution, and comparing this to a reference cell, which is maintained at constant 
temperature. In a typical ETC experiment, where protein - ligand binding is being 
studied, the temperature of a reaction cell (which may contain protein), is monitored 
and compared with the temperature of a reference cell, shown in figure F4-3. 
Titration of ligand into the reaction cell results in a change in enthalpy, and by 
making a series of titrations into the reaction cell, the associated temperature changes 
(AT) can be extrapolated to give information regarding affinity. The following 
equations show the relationship between AT, AH and AG:- 
AG= H-TAS 
AG = -RT InK 
where AG is the free energy, AH is the enthalpy, T AS is the entropy. K is the affinity 
constant, R is the gas constant (8.314 J mol' K 1 ) and T is the absolute temperature. 
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From the Van't Hoff equation:- 
lnK=AH/RT-&S/R 
A plot of InK versus I / T gives a straight line of slope -AH/RT 
and an intercept of AS / R. 





Fig F4-3 The feedback mechanism in the ITC cell system. From the microcal 
webs ite 
4:3:2 Materials and Methods 
4:3:2:1 Initial Studies 
Initial ITC experiments to examine the binding of dipeptides against hCypA were 
performed at the facility provided by Glasgow University. Dipeptide solutions were 
prepared in buffer (50mM Hepes, 100mM NaCl, pH 7.0) to a concentration of 
100mM. Protein solution was prepared to a concentration of 1mM, in identical 
buffer. Protein concentration was checked at A280. Expected Kd values for the 
dipeptides was in the region of 20 - 50mM. A major practical problem with this 
approach however, is that where affinities are very low (sub micromolar), the AH 
signal is very small. Background effects, such as heats of dilution, are high, and can 
all 
easily mask the enthalpy changes produced on ligand binding. This was evident 
when the experiment was run. A very high signal to noise ratio was apparent, and 
data could not be analysed with any accuracy, attributed, in part, to these heats of 
dilution. The other likely cause of the high background noise was in the maintaining 
a consistent p1-I across all solutions. Changes in pH on mixing solutions in the 
reaction cell were thought to be another contributory factor. 
4:3:2:2 Competition Binding 
Where ligand affinity is low, it has been shown how it is possible to measure the 
change in enthalpy by performing a competion assay, where a ligand of known 
affinity competes with one of unknown affinity for binding sites on the enzyme 
(157). 
A competitive binding assay was designed, with the help of Dr. R. O'Brien of 
Microcal, where, by titrating a solution of dirnedone derivative KMI9 against a 
solution containing hCypA only and measuring the enthalpy changes, the binding of 
the dimedone derivative KM19 to hCypA would be measured. Then by titrating 
KM 19 against a solution of hCypA which had been incubated with dipeptide (shown, 
fig 174-4), the KM 19 should compete with the dipeptide in binding to the protein, 
producing a different thermodynamic spectra, allowing the affinity of the dipeptide 
for the hCypA to be established, i.e 
Kapp = Ka (high affinity ligand}/1 + Ka {low affinity Iigand} 
Where Kapp is the apparent K,, value gained from a competition binding assay such as 
this, shows how the Ka value for the weaker binding ligand may be estimated, 




MM /IC\ p-\ + I 	tiM dipeptid 
Fig F4-4: the titration of KM 19 into the reaction vessels. KM 19 
competes for binding sires with dipeptide. 
Solutions prepared were therefore:- 
• Buffer A - 50mM 1-Lepes, 100mM NaCl, pH 7.0, 0.5% EtOI-l. ( protein, 
protein/dipeptide buffer) 
• Buffer B - 50mM Hepes, 100mM NaCl, pH 7.0 ( KM 19 buffer) 
Protein stock (1mM) was dialysed overnight against 5 litres buffer A, then diluted 
using the dialysate to give a final concentration of 50iM, with a final volume of 
25m1. Protein concentration was checked at A280. 
For each dipeptide, 3m1 of this protein solution was taken, and dipeptide dissolved to 
a final concentration of l00.tM. 
The KM 19 stock (100mM in EtOH) was diluted to 500p.M in buffer B, to a volume 
of lOrnl. The ethanol concentration in the KMI9 solution was therefore 0.5%. The 
pH of all solutions was checked. 
W. 
Unfortunately, due to the poor solubility and hydrophobicity of ligand KMI9, 
problems were incurred when injecting it into the reaction cell, and it appeared to be 
coming out of solution and sticking to the walls of the injection syringe. 
4:3:3 Discussion 
Whilst isothermal titration calorimetry has been shown to be an efficient technique 
for measuring protein-ligand binding, with many advantages, such as the direct 
measurement of reaction enthalpy, making the need for Van't Hoff analysis 
unnecessary (158) it is obviously not without its disadvantages. Often large amounts 
of protein are required, and where affinity is low, high concentrations of 
ligand/substrate are also necessary, which can lead to high background effects, heats 
of dilution and pH effects. It may also be a problem where ligand is not soluble in the 
same buffer as the protein, making the addition of organic solvents necessary. As 
solutions require to be identical, this would mean the addition of organic solvent to 
the protein solution in equal concentration. Prolonged exposure to organic solvent 
may denature the enzyme being examined. That said, where time is available, careful 
elucidation of an environment where both protein and ligand are stable, optimisation 
of the experiment, or the design of a competion style assay may allow kinetic 
parameters to be measured. 
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'4:4 Fluorescence Spectroscopy 
4:4:1 Brief Description 
This technique takes advantage of the properties of aromatic residues phenylalanine, 
tyrosine and tryptophan, which absorb radiation in the range X = 270 - 290nm, and 
emit fluorescence spectra in the range X = 305 - 340nm. The tryptophan residue, 
Trpl5l, which sits at the bottom of the binding site of hCypA, emits at X = 340nm, 
and can be utilised to measure ligand binding to the protein as this emission is 
quenched on binding of ligand at the active site of the protein. By titrating ligand 
solution against protein solution, therefore, the progressive quenching of the 
fluorescence spectra allows the measurement of the affinity of the ligand, and there 
are many good descriptions in the literature of fluorescence spectroscopy being used 
in the determination of ligand binding constants (146,159,160) 
4:4:2 Materials and Methods 
For the testing of ligand KM 19: 
Solutions prepared:- 
Protein solution:- l0iM /iCypA in 50mM Hepes, 100mM NaCl, pH 7.0 
Ligand stock:- 2.5 mM in EtOH. 
Although DMSO was considered as a solvent for some of the more insoluble ligands, 
its use was decided against, as it is known to bind hCypA. A series of titrations 
where only DMSO was titrated against protein solution were carried out and no 
change in fluorescence spectra was observed. It was therefore established that, whilst 
DMSO is known to bind hCypA, it is too small a molecule to have a quenching 
effect on the tryptophan residue, although where it is present, it is likely to interfere 
with the binding of other ligands to the protein. 
W. 
Protein solution was pipetted into the reaction vessel (quartz cuvette) to a volume of 
lml, and incubated for 30 minutes on ice. This was placed in the spectrophotometer 
(LambdaMax), and the fluorescence emission spectra recorded from 300 to 500nm. 
Ligand solution was then titrated into the reaction vessel at volumes from 1 to 5p.l, 
with the emission spectra recorded at each successive titration. Reaction vessels were 
maintained at 4°C throughout. 
4:4:3 Data Analysis 
Data was analysed using the software Sigmaplot 8.0 and Microsoft excel. 
Fluorescence spectra for titrations of the dimedone ligand KMI9 is shown in figure 
F4-5, the volumes used are shown in table T4-2. 
The Michaelis constant, K 01 , described in section 4-1-6, was determined by plotting 
fluorescence data obtained on an Eadie - Hofstee plot, ie, the change in 
fluorescence/ligand concentration versus the change in fluorescence. The slope of the 
resulting plot is equal to -1/K 01 . This is shown in figure 174-7. The Eadie-Hoffstee 
equation is shown:- 
V0 = Vmax - Km ( V(J[Si) 
The dissociation constants for each ligand were obtained by plotting the ligand 
concentration in the reaction vessel at each titration vs the resultant change in 
fluorescence signal, sigmaplot 8 was then used to calculate Kd. 
The change in fluorescence was taken to he the initial, unquenched tryptophan signal 
(F0 ), minus the quenched tryptophan signal (17 1 ), divided by F0. The equation for 
fluorescence quenching:- 
AF= FO- F 1/F0 
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Figure F4-5. Fluorescence spectra showing quenching of tryptophan 
fluorescence with successive titrations of KM 19, concentrations ranging from 
01tM-76. I 6tM. Spectra was recorded from 300-500nm. tryptophan peak can he 
seen at 340mm, with unquenched maxima at 150x10 ° counts per second 
The Kd value for KM 19 obtained using sigmaplot was 29.5 lpM, with a Vmax of 1.1. 
From the Eadie Hofstee plot the K m  value was 25.0611M. The data for each 
successive ligand titration is shown in table T4-1, the graph in figure F4-6 shows the 
curve obtained when ligand concentration is plotted against change in fluorescence, 
and the graph in figure F4-7 shows the Eadie - Hofstee plot, from which the Km 
value was obtained. 
ligand conc. 
(micromol)  
Fluorescence dF dF/[L] 
0 51651590 0 0 
2.5 45837783 0.112 0.0448 
4.99 43940483 0.149 0.0298 
9.96 35769788 0.3 0.0301 
12.4 34258232 0.336 0.027 
14.9 31408369 0.392 0.026 
17.37 30297468 0.413 0.023 
22.3 29185890 0.435 0.019 
27.3 24673819 0.522 0.019 
29.64 22230237 0.569 0.019 
34.5 19429732 0.624 0.018 
39.37 19702196 0.62 0.015 
44.2 17148178 0.66 0.014 
49 15802208 0.69 0.014 
53.8 14750217 0.714 0.013 
58.5 13483376 0.74 0.012 
63.4 12327945 0.76 0.011 
75.16 9414653 0.817 0.0108 
Table T4-2. Volumes, concentrations and fluorescence intensities for titration of KM 19 
against hCypA. 
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Figure F4-6 Graph plotted using sigmaplot 8. showing change in fluorescence 
signal at increasing concentrations of ligand KM 19. Calculated Kd value from 
this curve was 2 I M. with a Vmax of 1.1 
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Figure F4-7.Eadie-Hofstee plot showing change in fluorescence vs change in 
tluorescence/KMI9 concentration. The slope of the line is equal to -I/Km. 
4:4:5 Other Ligands 
Other ligands tested for binding to hCypA using fluorescence spectroscopy were 
KM 135, for which a Kd value of 12611M was determined, E3, with a Kj of 24.8p.M. 
Structures of these ligands and the Kd values obtained are shown in figure F4-8. 
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Figure F4-8 Structures of dimedone derivative based ligands tested for binding to hCypA by 
fluorescence spectroscopy, and the Kd values obtained after analysis with sigmaplot 
More recent fluorescence analysis has since been performed by Dr. M. Wear on 
dimedone based ligands as they became available, at 25 °C. The structure of these 
ligands and the K(I values obtained from this set of experiments are shown in figure 
F4-9. 
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Figure. F4-9 More recent fluorescence analysis of other dimedone based ligands showed 
Kd values compararable to those obtained previously 
4:4:6 Discussion 
The initial studies (figure F4-8) allowed further research into this new range of 
dimedone - derived potential hCypA inhibitors, in that we were able to confirm to 
our colleagues in the chemistry department that binding did occur, and that ligand 
KMI9 was still our'lead' compound, although the addition of the tertiary butyl 
and/or the removal of the phenyl group on ligand E3 may have a positive effect on 
binding affinity. Potential sources of error which were not accounted for during these 
early studies were the 'inner filter effect' (161), whereby fluorescence intensity is 
quenched by ligand leading to underestimation of the association constant. Neither 
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was the contribution made to fluorescence quenching by collisional and static 
quenching allowed for. This occurs where more than one tryptophan residue (or 
whichever is being used as the fluorophore) is present. Collisional quenching occurs 
where ligand binds non-specifically, quenching the fluorescence emitted by these 
other residues, and may be examined by collecting data at two different temperatures 
(usually 4°C and 25°C), and analysing the difference in fluorescence with a Stern-
Vollmer plot. This potential error source was however unfounded in the case of 
hCypA, as the enzyme has only one tryprophan residue, that at position 121. 
Further fluorescent analysis of dimedone based ligands were performed as they 
became available, and showed that these ligands also had a high affinity for hCypA, 
with Kd values in the micromolar range (figure vF4-9) comparable to those results 
obtained earlier (figure F4-8), and to those results obtained by surface plasmon 
resonance, described in chapter 4:6. 
A potential increase in binding affinity on addition of a hydrophobic group, such as 
that seen on ligand KM 184 and on ligand E3 can be seen. This is described further in 
sections 4:6:8 and 7:1. 
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4:5 Mass Spectroscopy 
4:5:1 Introduction 
One mass spectrometric technique has been briefly described in chapter 3, where 
MALDI-TOF (Matrix Assisted Laser Desorption Time of Flight) Mass Spectrometry 
was used as a tool to help characterize protein which had been purified and run on SDS-
PAGE prior to being subjected to digest by the protease trypsin. In this section, the 
technique of Electrospray tonisation (ESE) is briefly explained as a tool for the analysis 
of protein-ligand binding, and was used here to examine the binding between hCypA 
and some of the compounds from the dimedone based ligand library. The hands-on' 
mass spectrometric data collection was carried out by Hannah Florance and Perdita 
Barran, of the Department of Chemistry. 
4:5:2 Brief Overview 
Electrospray lonisation Spectroscopy, developed by Fenn and co-workers in the 1980s 
(162), is a powerful technique for the analysis of proteins and of protein-ligand 
complexes (149,163). It involves the introduction of a charge to the analyte being 
examined (the protein/protein-ligand complex) in order to ionize, which may be either 
positive or negative depending on whether the analyte is to be examined as an anion or a 
cation; and the application of a temperature to vapourise the subject and form charged 
droplets. 
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4:5:3 Materials and Methods 
Human hexa-histidine tagged cyclophilin A was purified as described, and prepared to a 
concentration of 20mg.mi' (-.1.0mM) in 50mM hepes, pH 7.0, 100mM NaCl. Samples 
were then submitted to the chemistry department for mass spectrometric analysis. 
Protein samples were then dialysed overnight at 4 °C into 10mM arnmonium acetate, pH 
6.8, and diluted to 20tM. Ligands were suspended in methanol, and incubated at room 
temperature for 1-2 hours at protein ligand ratios of 1:1 (20.tM ligand), 1:5 (l00l.tM 
ligand), 1:7.5 (150jM ligand) and 1:10 (200iM ligand). Ligand stock solutions were 
adjusted so that the final protein-ligand solution consisted of lOmM ammonium acetate, 
pH 6.8, 10% methanol. Voltages were maintained at 45-50V, and the desolvation 
temperature was 90-100°C. 
4:5:4 Results 
Ligands KMI9 and KMI84 were tested across a range of concentrations, shown in 
figures F4-8 and 174-9 respectively. At low ligand concentration, the K1 values obtained 
appear to he unexpectedly high. This is likely to be attributable to the fact that at this 
concentration, the molarity of ligand in solution is approximately the same, or lower 
than, the expected Kd value, and therefore little binding is seen, and [E] 2 [EL]. At 
higher concentrations of ligand the dissociation constants appear to be more consistent. 
as [E] 	[EL]. All values obtained are shown, and the average values have been 
calculated across the higher ligand concentrations. The K. values obtained at low ligand 
concentrations have essentially been disregarded, although the average values including 
these is shown in brackets for comparison. 
KM19 [1 -(3,3-dimethyl-5-oxo-cyclohex- I -enylcarbamoyl)-2-methyl-propyl]-carbamic 
acid benzyl ester. 
0"~o N NJ LO 
PROTEIN:LIGAND RATIO 1:1 1:2 1:5 1:1.75 AVE. KD 
Kd (tM) 94.53 30.81 39.72 39.64 48.6 
75.49 101.09 45.99 34.74 (5775) 
Table T4-3. Table showing Kd values for ligand KM 19 across a range of 
concentrations. The average Kd value, disregarding the Kd values obtained at 1:1 ratio 
is shown in bold print. The average Kd including the low concentration values is shown 
in brackets. The structure of KMI9 is shown. 
KM184 	[I -(4-aIIyl-3,3-dimethyl-5-oxo-cyclohex- I -enylcarbamoyl)-2-methyl-propyl]- 
carbamic acid benzyl ester. 
C::I'~o N 
PROTEIN:LIGAND RATIO 1:1 1:5 1:10 AVE. KD 
Kd (PM) 290.90 74.12 26.80 41.56 
221.56 34.05 33.57 (102.89) 
39.25 
Table 14-4. Table showing Kd values for ligand KM 184 across a range of concentrations. 
The average Kd value, disregarding the Kd values obtained at 1:1 ratio is shown in bold 
print. The average Kd including the low concentration values is shown in brackets. The 
structure of KM 184 is shown. 
Ligand KM 198 was also tested, at a 1:5 ratio of protein to ligand, as was ligand CD278, 
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Kd = 17.83 jiM 
4:5:5 Discussion 
In some respects, the values obtained here ought to be regarded as tentative, as 
techniques for optimizing the measurement of dissociation constants were being 
optimized at the time of data collection. Possible sources of error are problems involving 
ligand aggregates forming in solution, thereby lowering the concentration of free ligand 
in solution, or potentially competing with free ligand for binding sites; there may also 
have been carry-over between successive runs. It has also been suggested that peak 
intensities showed a high degree of variability and that it may be more accurate to 
calculate Kd values according to peak shape, which could not be done due to software 
limitations. 
The average dissociation constant obtained for ligand KM 19 (48.6j.tM) was remarkably 
close to that obtained by surface plasmon resonance (46.911M); as was that for ligand 
KM 184 (41 .56pM) which also compared favourably with the SPR derived Kd of 36iM, 
(described in section 4:6:7). The Kd value obtained for ligand KM 198 (15.85tM) was 
unfortunately not so close, with an SPR derived Kd of 73.6iiM, although this may be 
attributed to one of the potential sources of error described above. That said, it was 
encouraging that the Kd values obtained for KMI9, KM 184 and KM 198 were all in the 
low micromolar range. 
It is also interesting to see that the Kd for the cyclised dimedone derivative CD278 was 
in the low micromolar range. Whilst the structure of this appears quite different from the 
other dimedone derivatives, it may be that the cyclised dimedone moiety is assuming a 
similar conformation in the hydrophobic pocket, and the extra oxygen contributes to 
hydrogen bond interactions, possibly with the Arginine residue at position 55, although 
without the complex structure the conformation this can only be conjectured. Structure 
activity relationships of ligands are described in section 6:4:9 and in chapter 7. 
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4:6 Surface Plasmon Resonance 
4:6:1 Brief Description 
A relatively new technique, surface plasmon resonance has become more widely 
exploited as a means of characterising protein interactions since the first commercial 
instrument became available in 1990 (150), and there are many examples in the 
literature describing its use in the study of protein ligand binding (150,164-168). 
Surface plasmon resonance is a measurable effect caused when energy is transferred 
from photons of light to surface plasmons. When light passes across two media, 
some of the radiation is reflected back at the incidence angle whilst some is able to 
pass through. Above a critical angle, however, all the light is reflected back, and an 
electromagnetic wave oscillates from the surface. When a metal film is placed at the 
interface between the two media, a surface plasmon state is created, where these 
oscillating electrons become weakly bound (fig F4-10). It is these weakly bound 
electrons which resonate with light at the same frequency, causing a drop in the 
intensity of the reflected light. The plasmon field extends to -lOOnm above and 
below the interface, and is sensitive to any change in this environment. A change in 
chemical composition in this area therefore results in a change in the wavelength of 
light which is absorbed, and it is this quality which is utilised in SPR analysis of 
biochemical interactions. 
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Fig 174-10. The plasmon held oscillates within an area of —lOOnm above 
and below the metal film, resonating with photons at the same frequency. 
A typical SPR sensor surface consists of a glass plate which is coated on one side 
with a thin gold film. The opposing surface of the gold film has a coating, usually 
carboxymethylated dextran, to which protein molecules may attach themselves, 
although more recent developments have seen the production of sensors which utilise 
other materials in order to more specifically bind molecules being investigated. 
Having one of a pair of interactants captured on the sensor, a solution containing the 
other can he injected across the surface, and changes in the environment (such as that 
caused by binding) will cause a change in wavelength of absorbed light, and 
therefore a change in intensity of reflected light ( fig F4-1 1). 
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Fig 174-11: schematic diagram showing sensor chip and flow channel. Interactant binding on 
the sensor surface causes a change in environment, which has an effect on the intensity of the 
reflected light. 
Any change in the environment, such as that caused by binding, therefore causes a 
change in intensity of reflected light, which is detected by the optical detection unit. 
This is then output and visualised as a sensorgram, which records the changes in 
resonance units (RU), showing association of ligand with bound molecules, followed 
by dissociation of the ligand and regeneration of the sensor as buffer is injected 





Time (seconds)  
Fig 174-12. A typical response curve showing protein-ligand association 
and dissociation, and sensor chip regeneration 
4:6:2 Materials and Methods 
All experiments were performed on a Biacore 3000, on loan from Biacore, with 
significant help from Dr J. Butler of Biacore and Dr. M. Wear. Three different 
approaches were taken in order to capture hCypA on sensor chip surface. A Biacore 
CM5 chip was used to capture native hCypA; a Biacore streptavidin (SA) chip was 
used to capture biotinylated hCypA; and a Biacore NTA sensor chip was used to 
capture His-hCypA. 
All are described in the following sections. 
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4:6:2:1 Buffers and Reagents: 
l-IBS-EP2:- 10mM Hepes, pH 7.4; 150mM NaCl; 3mM EDTA; 0.005% surfactant 
P20; 2% ethanol (Biacore) 
EDC:- l-ethyl-3-(-3-diaminopropyl) carbodiimide hydrochloride (Biacore) 
NHS:- N-hydroxysuccinimide (Biacore) 
4:6:2:2 Immobilisation of Native hCypA 
Pure hCypA was made up to a final concentration of between 20-100mg.mi' (-1-
5mM) in acetate buffer, pH 4.9. The CM5 sensor chip was activated by injection of 
buffer consisting of 1 lSmg.mF' NHS and 750rngml EDC at a flow rate of 5ilmin' 
for 7 minutes. Protein solution was then injected across the chip at a flow rate of 
5jil.min' until a saturating RU signal was seen. A final injection of 1M 
ethanolamine, pH 8.5 at 5p1.min 1 for 7 minutes was then performed to quench any 
unreacted succinimide esters on the chip surface. 
4:6:2:3 Immobilisation of Biotinylated h CypA 
Pure hCypA was biotinylated using the EZ Link NHS-LC-Biotin kit (Pierce), as per 
the manufacturers instructions. Biotin, which binds the protein streptavidin, reacts 
with primary amines, ie, N-terminal amines, or the c-amine on lysine residues. 
Biotinylated hCypA was then injected across an SA sensor chip in HBS-EP2 buffer, 
at a flow rate of Spimin'. 
4:6:2:4 Immobilisation of His - hCypA 
The Biacore NTA sensor chip was activated with Ni21,  according to Biacore 
recommended protocols. His-hCypA, at a concentration of -200nm in HBS-EP2 
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buffer, was passed over the Ni-NTA sensor surface at a flow rate of 5tlmin 1 . This 
was followed by surface activation and coupling involving a 30sec, 15.tlmin 
injection of NHS at a concentration of 1 l5mgml- 1 and EDC at a concentration of 
750mgm1'. A further 30sec, 151.tlmin 1 injection of IM ethanolamine, pH 8.5 was 
then performed to quench unreacted succinimide esters on the sensor surface. 
Activity of the Ni-NTA sensor bound hCypA was assayed by injecting cyclosporin A 
at a concentration of 1mM in HBS - EP2 buffer. 
4:6:3 Cyclosporin Binding to Surface Bound hCypA 
In order to assay the activity of surface bound hCypA, cyclosporin A was injected 
across the chip in various concentrations from 3 - 800nM in HBS-EP2 buffer, 3mM 
EDTA, at a flow rate of 50tlmin' 
4:6:4 Competition Binding Assay 
Owing to their small molecular weight, binding of the dimedone derivative ligands 
KMI9, KMI98 and KMI84 to hCypA could not be accurately measured by SPR. 
They were therefore assayed by competition with CsA for binding sites on surface 
bound His-hCypA. In HBS - EP2 buffer, 2% EtOH, 25nM CsA was injected across 
the sensor in the absence of any competitors, and then in the presence of increasing 
concentrations of the dimedone derivative based ligands. Data was therefore 
collected from injections of 25nM CsA alone, 25nM + 1 .6jiM derivative, 25nM CsA 
+ 3.12tM derivative, 25nM CsA + 6.25p.M derivative, 25nM CsA + 12.OjiM 
derivative, 25nM CsA + 25.0p.M derivative and 25nM CsA + 62.5iM derivative. All 
injections were at a flow rate of 5Oxlmin1. 
4:6:5 RESULTS 
4:6:5:1 Immobilisation of Native hCypA 
The amount of native protein which could be captured on the surface of the CM5 
sensor chip was between 1000 and 5000 RU. The activity of the surface bound 
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Figure F4-13. Graph showing the maximum theoretical response signal (white) and 
the maximum experimental response signal (black) for 4 CM5 chips. The numbers 
below indicate the actual amount of protein (in RU) stabilised on each chip. 
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4:6:5:2 Immobilisation of Biotinylated hCypA 
The amount of biotinylated hCypA which could be captured on the surface of the SA 
sensor chip was 1800 RU. Again, however, the activity of the surface bound protein 
was only around 5%. 
4:6:5:3 Immobilisation of His-h CypA 
It was found that dissociation of the 6X his-tagged protein from the chip surface 
caused significant baseline drift, and that washing with running buffer could 
dissociate all bound protein over a period of 2 hours. This is illustrated in figure F4-
14. which shows the sensorgram output of 3.100 RU on injection of His-/iCypA, and 
the fall in the response signal as buffer is injected across the chip surface and protein 
dissociates. Elimination of this was achieved by covalently coupling the surface 
bound protein immediately by injecting NHS/EDC, followed by an injection of 1M 
ethanolamine, immediately after capturing the protein on the chip surface, as 
described in materials and methods (above). The amount of protein which could be 
stably captured on the chip surface in this way was between 850-1600 RU. This is 
shown in figure F4-15. Activity of the surface bound protein was in excess of 85%. 
Figure F4-16 shows a comparison of the activity of five Ni-NTA chips. 
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Figure 174-14. Sensorgram output showing association/dissociation of His-CypA 
from the chip surface. 
Figure 174-15 Sensorgrarn showing the covalent capture of E-lis-hCypA on the chip surface. Phase 
al shows the association of hCypA to the chip surface, phase a2 shows dissociation and loss of re-
binding of protein. Phase h shows the steady drop in RU due to protein dissociating from the chip 
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Figure F4-16. Graphical representation showing maximum theoretical response 
signal (white) and the maximum experimental response for 5 NTA chips. The 
numbers below give the actual amount of protein (in RU) finally stabilised on 
each chip. 
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4:6:6 Cyclosporin Binding 
The Kd of CsA for the surface bound His-hCypA was -18.5nM. (calculated from the 
on- and off rate constants). This compared favourably with the published results of 
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Figure F4-17. Sensorgram output showing the association/dissociation of various 
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Figure 174-18. Three repeat injections of 20nM CsA over the same surface 
show the reproducibility of the results. 
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4:6:7 Competition Binding 
The dimedone-based compounds KM 19, KM 184 and KM 198 were assayed by 
competion with cyclosporin for binding sites. The dissociation constants obtained for 
the ligands are shown in table T4-3. The response unit curves for competition 




CONSTANT (K[) ) 
KM 184 361iM 
KM 19 46.9.tM 
KM 198 73.6p.M 
Table T4-3. The dissociation constants derived from 
competion binding analysis. The structures of these ligands 














Figure F4-19 Response unit curves for KM competing with 25nM CsA for binding to 
CypA. 
a-CsA alone: h-CsA +1 .611M KM 19; c-CsA + 3.1 2iM KM 19; d-CsA + 6.25itM KM 19; e-
CsA + I 21iM KM 19; f-CsA + 25jiM KM 19; g-CsA + 62.5iM KM 19 
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4:6:8 Discussion 
The results obtained here illustrate how surface plasmon resonance may be utilised 
as a screen for potential enzyme inhibitors. Whilst some initial difficulties had to be 
overcome in the preparation of the chips, it has been shown that by first 'capturing' 
the enzyme by the N-terminal histidine tag, and then covalently coupling the protein 
to the chip surface, a stable and active sensor surface may be generated. The baseline 
drift caused by the dissociation of enzyme from the chip (the affinity of the hexa-his 
tag for the chip has been shown to in the region of 0.5-31.IM (169))was prevented by 
modifying the carboxymethyl groups on the chip surface with a solution of 
NHS/EDC, thereby turning them into highly reactive N-hydroxysuccinimide esters, 
which reacted with primary amine groups on the protein. It is likely that covalent 
coupling to the chip surface when the enzyme has been captured in this way is via 
the N-terminal residue and does not involve any surface lysines, which may 
otherwise bind via their s-amino group. The capture of the protein via the N-terminal 
tag apparently causes the enzyme to be oriented in such a way that a high level of 
activity is retained, whereby the active site is exposed to ligand within the flow 
channel, and steric effects which may otherwise limit ligand binding are kept to a 
minimum. These steric effects are likely to have been the cause of the low activity of 
the CypA attached to the CM5 and the SA chips. Had the N-terminal 6X His tag 
been close to the active site then it is unlikely that this method of immobilisation 
would have been suitable. This is illustrated in figure 174-20. The position of the N-
terminal of the protein relative to the binding site can be seen in figure 174-21. 
Another potential advantage of capturing the protein in this manner is that it may be 
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possible to dispense with the protein purification step and pass crude extract across 
the chip surface, although considering the ease with which the protein purifies, 
(described in chapter 3), this may be rather wasteful, and was not tried here. 
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Figure F4-20 Shown in blue are representations of enzyme, with binding site labelled, and N- and C-
terminals marked in red. Where enzyme is permitted to bind in random orientations this may result in 
steric effects blocking the binding site (top). Where the enzyme is bound via an N-term his tag. and this 
is far enough from the binding site, then molecules are bound uniformly to the chip surface and the 
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Figure F4-2 I Cartoon representation of hCypA, with active site residues Arg55. Tm 12 1.  Asn 102 
and Phd 113 labelled. The position of the N-terminus relative to the active site can he clearly seen to 
he tar enough away not to interfere with protein-ligand binding when hound to the chip surface via 
an N-terminal tag. 
Good data was obtained from the competition binding assay. The RU signal obtained 
from the direct application of ligand solution across the surface bound protein were 
noisy and had large spikes in the injection phase which made data interpretation 
unreliable This was attributed to the high concentration of ligand in solution 
(120jiM), and the presence of insoluble material in the injected buffer. Attempts to 
remedy this by increasing solvent concentration to above 2% resulted in rapid 
denaturation of surface bound enzyme. The competition assay allowed the dimedone 
derivatives to be tested at lower concentrations, thereby minimising the potential 
presence of precipitate in the buffer, and the need for a high (and damaging) solvent 
concentration. 
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The affinity constants obtained for the three dimedone derivates are approximately 
one-third of that obtained by fluorescence analysis (shown in section 4:4:5), and the 
rank order of tightest-weakest binding is maintained. Whilst resolution of the crystal 
complex of hCypA/ligand KM 19 was a major focus of this project, KM 19 being the 
classic dimedone derivative around which other compounds in the library were 
modelled, it is interesting to note that the affinity of compound KM 198 for hCypA is 
greater than that of KM 19. It is likely that this is attributable to the methyl group on 
the dimedone moiety, the only difference between this molecule and KM 19. It is 
therefore surprising that the affinity of KM 198 is less, as it might be expected that 
the carboxyl group may contribute to hydrogen bonding between ligand and protein. 
It may be that the methyl group contributes to hydrophobic interactions. This is 
further discussed in chapter 7. It has been stated that measuring binding of two 
interactants, where one has been immobilised may affect the results, and perhaps not 
be a true gauge of the affinity between the molecules (170). Tethering a reactant 
may restrict its rotational freedom and diffusional qualities (170,171). Whilst this 
may be a consideration, surface plasmon resonance has been shown to be an 
extremely accurate and precise method for analysing the kinetics of protein ligand 
binding (171,172), That the results obtained here are comparable to those obtained 
by fluorescence analysis show that this is indeed the case, with the binding of small 
molecules (in the region of 300-50013a) to surface bound protein having been 
measured. 
With the sensitivity and reliablity of surface plasmon resonance equipment being 
constantly optimised, and new generations of biacore instuments being released, 
130 
much work is being done in order to find new applications for the potential provided 
by surface plasmon based techniques (151,164, 165,173,174). 
It is hoped that the methods described here may be applied to other systems, 
particularly where protein activity is reduced when bound to sensor chip surface, due 
to the protein binding in random orientations, or where protein is not stably bound, 
and that further work using SPR to examine hCypA-ligand interactions may be 
performed based on the system described here. 
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Ch 5: Protein Crystallography 
5:1 Brief Overview 
The field of protein crystallography has grown dramatically since the structure of 
myoglobin was first published in 1960 (175), followed by lysozyrne (176, ribonuclease 
A (177), ribonuclease S (178), x- chymotrypsin (179), and papain (180). There are now 
over 30,000 protein structures solved by x-ray crystallography in the protein data bank 
(181). In its infancy, solving a protein structure was a long and laborious process, 
involving much hands on work studying x-ray diffraction patterns collected on 
photographic film, calculating intensities and structure factors, drawing and overlaying 
electron density maps and building molecular models. With modern techniques, 
however, the availability of high intensity x-ray sources at synchrotrons, and computer 
packages such as those from CCP4 (182), it is now not unknown for a protein structure 
to he solved in a matter of hours. 
The overwhelming advantage of using x-rays in order to visualize biological 
macromolecules is that the wavelength of the x-rays used, generally from 0.5 - 1.6A (I A 
= I X 10 0 m, or 0.Inm), allows the resolution of the atoms which make up the 
structure. As the wavelengths of visible light are in the region 400-700nm, objects 
smaller than this cannot be resolved. The penetrative quality of x-rays also allows 
observation of the molecule being studied in 3 dimensions. Disadvantages involve the 
necessity to obtain crystals of the molecule in question, where many identical molecules 
(perhaps I X lOh  molecules) form a well ordered lattice; maintaining crystal integrity 
whilst collecting data - using high energy x-rays often cause irreversible radiation 
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damage to crystals (crystal resolution can be seen to fall away over the course of data 
collection); and in the processing of data, in calculating the unit cell and spacegroup, in 
solving the phases, and in refining the final structure. There are, however, many tools 
available to the crystallographer to make these tasks easier. 
5:1:2 Growing Crystals 
Crystals are grown by achieving a state where the thermodynamically most stable is that 
where crystals are present, generally by slowly precipitating the protein out of solution. 
This can involve screening countless different possible conditions, and there are many 
different 'sparse matrix' screening kits on the market (such as those marketed by 
Hampton) containing previously prepared known crystallisation solutions, allowing the 
testing of a wide range of possible conditions. Where a 'hit' is established, screening 
around these conditions can then be further explored, by making small adjustments to 
pH, temperature, precipitant and protein concentration, the crystallisation conditions can 
be refined. 
There are many techniques employed for growing protein crystals, such as microbatch, 
dialysis and vapour diffusion. Of these, vapour diffusion is probably the most popular 
and widely used. This involves slowly dehydrating a protein solution by mixing it with 
precipitant and suspending above a reservoir at a higher precipitant concentration, in a 
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Fio F5-1: Hanging drop vapour di fusion. Delidrat ion of the Ii iciri drop containing the 
protein solution occurs as water molecules are sequestered by the precipitant in the well 
solution, leading to slow precipitation of the protein in the drop. 
5:1:3 Data Collection 
Crystallographic data may be collected either in the lab, or home source", where the X-
rays are produced by a rotating anode generator. A beam of electrons from a cathode is 
focussed through a vacuum onto the rotating anode, at a sufficient energy to cause 
photons to be released. Depending on the type of anode used, these X-rays produced are 
at a specific wavelength (CuKu = 1.54A wavelength, MoKcL = 0.7 IA). Another means 
of producing X-rays is the synchrotron, where electrons are accelerated up to = 99% the 
speed of light and are maintained in a storage ring by electromagnetic fields, emitting 
high energy X-ray radiation, which is tunable to a range of usable wavelengths. 
Some of the photons in the X-ray beam are absorbed by electrons in the crystal, causing 
scattering of X-rays. These scattered photons are collected by the X-ray detector, giving 
the characteristic diffraction pattern, or reciprocal image. X-ray photons which do not 
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interact with the crystal, but pass directly through, are halted before they reach the 
detector by the backstop. 
Detectors have evolved somewhat over the years. Where previously X-ray film was 
used, and had to be removed and replaced between each image, then developed; these 
were superseded by re-usable image plates, which store diffraction patterns in the form 
of excited atoms on the plate, and are read fluorescently. Further developments have led 
to the charge—coupled detector (CCD), which uses fibre optics to conduct diffraction 
images from a fluorescent screen, and are more commonly used at synchrotron facilities. 
The maintenance of crystal integrity during data collection must also be considered. 
Where previously crystals were placed in sealed capillary tubes to prevent them drying 
out whilst collecting data, it is now more often the case that crystals are mounted on a 
loop and flash frozen by plunging into liquid nitrogen. They are then kept at cryogenic 
temperatures by a stream of liquid nitrogen during the course of data collection. It is 
important to select a good freezing solution in order to displace solvent from the crystal 
prior to freezing, to reduce the incidence of ice rings. 
5:1:4 Data Processing and Reduction 
5:1:4:1 Indexing and Integration 
Once the data set has been collected, the Bragg reflections must have their indices h, k 
and / assigned. To do this it is necessary to precisely know the wavelength of the 
radiation, the central position of the beam, and the distance from the crystal to the 
detector. 
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From Bragg's Law:- 
,,=2dsinO 
where k is the wavelength, and n is the integer known as the order of diffraction. 0 is 
the glancing angle and d is the spacing between the planes. Where light waves which are 
traveling in phase are reflected from a single plane, then the reflected waves are still in 
phase. If, however, only some of the waves are reflected, and others pass through the 
plane to be reflected from a second plane, then the waves will only be in phase if the 
distance (d) between the first and second plane are iz. apart. For crystal structure 
Braggs Law is expressed as:- 
= 2d,,, sinO 
where hkl are the reciprocal indices, and may be rearranged for d so that:- 
sinO= i2d /, kl 
Provided this information is known, the unit cell (the smallest repeating structure which 
makes up the crystal lattice, represented by the dimensions a, b, and c, and the angles (x, 
3, and y) and spacegroup (the symmetry operations present within that cell) can then be 
calculated. 
Once the dataset has been indexed and the spacegroup and unit cell determined, the rest 
of the dataset may be integrated, where the profiles of all reflections are fitted. 
136 
5:1:4:2 Scaling 
This step is necessary because, due to possible variations in beam intensity, radiation 
damage in the crystal, the occurrence of bad' batches, amongst other things, the 
intensities of reflections may differ from image to image, or fall away steadily over the 
course of data collection. Scaling the data is an essential step in data processing as it 
allows the adjustment of any inconsistencies, and the overall quality of the data may be 
examined. This is the step where such things as the overall completeness of the dataset, 
the values of R (reliability factor, indicative of errors in the data and a measure of 
accuracy) may be checked, and where some compensation can he made them. 
Statistically, R is an average ratio of:- 
difference between values which should be the same/magnitude of measured values 
Where scaling shows an unexpectedly high R-syrn (which is the R factor for symmetry 
related intensity measurements, closer examination may identify images (or batches) 
which have contributed to this, allowing them to be excluded. 
5:1:4:3 Phases 
There are many good descriptions of the 'phase problem' in the literature (183). Briefly, 
in order to calculate structure factors (F,1k!), which describes each reflection on the 
diffraction pattern as being contributed to by all atoms in the unit cell, it is necessary to 
know the corresponding timing of each wave. Waves which arrive In phase' are 
additive, waves which arrive at A./2 out of phase, le peak vs trough, cancel each other 
out. There are several techniques which may be used to overcome the 'phase problem'. 
For instance, where the structure of a protein is to be solved, and its structure is expected 
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to be very similar to another known structure, which may be a homologous protein from 
a different organism, molecular replacement may be a suitable approach, as the known 
structure, or specific areas of secondary structure, may be used as a model. Another 
approach to the phase problem may be isomorphous replacement, using heavy atom 
derivatives, and involves being able to collect data from a parent', or 'native' crystal, 
then collecting data from heavy atom derivative crystals, where the crystals have either 
been soaked in, or grown in the presence of, a heavy atom such as mercury or lead. The 
change in diffracted intensities allows the calculation of structure factors. The use of 
heavy atoms in this way depends on the derivative crystals having the same cell 
dimensions and symmetry as the native crystal, ie, that the replacement is isomorphous, 
and it is usual to have two or three derivative crystals (Multiple Isomorphous 
Replacement, MIR). Other methods for dealing with the phase problem include the use 
of anomalous scatterers, such as selenium; or combining both isomorphous replacement 
with anomalous scattering (single isomorphous replacement with anomalous scattering, 
SIRAS). Once the phases have been calculated, the structure factors, which have a 
length FI,kf and a phase UhkI, can be used to obtain the electron density Px yi, by Fourier 
transformation. 
5:1:4:4 Refinement 
Once the data has been indexed, integrated, scaled, 'bad' data has been identified and 
excluded, the phases have been determined, and the electron density calculated: the 
process of refinement, involving fitting the electron density maps to the model, 
examining the fit and resulting R factors is the next stage. By fitting the map to the 
model it is possible to calculate density of the form fo - fc and 2fo - fc (where fo is the 
observed electron density and fc is the calculated electron density), density surrounding 
the model can be visualized (from 2fo - fc). Other areas of density, from the fo - fc, may 
indicate possible alternate configurations of the protein, or the presence of ligand or 
other molecules. By manipulation of the model, involving what may be many rounds of 
refinement and close observation of the R factors at each step, the phasing and resulting 
model are brought to a point of convergence. The flowchart (fig F5-2) shows the stages 
involved in obtaining a crystal structure. 
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Figure F5-2 Flowchart describing the steps involved in growing crystals, collecting 
data, processing data and relining crystal structure. As described in the text. 
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5:2 Materials and Methods 
Crystals were grown using concentrated His-hCypA, expressed using cells 
transformed with the pET 15b vector containing the insert for hCypA. The 6X His tag 
was not cleaved. The purified protein was partially concentrated using a vivaspin, 
molecular weight cut-off 500013a, at 4000rpm buffer was then exchanged for 50mM 
Hepes, 100mM NaCl, pH 7.0, using a PDIO column. Protein was then further 
concentrated to a final concentration of 20-25mgm1 1 , measured by Bradford assay. 
Protein was crystallised by hanging drop method, well solution consisted of 20-22% 
PEG 8K, 100mM NaCI pH 7.8 to pH 8.2. Hanging drop was made up from 2t1 well 
solution and 2p1 protein solution. Crystals were grown at 4 °C, and crystals usually 
appeared after 7-10 days. 
Crystals were mounted on loops and passed briefly through a drop of freezing 
solution (35% PEG 8K, 100mM NaCl, pH 7.9) prior to flash freezing by plunging 
into liquid Ni, in order to reduce the incidence of ice rings. 
5:2:1 Data Collection 
Data was collected either at home (inar59l. mar571, rotating anode x-ray 
generators), at the synchrotron at Daresbury (stations 9.6, 14.1 14.2), or at the 
synchrotron at Grenoble, BM14. A minimum of 90 ° of data was taken. In all cases, 
after taking the first image, this was indexed and the strategy option on mosfim used 
to identify the optimum starting phi for data collection, in order to collect as 
complete a data set as possible. 
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5:2:2 Data Processing and Structure Determination 
Programs from the CCP4 package (182) were generally used to process crystal data. 
Indexing, integration and scaling of the crystal data was performed using Mosfim 
(182,184) and Scala (182). Refmac 5 (182,185) was used to refine the data. Other 
programs used include ArpfWarp (182) and Procheck (182). Ono8 (186) was used to 
visualise structures. Shelx (187) was used for the occupancy refinements, to refine 
the occupancies of dipeptides vs waters at the binding site, and the change in 
conformation at specific residues on ligand binding, such as the Arg55 and Met6l. A 
full explanation of the steps taken and the programs used at each step is given below. 
5:2:2:1 Mosflm (182, 184) 
This program was used to index the Bragg reflections and integrate their intensities. 
When processing a dataset, the first image was read into Mosfim, and spots were 
counted. The autoindex option was then used to index the image and the result giving 
the highest score with the lowest penalty accepted. Mosaicity was then estimated. 
This was repeated for images 45 and 89. Once three images had been indexed, the 
cell dimensions were refined. If, as occasionally happened, an image would not 
index, this could usually be remedied by correcting the position of the beam centre 
using an ice-ring, or by using the data exclude option to omit areas showing 
particularly intense dark ice-rings. After indexing data and refining the cell, data was 
integrated. 
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5:2:2:2 Scala (182) 
The .mtz file ouput by Mosfim was read into scala, and scaled by batch mode 
(although some later datasets were scaled by rotation axis), excluding 0.05% of data 
which was used to calculate Rfree. Once data had been scaled, ouput files and graphs 
were examined, with particular attention paid to percent completeness, Rsym, and 
IlSigma values. Rsym gives an estimation of error within resolution shells. An 
overall Rsym value of < 0. 1 was aimed for. I/sigma refers to the intensity of a 
reflection over the background intensity. A value of one therefore indicates that spot 
and background intensity are equal. Data in a resolution shell with I/Sigma values < 
2.0 was examined and, in most cases, excluded. The % completeness was referred to 
in order to identify those resolution shells which had a markedly detrimental effect 
on overall data quality. In some cases, the initial scala ouput .mtz file could be used, 
although it was often necessary to exclude certain areas of resolution and re-run scala 
in order to bring the values for % completeness, Rsym and llSigma within acceptable 
parameters. 
5:2:2:3 Refmac (182, 185) 
The scaled data was then refined against a known structure of hCypA, in its native 
form, which had previously been processed at Edinburgh. In most cases, refmac was 
run for 20 cycles of restrained refinement, with maps. Values for R, Rfree and figure 
of merit were examined at each cycle of refinement. 
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5:2:2:4 Ono 8 (186) 
Used to visualise the refined data output by refmac. The refmac output files 
DELFWT.map (fo-fc), FWT.map (2fo-fc), and the pdb files were input into Ono8 
and areas of electron density and protein examined. Ono8 allowed overlayed 
structures to be examined, residue movement to be established, and residues and 
ligands to he modelled into density. 
5:2:2:5 Shelx (187) 
Shelx is another refinement program. This was generally used when refining ligand 
structures in order to obtain the occupancy of ligand at the active site. The two 
components of sheix which were utilised were shelx97, which was used to compile 
input files, and sheixi, which was used to run the refinement. In all cases, before 
running shelx, it was necessary to use the 'convert from mtz' option in the ccp4 
package to create an hkl file for shelx out of the scala.mtz file. This is explained 
more fully in the chapter describing hCypA crystal complex structures. 
5:2:2:6 Pymot (188) 
Although not used for structure refinement, Pymol (188) has been used to visualise 
crystal structures, and to prepare images. 
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5:3 Results 
Crystallisation conditions are described in materials and methods. Good quality 
diffracting crystals of hCypA generally appeared within 7 to 10 days, with no further 
apparent crystal growth after around 20 days. As shown in figure F5-3, in some cases 
crystals grew from the faces of others, in different orientations, which often led to 
smeary diffraction patterns, and caused problems with data processing. This could 
usually be avoided, however, by carefully prising the crystals apart, or where the 
crystals were large enough, by breaking them up, before soaking and freezing. 
Hg F5-3. Photograph showing drop containing crystals of His-CypA. Some crystals can 
he seen to be growing from the laces of others, in different orientations. 
Crystals diffracted to between 1.7 and 2.4 A, depending on source and quality of 
the crystal itself, with a spacegroup of P2 1 2 1 2 1 , with unit cell dimensions of around 
a= 42A, b= 52A, c = 89A. a = 3 = y = 90°. Specific unit cell dimensions for each 




5:3:1 Mass Spectrometric Analysis of Crystals 
Whilst it has already been mentioned that the protein used for crystallisation was that 
with the 6X His tag, which was not cleaved, it was noticed that crystals appeared to 
grow more readily from protein which had been stored for around a week. Although 
no trace of the 6X His tag could be seen in the electron density map, a large, 
disordered region of density could in some cases be seen. The N-terminal sequence is 
shown in figure F5-4. The electron density map showing the density at the N-
terminal is shown in figure F5-5. 
His-His-His-His-His-His-Ser-Ser-Gly-Leu-Val-Pro-Arg-/-Gly-Ser-His-Met.lMet-Val-Asn 
6X His tag 	 hCypA 
Thrombin cleavage site 
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Fig F5-5. The N-term of hCypA showing density, and possible orientations of the Met and 
His on the linker region. The density to the right is from a symmetry related molecule 
me 
It therefore appeared that the 6X His tag was being degraded, possibly whilst the 
protein was stored, or that it was actually cleaving from the protein, although care 
was taken not to expose the protein to any proteases. Attempts were made to model 
the N-terminal sequence into the density, but the disorder was too great and residues 
could not be placed with any degree of confidence. A possible orientation of the two 
N-terminal methionines and the histidine on the linker sequence is shown in figure 
F5-5. It was, however, decided to submit crystallised protein for mass spectrometric 
analysis. 
5:3:1:1 Preparation of Samples for Mass spectrometry 
Crystals were taken from 10 hanging drops and dissolved in 50j.il sodium acetate. 
Where protein concentration in drops was 10-12mg.mF 1 , and the drop size was 4jil, 
then each drop contained -40tg of protein. It was assumed that where drops 
contained crystals, and crystal growth had reached equilibrium, then 50% of protein 
in the drops was in crystal form. This meant that each drop contained —20.tg of 
crystallised protein. Taking all crystals from 10 drops and dissolving in 50il 
NaCH3CO2 therefore gave a solution of 4mg.mF' 
5:3:1:2 Results 
The spectra obtained by MS analysis showed a clear peak at 183721)a (fig F5-6). 
Assuming a cleaved protein mass of 1842913a, then this is -0.3% calculated mass, if 
the glycine had also gone, then cleaved protein mass would be 18354, and the MS 
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Fig F5-6. MS spectra from crystallised protein showing peak at I 8372Da 
5:3:2 Discussion 
The crystal structure of hCypA obtained here is in good agreement with other 
published structures. The structure of native hCypA published by Ke, et a! (32) 
grown from non-tagged hCypA was of the same spacegroup, and had unit cell 
dimensions of a = 43.0A, b= 52.6A, c = 89.1k, a = P = = 90, although the 
crystallisation conditions were slightly different (189) The N-terminal methionine 
residue was not modelled in, due to poor electron density. 
Figure F5-7. The packing of hCypA crystallised in house. The top image shows 
one molecule of hCypA in the unit cell. The bottom image shows six symmetry 
mates within a 4A radius. Circled in blue is the molecule corresponding to that 
circled in the figure showing the published structure. 
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Figure F5-8. The packing of the published hCypA structure. The top image shows 
one molecule of hCypA in the unit cell. The bottom image shows six symmetry 
mates within a 4A radius. Circled in blue is the molecule in the same orientation 
within the cell as that shown in the figure above. 
The packing within the unit cell for both structures was identical, as can be seen from 
examination of the images (figures F5-7 and F5-8), which show the crystal structure 
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obtained in house' and the published structure. The figures show the corresponding 
molecules circled in blue. 
The structure hCypA co-crystallised with cyclosporin (190), also had the same 
spacegroup, but with slightly different unit cell parameters (a = 36.18A, b= 61.57A, c 
= 72.44A, a = 0 = y = 900)• The packing and conformation was also slightly 
different, as can be seen from figure F5-9. 
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Figure F5-9. The unit cell and crystal packing of hCypA co-crystallised with CsA. The top image 
shows one molecule within the unit cell. The bottom image shows 6 symmetry mates within a 4A 





The structure of cCyp3, although very similar to that from hCypA, had different unit 
cell dimensions (a = 60.61A, b= 60.61A, c = 123.14A, a = 13 =y = 900), and 
spacegroup (P4 1 2 1 2) (34). The packing within the unit cell is shown in figure F5- 10. 
Figure F5- 10. The packing of cCyp3 within the unit cell. The top image shows one 
molecule of cCypA within the unit cell, and the bottom image shows symmetry mates 
within a 4A radius. There are 6 symmetry mates, but 3 cannot he seen from this 
orientation 
It is apparent that, whilst the crystal structure of hCypA derived 'in-house' is 
identical to that published, differences in ligand size can affect crystal packing and 
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unit cell size, as the exposed area of CsA obviously affects packing within the crystal 
lattice (as seen from the CypA-CsA complex structure). The difference seen in 
packing, unit cell and space group for the cCyp3 structure, whilst likely to be due in 
part to the extra loop (described in chapter one), will also be brought about by 
sequence differences within the peptide chain (67% sequence identity, figure Fl -I). 
The extra residues at the N-terminal might therefore have been expected to affect the 
packing of the molecules within the crystal, but this is evidently not the case. 
Whether the hexa-his tag was being cleaved by protease or not is unknown, although 
this may have been occurring, as buffers used when protein was being purified prior 
to crystallisation did not contain any protease inhibitor cocktail, and active proteases 
may have been present in the protein solution during the purification process. The 
absence of an N-terminal methionine may also contribute towards protein 
degradation. 
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Ch 6: Protein-Ligand Crystal Complexes 
6:1 Brief Description 
A well established technique for the crystallographic study of protein—ligand 
complexes involves placing a protein crystal into a solution of the ligand to be 
examined, allowing the ligand (or potential ligand) to permeate, or soak, into the 
crystal lattice and bind the protein molecules which form the crystals. Although this 
can be a fairly efficient method of obtaining crystal structures of protein—ligand 
complexes, it is not without its drawbacks. Crystals need to be strong enough to 
withstand the transfer into what may very different conditions to those in which they 
were grown, differences in pH, salt content, buffers and solvent availability can all 
have an affect on crystal integrity. The (potential) ligands need to be small and 
flexible enough to make their way into the crystal lattice, and into the active, or 
effector, site of the protein molecule, without causing damage to the crystal. It is also 
necessary to be able to 'see' the ligand in the electron density, that is to say, the 
occupancy of the ligand must be great enough so that the electron density map after 
scaling and refining of the data shows the conformation of the ligand, allowing it to 
be modelled into the structure. This may mean that the soaking solution contains a 
high ligand concentration, and crystals have be left in the soaking solution for long 
periods of time. 
Where crystals are already available, however, crystal soaking is generally the first 
step taken in attempting to obtain a complex structure, as the alternative, co-
crystallisation with ligand, can often alter the crystallisation conditions dramatically. 
Where the ligand is reasonably soluble, however, or small enough to soak into the 
crystal lattice without damage, or where it has been possible to slowly present the 
ligand to the crystal in increasing concentrations without damaging the crystal, it can 
he a productive technique. 
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6:2 Small Molecules 
6:2:1 Brief Overview 
It has previously been shown that the small molecules tetramethylene sulphoxide 
(TMSO), methyl sulphinyl-methyl sulphoxide (DSS). 5-diethylamino-2-pentanone 
(DAP), and 3-acetyl-1-propanol (PROP) bind to /iFKBPI2, and the crystal structures of 
hFKBPI2/DAP and hFKBPI2/PROP hFKBPI2/DSS have been solved (139). It was 
therefore decided to attempt to soak these molecules into crystals of hCypA, in order to 
examine their conformation at the active site of hCypA, and compare this to /ZFKBPI 2. 
The compounds are shown in figure 176-1, and refinement statistics for all three 








Figure F6-l. Table showing structures of the three small molecules soaked into crystals of hCypA 
157 
6:2:2 Materials and Methods 
The ligands were supplied by Sigma. In all cases, crystals were soaked in solutions 
consisting of 20% TMSO, DAP or PROP. A stock solution of 35% PEG 8K, 100mM 
NaCl pH 7.9 was prepared. This was then used as a well solution over which crystals of 
hCypA were suspended in order to equilibrate. Soaking solutions consisting of 5%, 10% 
and 20% ligand were prepared from the 35% PEG stock, and placed on the same 
coverslip. Once the system had equilibrated overnight, crystals were transferred into the 
soaking drops, sequentially from low ligand concentration to high ligand concentration, 
to minimize crystal shock, allowing 5-10 minutes in each, as shown in section 6:3, 
followed by an hour at 20% ligand concentration. Crystals were then mounted on a loop 
and flash frozen in liquid nitrogen. No separate freezing solution was used. Data was 
collected from all three crystal complexes at the synchrotron at Daresbury. 
M. 
6:2:3 Results 
Crystal data for all three structures are shown in table T6- I. Descriptions and figures of 
each structure are shown in the relevant sections. 
COMPOUND TMSO PROP DAP 
X-ray source SRS [)ARESBURY SIN 9.6 SRS I)ARESBURY STN 9.6 SRS DARESBURY STN 9.6 
Wavelength(A) 1.488 1.488 1.488 
Unit cell(A) 42.38,52.17. 87.83, 
u==y=90.90.90 
42.43, 52.75. 87.58. 
a=(=y= 90,90,90 
42.0.52.31. 87.54. 
u==y= 90,90, 90 
Resolution) A) 1.75A 1.9A 1.9A 
Rsym 0.068 (0.299) 0.095 (0.339) 0.058 (0.162) 
% completeness 98.5 97.2 (94.2) 94.8 (88.4) 
Redundancy 4.2 4.4 3.5 
I/sigma 6.4 (2.2) 6.5 (7.1) 10.0 	4.7 
Rfactor 0.2087 0.1917 0.1852 
Rfree 0.2378 0.2316 0.2284 
Table T6-1. The crystal data for the complex structures of 
hCypA hound to TMSO. DAP and PROP. 
TMSO (tetramethylene sulphoxide) 
Crystallographic data is shown in table T6-1, and the structure of TMSO in electron 
density at the active site of hCypA is shown in figures F6-2 and F6-3. The structure 
shows the TMSO deep in the hydrophobic pocket of hCypA, with no apparent 
movement of Arg55 to accommodate ligand. Residue Met6 I can however be seen to 
have adopted an alternative conformation, similar to that observed for dipeptide Val-Pro 
binding. Possible hydrogen bonding is likely to be between the ligand oxygen and 
solvent molecules W6 and/or W20 which may also be interacting with residues AsnIO2 





t:igtjrc  F6-2.TMSO in density at the binding site of hCypA. Electron density  
level SCL at I 





Figure F6-3. TMSO at the binding site of hCypA . Solvent mediated 
hydrogen bonds can he seen via W20 to G1n63 and W6 to Asn 102 
PROP (3-acetyl-1-propanol) 
Crystal data shown in table 16-1. Images of PROP at the binding site are shown in 
figure F6-4 and 176-5. The ligand can be seen to be directed down into the binding site, 
with possible hydrophobic interactions between the methyl group and Phe I I 3. There are 
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Figure F6-5. PROP at the active site of hCypA. Two hydrogen bonds appear to be 
made between the molecule and solvent molecules W20 and W6, and the methyl 
group is directed into the hydrophobic pocket. 
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DAP (5-diethylamino-2-pentanone) 
Crystal data shown in table T6-1. Images of the ligand at the binding site are shown in 
figures F6-6 and 176-7. The ligand appears to have adopted a conformation where the 
two methyl groups are directed into the hydrophobic pocket. No hydrogen bonds can be 
seen. 
\ 	71 





Figure F6-6. DAP in density at the binding site of hCypA. Electron density level set at 1.0 
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Figure F6-7. DAP at the binding site of hCypA. Whilst the molecule may he assumed to have 
adopted what is likely to he the most energetically favourable conformation, with the 2 methyl 
groups directed into the hydrophobic pocket, optimizing hydrophobic packing interactions, there 
are no hydrogen bonded interactions. 
6:2:4 Discussion 
The electron density maps for all of these ligands were strong, allowing them to he 
modelled in with a high degree of confidence. Whilst all of these small molecules appear 
to have adopted conformations with their more hydrophobic areas directed into the 
hydrophobic pocket at the binding site, with the exception of TMSO, there appears to be 
little hydrogen bonded interactions to stabilize the complexes. The structures of DAP 
and PROP bound to hFKBPI2 apparently form 2 hydrogen bonds to the protein, one to 
the amide nitrogen on 11e56 at the bottom of the active site cleft and another to the 
carboxylate oxygen on Asp37 at the top of the cleft. There are no such hydrogen bonds 
present on the complexes of hCypA/DAP or hCypA/PROP. 
All molecules displace waters 15, 51 and 112 (which can be seen in figure F6- 10) on 
binding. With only three water molecules displaced, entropic effects are relatively small. 
In the case of TMSO, approximately half of its surface area is buried, making close van 
der waals contact with Phel 13 at the base of the binding site. Whilst the larger DAP 
ligand makes optimal hydrophobic packing interactions with hFKBPI2, this does not 
appear to be the case with hCypA. DAP at the binding site of hCypA is exposed, with 
only the two buried methyl groups making van der waals contacts with Phel 13. 
Although DSS does not appear to be buried to the same extent, the complex of 
hCypA/TMSO appears to be similar to that of hFKBPI2/DSS, where there are two 
hydrogen bonded interactions. One of these is from the sulphur bound oxygen atom via a 
solvent molecule to Tyr82, the other is a direct hydrogen bond from the same oxygen to 







Figure F6-9. The conformation of DSS at the binding site of hFKBPI2. The 
suiphoxide can he seen to he binding to the OH on Tyr82 via a water molecule, 
and making a direct hydrogen bond to the N atom on 11c56. PDB ID I D71. 
Examination of the binding site of hFKBPI2 reveals it to be largely hydrophobic in 
character. Figure F6-9 shows the binding site formed by four phenylalanine residues, 






Figure F6-9. Cartoon representation of hFKBPI2, showing the 
hydrophobic binding site residues. 
Although these small molecules bind to hFKBP, it does not necessarily follow that they 
will bind hCypA, but they appear to do so, albeit with what are slightly different 
conformations, and with different hydrogen bonding interactions. Whilst DAP and 
PROP have affinities for hFKBPI2 in the low millimolar range (2mM PROP-hFKBPI2, 
0.5mM DAP-hFKBPI2) (139), their affinity for hCypA is likely to be less where van 
der waals interactions do not appear to be so great and the hydrogen bond is absent. The 
dissociation constant for TMSO-hCypA is likely to be greater than that for DAP-hCypA 
or PROP-hCypA with the greater buried surface area and the hydrogen bond. That said, 
the major driving force behind protein binding is the hydrophobic effect and the 
167 
reduction in entropy (192,193), so the expulsion of the extra water molecule during the 
association of these hCypA complexes may bring the K4j down. 
W. 
6:3 Dipeptide Soaks 
6:3:lBrief Description 
It has previously been shown how a ligand binding constant may be determined 
crystal lographically, by refining the occupancy of the ligand at a range of 
concentrations (138). These studies have been extended to include a range of 
dipeptides of the form X-Pro, in order to examine the contribution made to binding 
by the side chain on the amino-acid preceding the proline residue. The dipeptides 
Thr-Pro and Val-Pro were soaked into crystals of hCypA at concentrations extending 
from 6.25mM to 100mM. Whilst solubility of these ligands was not such a problem 
as for the dimedone derivatives described above, it was found that at the higher 
concentrations of some of these dipeptides that crystal integrity was a problem, as 
crystals could be seen to be cracking after relatively short soaking times, in the 
region of 5-10 minutes. This was attributed to a sudden exposure to a different 
environment, where the dipeptide solution was at a different pH to that of the 
solution in which the crystals had originally been grown, or the where the dipeptide 
solution was at too high a concentration, and the dipeptide itself was entering the 
crystal lattice at too great a force, disrupting the network of hydrogen bonds and 
hydrophobic interactions within the crystal lattice and overall crystal integrity. 
6:3:2 Materials and Methods 
Soaking solution:- 50mM Hepes, pH 7.0, 100mM NaCl; 35%PEG 8K, 100mM Tris 
pH 7.9. 
Well solution:- 35% PEG 8K, 100mM Tris pH 7.9 
Protein was crystallized as described previously. Soaking solution was prepared by 
first making a 50% PEG 8K solution, then taking 35m1 from this and making it up to 
40ml by addition of Sm! 100mM Tris pH 7.9. Then a solution of 250mM Hepes, pH 
7.0, 500mM NaCI was prepared, and lOmI of this was taken and added to the 40m1 
PEG solution. Final pH of the soaking solution was —7.0-7.5. Stock solutions of the 
dipeptide ligands were then prepared in soaking solution to concentrations of 
100mM, which were then further diluted in soaking solution to concentrations of 50, 
25, 12.5 and 6.25mM. The pH values of all soaking solutions were checked and 
adjusted as necessary using NaOH/HCI, and the final concentration of dipeptide in 
solution calculated. 
Prior to soaking crystals in dipeptide solution, crystals were first placed over well 
solution consisting of 35% PEG 8K, 100mM Iris pH 7.9, with a drop of the soaking 
solution on the same coverslip, and left overnight to allow the system to equilibrate. 
The crystals were then transferred into the soaking solution and the coverslip placed 
back over the well. At higher concentrations it was necessary to soak the crystal 
stepwise at increasing concentrations of dipeptide, in order to minimalise crystal 
shock. After a period of one hour, crystals were flash frozen in liquid nitrogen. No 
separate freezing solution was necessary. The soaking protocol is described in figure 
F6-13. Data was collected either at home, at the synchrotron at Dareshury, or at the 
synchrotron at Grenoble. 
6:3:3 Data Processing 
The programs Mosflrn (182, 184), Scala (182) and Refmac (182. 185) were used to 
process and refine X-ray data. Ono-8 (186) was used to visualise structures, and have 
been previously described. Shelx (187), briefly described earlier, was used to refine 
the occupancy of dipeptide molecules against displaced water molecules at the 
binding site. Figure F6-10 shows the binding site of the native structure, with water 
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TrPI25'  
molecules 6, 15, 51, 92 and 112 clearly visible. Figure F6-11 shows the dipeptide 
Val-Pro (in orange for clarity) at the binding site, with these water molecules no 
longer present. An alternate view of this can also be seen in figure F6-12 It can also 
he seen that Arg55 and Met6l assume slightly different orientations on ligand 
binding. The displaced water molecules and the alternative conformations of Arg55 
and Met6 1 were used to calculate the occupancy of dipeptide. 
Briefly, a shelx instruction file was created using the facility on shelx97. This was 
then divided into parts one and two, where part one included all residues and solvent 
molecules which were not having their occupancy refined, and part two included 
those residues and water molecules whose occupancy was being refined. The 
coordinates of all atoms in part two were then fixed, and a second free variable 
assigned to this section. 
Examples of the shelx instruction file is shown in appendix Al-I, Al-2, Al-3 and 
A 1-4. 
Figure F6-IO.Binding site of hCypA, Note the orientation of the arginine at position 55 and 
methionine at position 61 when no ligand is present, compared with that in figure F6-1I. Waters 





Fig F6-I I Dipeptide Val-Pro (shown in orange for clarity) at binding site othCypA. 
The movement of the arginine at position 55 and the methionine at position 61 and the 








Figure F6-12 Dipeptide Val-Pro at the binding site of hCypA. There are 4 potential 
direct hydrogen bond interactions between proline and Ar g55, and between valine and 
Asn 102 can he seen. There is also potential for solvent mediated hydrogen bonding 






Figure F6-13. Diagram showing dipeptide soaking protocol. 1) A-undisturbed 
crystal in drop of mother liquor. B-drop of soaking solution placed alongside. 
C-well solution, 35 1"7(- PEG 8K, 100mM Tris pH 7.9. 2) after overnight 
equilibration crystal transferred into soaking solution and left for I hour. 3) 
example showing drops of increasing concentration of dipeptide soaking 
solution placed alongside undisturbed crystal in mother liquor. Crystals 
transferred stepwise from low to high concentration where concentration 
increases from B-C-D-E. 
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6:3:4 Determination of Crystallographic Binding Constant 
Where Q is defined as the fraction of protein molecules in the crystal structure with 
bound ligand, and Qn is the fraction of protein molecules which have not, then Qn + 
Q' = 1. The relationship between Ql, Qn and Kc may be considered in the following 
way:- 
Kc = [P][L]/[PL] 
[P] —[PII1 + [P] 
[PL = Qi IIP]0 
[P]=(1 — Qi)[Pltot 
Therefore: Kc = { [P] 0 (1-Q) }[L] / Qi [P] 0 
And: Q1/Qn=[L]/Kc 
(where [P] is free protein concentration, [P]11  is total protein concentration, [PL] is 
bound protein ligand complex, and [U] is ligand concentration) 
A plot of Q' /Qn against ligand concentration therefore gives a line with slope equal 
to l/Kc. 
6:3:5 Results 
All crystal data is shown in table T6-2. Only one crystal complex structure with Thr-
Pro was solved, this one after being soaked in a solution of Thr-Pro at a 
concentration of 70mM. The table shows, on the top row, the concentration of 
dipeptide for each dataset. Four datasets were collected for Val-Pro, as shown. 
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DIPEPTIDE THR-PRO(70) VAL- VAL- VA-PRO(25) VAL-PRO(l2) 
PRO(96) PRO(48) 
X-ray source SRS ESRF ESRF SRS SRS 
Dareshury. Grenoble Grenoble Daresbury, Daresbury, 
Stn 9.6 BM 14 BM 14 Stn 14.2 Stn 14.2 
Wavelength 1.488 0.954 0.954 0.9795 0.9795 
A 
Unit cell A 40.193. 	52.86, 41.95, 	53.50, 41.73. 	52.33, 42.35. 	52.24, 42.44, 	52.55, 
89.78. 89.34. 88.91. 88.16. 88.13. 
u=y=9() a=13 =y= 90 u=3=y=9() a=13='y=90 a=3=y=9() 
Resolution 2.1 2.2 1.8 1.9 1.9 
(A) 
Rsym 0.075 (0.07) 0.084 (0.216) 0.043 (0.112) 0.073 (0.333) 0.070 (0.227) 
94.44 (98.2) 95.8 (97.3) 86.6 (86.6) 99.5 (99.3) 98.3 (97.4) 
completeness 
Redundancy 4.0 3.2 4.6 3.6 3.9 
1/sigma 7.4 (7.0) 6.5 (3.0) 9.6 (5.5) 8.6 (2.2) 7.4 (3.0) 
Rfactor 0.2152 0.1761 0.1850 0.1868 0.1988 
Rfree 0.3055 0.2797 0.2797 0.2478 0.2303 
Occupancy 86.2% 79.9% 65.4 1/c 37.2% 22.1 1h 
Table T6-2. The crystal data for crystals of hCypA soaked with dipeptides at varying 
concentrations. 
6:3:5:1 Threonine Proline 
Only one crystal structure of the crystal complex of hCypA/Thr-Pro was obtained, 
where a crystal of hCypA had been soaked in a solution of Thr-Pro at a concentration 
of 70mM, although it can be seen that the Rfactor and the Rfree were high. The 
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crystal data is shown in table T6-2. Figure F6-14 shows Thr-Pro in electron density 
at the active site of hCypA, and figure 176-15 shows the direct hydrogen bonding 
between proline and Arg55, and threonine and Asn 102, and solvent mediated 
hydrogen bonding to G1n63 via W20. 
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Figure Fo- 14. The dipeptide Thr-Pro in electron density at 





Figure F6-15. Dipeptide Thr-Pro at the binding site of hCypA. showing 5 direct 
protein ligand H-bonds, and 2 H-bonds mediated by water rnolccuk20 
6:3:5:2 Valine Proline 
The dipeptide Val-Pro was soaked into crystals at concentrations of 96rnrvl, 48mM, 
25mM, 12mM and 6mM. The final pH of the stock 100mM Val-Pro solution was 
found to be slightly acidic, and 1M NaOH was added in ljil drops until the pH was 
around 7-7.5. The final concentration was calculated as 96mM. 5001.tl of this solution 
was then taken and diluted with 500xl soaking solution to give a 48mM solution. The 
100mM solution was used as stock and serial dilutions were performed to give 
soaking solutions of 25mm, 12.5mM and 6mM, the pH of these required no 
adjusting, which was attributed to the lower concentration of dipeptide in solution. 
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Crystal data statistics are given in table T6-2. The reduction in electron density 
corresponding to ligand can clearly be seen as ligand concentration is lowered. This 




Figure 176-16. The reduction in ligand electron density as ligand concentration is decreased. Top to 
bottom(A-D):- (A) 96mM Vat-Pro; (B) 48mM Val-Pro (C) 25mM Val-Pro, (D) 12mM Vat-Pro. 
179 
6:3:6 Crystallographic Dissociation Constant 
Dipeptide occupancies for the four crystal structures were 96mM-79.9%; 48mM-
65.4%; 25mM-37.2%; 12.5mM-22.1%. This gave Ql/Qn values of 3.97, 1.89, 0.59 
and 0.29 respectively. A plot of these gave a straight line with a slope of 0.0429, 
shown in figure 176-17, and a K value of 23.3 1mM. 
Kc Val-Pro 
y = 0.0429x - 0.2048 
R2 = 0.9884 
. Senesi 
Linear (Series 1) O*za 
1 0 
	 50 	100 	150 
Lig [mM] 
Figure F6-17. A plot ofQl/Qn gives a straight line with a Slope of 0.0429. 
The Kc value derived From this is 23.31mM. 
6:3:7 Discussion 
The structures of the dipeptides Val-Pro and Thr-Pro bound at the active site of cypA 
represent novel cyclophilin crystal complexes. Comparison between these structures 
and the published structures of Gly-Pro, Ala-Pro, His-Pro and Ser-Pro (189) show 
similar conformations, with dipeptides bound in a cis conformation, and two 
hydrogen bonds between the proline and Arg55. 
LA- 
UuII 
Figure F6-18. The conformation of dipeptide Gly-pro at the binding site of 
hCypA. Comparison with structures of Val-Pro and Thr-Pro shows almost 
identical conformation. Pdh ID 5CYH.pdh. from Ke et al (184) 
The threonine side chain on the Thr-Pro/hCypA complex is exposed, forming one 
direct and one solvent mediated hydrogen bond with the protein. Surprisingly, the 
valine side chain on the Val-Pro/hCypA complex is in an almost identical 
conformation. It may have been expected that the hydrophobic valine may have 
assumed a configuration whereby it was in a more hydrophobic environment, 
possibly directed into the hydrophobic pocket, close to Phe 113, in a similar fashion 
to that observed on the natural ligand CsA (shown in figure F 1-9). Although electron 
181 
density surrounding the valine side chain was obvious, it was poorly defined 
compared with that for the rest of the molecule, possibly attributable to some 
mobility here. The overall contribution made to binding by the hydrogen bonding 
interactions between proline and Arg55; and the valine NH2, and 01 on Asn102, 
together with the contribution made by solvent molecules, appear to overcome any 
tendency for the valine to enter the hydrophobic pocket. It can be seen from a 
comparison of figures F6-12 and F6-15 showing Vat-Pro and Thr-Pro at the binding 
site of hCypA that the absence of an oxygen on the side chain reduces the number of 
direct hydrogen bonding interactions by one. 
Further comparison with the CypA/HAGPIA complex (figure Fl-17) also shows 
striking similarity, where the proline sits in almost exactly the same position, with 
hydrogen bonding between the 0 atom on the proline and the NH2 on Arg55, and the 
aliphatic isoleucine residue on HAGPIA exposed. 
Despite that fact that the concentration range involved only four data points, the 
Kcryst value obtained (23.31mM) is in good agreement with the Ki value from the 
PPIase (section 4:2:3) of 18.6 ± 8.7mM for this dipeptide. It also agrees well with the 
crystallographic for Ala-Pro binding cCyp3 of 26.8mM (138). 
Comparison with the cCyp3/Ala-Pro structure shows similar hydrogen bonding 
contacts. Just as the Arg55 on hCypA adopts a different conformation on ligand 
binding, and forms two direct hydrogen bonds with the proline on the dipeptide, 
Arg62 on cCyp3 makes the same shift in conformation, and also forms two hydrogen 
bonds. Other hydrogen bonds are made between ligand and Asn 109 and Gln70 (the 
numbering of the active site residues on cCyp3 is seven higher than for hCypA, 
owing to the extra loop on the former) (34). These are also the same as those 
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observed for hCypA/Val-Pro, one less than that observed for the hCypA/Thr-Pro 
structure which has an extra hydrogen bond via the hydroxyl group on its side chain. 
Therefore dipeptides of the form Xh-Pro (where Xh is a residue with a hydroxyl side 
chain) appear to form one more hydrogen bond than those of the form Xa-Pro (where 
Xa is a residue with an aliphatic side chain). 
Unfortunately no binding constant has yet been determined for Thr-Pro binding to 
hCypA, in order to compare the contributions made by hydrogen bonded 
interactions. Although hydrophobic effects play a major role in enzyme-ligand 
binding, other effects such as electrostatic interactions, van der waals and hydrogen 
bonds also contribute (158, 194), therefore the extra hydrogen bond on Thr-Pro may 
result in an increased binding affinity. 
6:4 Dimedone Derivatives 
6:4:1 Description 
The dirnedone derivatives have been described in chapter one. Various techniques were 
employed in attempting to obtain crystal structures of hCypA with many examples from 
this range of ligands at the binding site as they became available. The lead dimedone 
derivative was ligand KM 19 (figures F4-8, F6-23) which showed best binding affinity. It 
was important to characterise the structure of this ligand at the binding site, although 
similar to EM234 (figure Fl-21), the replacement of the ester bond with an amide bond 
makes the ligand more planar and less flexible, with less rotational freedom. 
6:4:2 Crystal Soaking 
Various strategies were employed in order to obtain crystal complex structures, with 
examples from the dimedone derivative range of ligands bound, by soaking crystals in 
solutions containing ligand. Results were disappointing, with crystals often visibly 
cracking, dissolving or turning yellow. In some cases, the crystals appeared to survive 
the soaking conditions, but did not diffract x-rays, or where they did the diffraction 
patterns were almost always very smeary, making integration and scaling difficult. In the 
few cases where soaked crystals did give good quality diffraction patterns, and data 
could be processed, ligand was absent. 
As the Kd value of KM 19 had previously been ascertained by fluorescence analysis 
(chapter 4:4) as being in the region of 20-30tM; and from SPR analysis (chapter 4:6) as 
46.9jiM, a final ligand concentration in excess of lOX this (ie., - 200-5OO.tM) was 
generally aimed for, although in some cases, particularly where crystals could be seen to 
be dying in the drop, they were frozen before this concentration was reached. Ligands 
were insoluble in water. 
Some of the strategies which were pursued are outlined below, together with results 
where appropriate. 
I) Stock solutions were prepared to a concentration of 1mM in either DMSO, MPD 
or EtOH. Addition of I tI ligand to 4tl crystal drop caused crystals to crack and/or 
turn yellow. Crystals dissolved after a period of Sminutes. Moving crystals from 
their original 4j.t1 drop and placing them in quantities of up to I ml mother liquor 
allowed ligand solution to be added in smaller increments, but crystals did not 
survive. Those which were removed and frozen at lower ligand concentrations 
before they deteriorated showed no ligand density at the binding site. 
As it was assumed the high concentration of solvent was a likely cause of the poor 
crystal stability, ligand solubility was examined. Higher concentration ligand 
stocks (100mM) were prepared in solvent as before. These were then serial diluted 
using dH20 or well solution to concentrations of 50mM (50% solvent), 25mM 
(25% solvent), 12.5mM (12.5% solvent) and 6.25mM (6.25% solvent). Ligand 
precipitated out of solution almost instantly, but after leaving overnight 12.5mM 
solution and 6.25mM samples that had been diluted using well solution were clear. 
Ligand solution was prepared to 100mM stock in ethanol. This was then serial 
diluted down to 1mM and 0.5mM using well solution. Crystal soaking drops were 
prepared to a volume of 4.tl using well solution and ligand solution, to 
concentrations of 100.tM, 200jiM, 300.tM, 400.tM and 500PM. Crystals were 
placed in each drop and coverslips placed back over well solution. Ligands very 
quickly precipitated out of solution, particularly at high concentration, and often 
before coverslip had been replaced. Crystal survival was also very poor at higher 
ligand concentrations (300-5001jM). It was however, hoped that where crystals did 
survive, enough ligand was still in solution to bind protein with sufficient 
occupancy to be seen in electron density. This experiment was repeated several 
times, with some adaptations. 
• Coverslips were prepared with soaking solution drop beside crystal in mother 
liquor drop and the well sealed to allow system to equilibrate overnight. 
• Crystals were moved sequentially from low to high ligand concentrations to 
minimise crystal shock. 
• Solvent was added to well solution at an equal concentration to that in soaking 
drop to compensate for evaporation of solvent from drop containing ligand. 
• Soaking times were extended over periods of up to a week where crystals 
appeared to be surviving, with crystals removed and frozen at various intervals. 
4) Concentration of PEG 8K in well solution was increased from 20% w/v to 35% 
w/v, whilst the salt concentration and pH were maintained at their original values. 
This solution was then used to dilute the 100mM ligand stock to examine whether 
the higher PEG concentration helped to dissolve ligand, and maintain crystal 
integrity. This did appear to be the case, by letting the system equilibrate and 
moving crystals sequentially from lower to higher ligand concentrations, as before, 
soaking times could be extended, with less visible precipitation of ligand out of 
solution. On analysis of crystal data, however, ligand was still not present at 
binding site. 
6:4:3 Co-Crystallisation 
The disappointing results obtained through crystal soaking led to a co-crystallisation 
experiment being undertaken. 
6:4:3:1 Materials and Methods 
A stock solution of ligand KM 19 was prepared in 100% ethanol to a concentration of 
10mM. A 200iI solution of hCypA, in 50mM Hepes, lOOmM NaCl, pH 7.0 at a 
concentration of 20mgml-1 then had 2tl KMI9 stock added, giving a final ligand 
concentration of -iOOj.iM. After overnight incubation of hCypAIKMI9 at 4°C, the 
vessel was opened for one hour to allow any excess ethanol to evaporate prior to 
preparing the plates. Four plates were prepared, as described, with crystallisation 
conditions from 15-26% PEG 8K, pH range from 7.6-8.4, and placed at 4 °C. 
6:4:4 Results 
6:4:4:1 Co-Crystallisation 
After 18 days two crystals were seen in the same drop, 20% PEG 8K, pH 7.9. One was 
frozen, and data collected at Daresbury. Crystal data is shown in table T6-3. 
X-RAY SOURCE SRS DARESBURY STN 14.1 
Wavelength (A) 0.9795 
Unit cell (A) 42.455. 52.429. 89.568, 
u=13 =y= 90 ._90 ,_90 
Resolution (A) 1.7 
Rsym 0.086 (0.355) 
c/( completeness 93.5 (86.8) 
Redundancy 3.7 
1/sigma 5.5 (2.0) 
Rfactor 0. 18-0. 19* 
Rfree 0.220.23* 
Table T6-3. Crystallographic data for crystal of hCypA co-crystallised in the presence of 
ligand KM 19. * - The refined R and Rfree values are shown in following sections for the 
possible ligand conformations 
Visualisation of the structure after refinement in the absence of ligand and active site 
waters gave an R factor of 0. 189 and an Rfree of 0.234. A large area of fo-fc and 2fo-fc 
density at the active site, and movement of the methionine residue at position 61 could 








Figure F6-19. Pymol representation showing active site of co-crystallised CypAJKM 19, 
after refinement without ligand or active site waters modelled in. Large area of density 
(circled) shows possible presence of ligand KM 19. Fo-fc map (red) set at 2, 2fo-fc map 
(black) set at I. 
Ligand was modeled in, in various conformations, the two most likely are shown 
(figures 176-20, F6-21). The structure of ligand KMI9 is shown in figure F6-23 to 
indicate atom numbering used. An overlay of the two conformations is shown in figure 
F6-22. 
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Figure F6-22. Active site density showing an overlay of the two 
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Figure 176-23. Structure of KM 19 showing numbering of selected atoms 
considered involved in hydrogen bonding interactions 
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6:4:4:2 Possibility One 
This ligand orientation placed the dimedone moiety at the centre of the binding site, with 
the dimethyl group directed into the hydrophobic pocket and the oxygen directed 
towards Arg55. The valine side chain is directed into the area of density near Gin lii 
and Asn 102, in a similar conformation as that seen on cyciosporin binding. The benzene 
ring is situated between Asn7l and Arg55. Potential hydrogen bond contacts are 
His54(NE2)i-01 9; G1n63(NE2)4—'0 19; Asn 102(0)4—'N 10. 
Refinement of the structure with the ligand in this conformation gave an R factor of 
0.189 and an Rfree of 0.234. The refined structure is shown in figure F6-24. Figure F6-
25 shows the ligand at the binding site and potential hydrogen bond interactions. 
6:4:4:3 Possibility Two 
This ligand orientation placed the dimedone moiety in a similar position to that seen for 
possibility one, but with a turn of 90 ° . The climethyl group therefore is in a similar 
position as before, but the oxygen at position 9 is well placed to hydrogen bond with the 
nitrogen atom on protein residue Asn102. The valine side chain is exposed, and the 
benzene ring is in the area of density which was occupied by the valine in possibility 
one. Potential hydrogen bonding interactions are G1y72(0)i—*019; Gin  I l(NE2)4—*020; 
Asn 102(N)4-09; Asn 102(0) 09. 
Refinement of the structure with the ligand in this conformation gave an Rfactor of 
0.192 and an Rfree of 0.232. The refined structure is shown in figure F6-26. Figure F6-






Figure F6-24. Possibility one after refinement of I igand (in blue) at binding site, 
showing ligand in 210-fc density. Image made using Pymol. density level set at 1.0 
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Figure F6-25 Pymol image showing possibilty one at binding site. Potential 





Figure F-6- -1 6. Possibility two after refinement ofliyand (in blue) at binding site, 
showing ligand in 2fo-fc density. Image made using Pymol, density level set at 1.0 
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Figure F6-27. Pymol image showing possihilty two at binding site. Potential 
hydrogen bonds are shown 
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6:4:5 Comparison with CypA-EM234 
The structure of dimedone derivative EM234 is shown in figure Fl-21, and crystal 
structure of EM234 bound at the active site of hCypA has been previously solved, and is 
shown in figure F6-28. It can be seen from the image that there are four direct hydrogen 
bonds between ligand and protein, from Arg55(NHI)4-*028, Gln63(0)-028, 
Gln63(NE2)-)19, and His54(NE2)+-)19, and there are two solvent mediated 
interactions. A comparison of this with the two KMI9 possibilities shown shows a 
greater similarity with KMI9 possibility one, with a similar conformation of both the 
benzene ring, the valine side chain and the dimedone moiety. It is important to bear in 
mind, however, that the active site density was not sufficient to allow the modeling in of 
solvent molecules, and the KMI9 structures have been modeled without solvent at the 
active site. It may be therefore, that despite the apparent extra hydrogen bond between 
ligand atom NlO (at the amide bond) and residue Asn102(0), the extra planarity and 
lack of flexibility around this bond mean that the orientation of the ligand molecule 
approaches possibility two, with water mediated interactions between ligand atom N 10 
and protein residue Arg55 and/or Gln63. An overlay of EM234 with KMI9 possibilities 





Figure F6-2. The ester hiided dirnedtme derivative EM234 at the binding site of hCypA. 






Figure F6-29 Overlayed structures of KM IV possibility one (blue) and two (green) 
with EM-2 34 (yellow). The arginine residue at position 55 is labelled 
6:4:6 Comparison with CypA-CsA 
An overlay of the cyclophilin-cyclosporin structures with either of the two possible 
KM 19 orientations shows many similarities. 
Six direct ligand-protein hydrogen bond contacts are made between the oxygen atom on 
BMTI and the NE2 atoms on G1n63 and His54, between the oxygen atom on MLEIO 
and both NH  and NH2 on Arg55, between oxygen on MVAI I and the nitrogen on 
Asn 102, and between the oxygen on MLE9 and the NE I atom on Trp 12 1.  Of these, the 
His54/Gln63 interactions and the Asn102 interaction are present in KMI9 possibility 
one, and whilst there is only one similar direct hydrogen bonding interaction on 
possibility two (the Asn-09) bond, there are four direct hydrogen bonds present on 
possibility two. It is also worth noting that the valine at position II on cyclosporin, 
located in the hydrophobic pocket, is in almost the same position as the dimethyl group 
in the dirnedone ring in both possibilities. The direct hydrogen bond contacts on all 
structures are shown in table T6-4. The CypA-CsA complex is shown overlayed with 
possibility one (figures F6-30, F6-3 I), and possibility two (figures F6-32, F6-33). 
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Figure F6-30. KM 19 possibility one overlayed with cyclosporin. The valine at position II 
on cyclosporin is in a similar conformation to that of the dimethyl group on the dimedone 
ring. Viewed from the Arg55 side of the binding pocket. 
t, 
i 
Figure F6-3 I. KM 19 possibility one overtayed with cyclosporin. Viewed from the 
Asn 102 side of the binding pocket. 
L Trpl2l 
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Figure 176-32. KMI9 possibility 2 overlayed with cyclosporin. Viewed from the Arg55 side of 




Figure 176-33. KM 19 possibility 2 overlayed with cyclosporin. 





6:4:7 Comparison with HAGPIA 
The six residue section from the HIV-1 capsid protein shows five direct hydrogen bonds 
to residues at the binding site of hCypA, and two water mediated hydrogen bonds. The 
direct hydrogen bonds are from the oxygen atom on the isoleucine to the NEI atom on 
Trpl2I, from the oxygen atom on the proline to both the NHI and the NH2 atoms on 
Arg55, from the nitrogen atom on the glycine to the oxygen atom on Asn 102, from the 
nitrogen atom on the alanine to the oxygen atom on Gly72 and from the oxygen atom on 
the alanine to NE2 atom on G1n63. These can be seen in figure F6-34 which shows 
HAGPIA at the binding site of hCypA. Also shown are the overlayed images of KMI9 
possibility one and possibility two with the HAGPIA structure (figures F6-35, F6-36) 
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Trp12l(NE1) MLE9 (0) Ile(0) - - - 
Arg55(NH1) NILE1O(0) Pro(0) 028 - - 
Arg55(NH1) MLE10(0) Pro(0) - - - 
Asn102(0) - GIy(N) - N10 09 
AsnlO2(N) NVAI1(0) - - - 09 
G1y72(0) - Ala(N) - - 019 
G1n63(NE2) BNIT1(0) Ala(0) 019 019 - 
G1n63(0) - - 028 - - 
I-1is54(NE2) BMT1(0) - 019 019 - 
GlnlIl(NE2) - - - - 020 
Table T64: showing hydrogen bonded interactions for hCypA with the two KM 19 possibilities, 
and with CsA, HAGPIA and diniedone-ester derivative EM234 for comparison 
6:4:8 Discussion 
Many attempts at soaking crystals in ligand solution in order to obtain complex 
structures with examples from the dimedone range of ligands at the binding site, 
employing many different strategies, were made. Whilst it was relatively easy to soak 
the small molecules DAP, PROP and TMSO and the dipeptides Val-Pro and Thr-Pro 
into the crystals and see ligand density corresponding to these molecules at the binding 
site of the protein, the dimedone derivatives proved to he less amenable. Ligand 
solubility was a major problem, indeed, the disappointing isothermal titration 
calorimetry results obtained were attributed to ligand hydrophobicity, but it is also likely 
that ligand size and flexibility also made a major contributed. Protein crystals are 
notoriously fragile, and sensitive to changes in temperature and pH, therefore shock 
easily when placed in a different environment. Exposure to solvents can therefore cause 
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severe crystal damage and require to be used sparingly and carefully. Binding of these 
inhibitors may cause conformational changes which are incompatible with crystal lattice 
packing interactions, possibly due to the movement of solvent molecules from the 
vicinity of the binding site. Alternatively, it may be that lattice packing in the protein 
crystals inhibits access to the binding site (195). It may therefore be the case that the 
amide bond at the dimedone moiety contributed to a reduction in ligand flexibility. 
Where the dimedone moiety was previously bonded via an ester linkage in example 
EM234 (the incorporation of an amide bond here, whilst it may contribute more to 
hydrogen bond interactions {Nl04—.AsnlO2(0), 1.31A, possibility one}, it is likely that 
steric hindrance impedes movement around this bond, making it more difficult for the 
ligand to enter the crystal lattice without causing damage. 
It has been shown that ligand solubility and crystal stability may be improved by 
increasing precipitant concentration; where crystals of CDK2 had been grown in 15% 
PEG3350, and ligands were soluble at high (45%) PEG concentrations; crystals could be 
equilibrated against this high PEG concentration and later transferred into ligand 
solution, 45% PEG, without damage, and allowing high resolution crystal data to be 
obtained with ligand bound (196). An adaptation of this was also applied here, and 
whilst crystals were apparently more stable, and ligand solubility was less of a problem, 
the presence of electron density attributable to ligand binding at the active site could still 
not be attained. 
Another technique described in the literature for the stabilisation of protein crystals 
involves crosslinking at the F.-amino group on lysine residues using glutaraldehyde. and 
a protocol for carrying out glutaraldehyde crosslinking has been well described by 
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C.J.Lusty (197). Whilst this was not investigated here, it may be interesting to see what 
effect crosslinking has the stability of crystals of hCypA, and its effect on ligand 
permeability. 
Although co-crystallisation with ligand can cause changes in the crystallisation 
conditions due to the presence of another entity in the crystallisation solution, where 
crystal soaking is unproductive then co-crystallisation is the obvious next step and was 
tried here. Crystal complex structures of cyclophilin with HAGPIA (I 98) and with a 25-
mer fragment of HIV-1 gag (199) all involved very different crystallisation conditions to 
that required for cyclophilin A alone, but it was encouraging that the structure of 
cyclophilin A in complex with cyclosporin was achieved under similar conditions to 
those being employed for the crystallisation of hCypA here (190), albeit with some 
cross-seeding. It was therefore decided that some initial experiments involving co-
crystallisation with ligand KMI9 would he attempted. Whilst a ligand concentration of 
100tM was low, less than half the Kd, it was hoped that it might serve to indicate 
whether the protein was still conducive to crystallisation after exposure to solvent and 
ligand, and that if crystals did grow, that they might show some ligand occupancy at the 
binding site, or possibly be used for further crystal seeding trials. Had enough crystals 
grown, then they almost certainly would have been used for crystal seeding experiments, 
at higher ligand concentrations. As there was only one crystal, data was collected. 
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6:4:9 Conclusion 
Despite the fact that the occupancy of the ligand was not sufficient to model it with any 
degree of confidence into the electron density, and the exposed valine residue on 
possibility two has been seen to occur on binding of the dipeptide Val-Pro, it could be 
argued that the most likely conformation is possibility one. This option may have one 
less hydrogen bonded interactions with the protein, but the ones it has are also present 
on either the hCypA-CsA or the hCypA-HAGPIA complexes, unlike the H-bond 
interactions on possibility two. A careful look at the two structures also reveals that the 
amide bond at the dimedone moiety on possibility two seems to be twisted upwards 
away from the binding site, possibly placing more strain on the bond, and exposing more 
surface area around the binding site, with the valine side chain directed outwards. 
Comparison of the two structures overlayed with the HAGPIA and CsA complexes also 
show much more uniformity of conformation with possibility one. 
Further elucidation of the precise orientation of KM 19 at the binding is still required, as 
this is the 'lead' compound in the dimedone derivative library around which all the 
others are based. An intimate knowledge of the binding contacts made by KMI9 will 
allow a detailed structure activity relationship to be developed around the kinetic values 
obtained by biophysical means described in chapter four. Optimisation of contacts will 
allow the design of more dimedone derivatives, thereby developing the ligand library 
into a range of molecules with increased affinity for hCypA. It has been shown that co-
crystallisation of hCypA with ligand is a viable option, and it is likely that it is by this 
means that the crystal complex will be characterized. 
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Ch 7: Discussion 
7:1 Ligand-Protein Interactions: Stucture Activity Relationship 
Assuming that possibility one is closest to the correct conformation of [l-(3,3-
di methyl-5-oxo-cyclohex- 1 -enylcarbamoyl)-2-methyl-propyl]-carbamic acid benzyl 
ester (KM 19) at the binding site of hCypA then, by comparing this complex and the 
biophysically measured Kd (15.1jiM by fluorescence spectroscopy; 48.6 jiM by mass 
spectrometry; 46.9 jiM by surface plasmon resonance) with the dissociation constants 
of the other dimedone-derived ligands, structural differences which apparently affect 
binding and complex formation may be identified. A cartoon representation of 
hCypA is shown in figure F7-1, indicating those residues which may be interacting 
with ligand, and are discussed here. 
The Kd of ligand KM 135 is 126jiM (by fluorescence spectroscopy). With a phenyl 
group in place of the valine, and the removal of the ester bound phenyl, this ligand 
demonstrated reduced affinity for hCypA. This may be attributed to either of these 
two changes. It seems likely, however, that substitution of the valine with the phenyl 
group will optimise hydrophobic packing around Ala 103, Ala101, and the side chain 
of Gln 111 (in a similar conformation as that shown for possibility two), allowing the 
rest of the ligand to remain in the conformation seen for possibility one. The reduced 
affinity therefore is probably a result of the removal of the ester bound phenyl, and a 
decrease in hydrophobic packing around G1y72, Thr73, His54, and the side chain of 
Arg55. 
Ligand KM 184, with a Kd of 12.2j.tM (by fluorescence), 36jiM (by SPR) and 41.56 
(by MS) is very similar structurally to KM 19. It may be that the aliphatic side chain 
on the dimedone group is interacting with the hydrophobic patch around the 
'I, 
phenylalanine at position 60 and the leucine at position 122. This would optimise the 
hydrophobic interactions by further reducing the exposed surface area, although the 
effect on the orientation of the dimedone moiety at the binding pocket is unknown. It 
may direct the oxygen at position 9 on the dimedone moiety closer towards Arg55 
facilitating further hydrogen bonded contacts within the complex. 
Ligand KM 198 (Kd = 15.85iM by mass spectrometry, structure shown in chapter 4) 
has a carboxyl group at the position of this aliphatic side chain on KM 184. Therefore 
possible hydrogen bonded interactions between this and either Tm  121 or Arg55 (as 
seen for the proline containing dipeptides), or solvent mediated with other residues, 
such as His 126, would stabilise the hydrophobic interactions. 
Interestingly, the cyclised dimedone derivative CD278 was shown to have a K (f of 
17.83tM by mass spectrometric analysis and its structure is shown (chapter 4:5),It 
may be that that this cyclised dimedone moiety with the two oxygen atoms is in a 
conformation where the dimethyl group is directed into the hydrophobic pocket 
around Phel 13 as before, and the oxygen atom on the five membered ring forms a 
direct hydrogen bond with a nitrogen atom on the Arg55, or with G1n63 (NE2). This 
may allow the methyl group on the side chain to interact at the hydrophobic patch 
around Ala101, Asn102 and A1a103, which can be seen in figure 176-27 (KM19 
possibility two). The possibility for direct or solvent mediated hydrogen bonded 
interactions involving the three amines and the nitro groups with G1y72, Asn 102 and 
Thr73 would further stabilise the complex. Alternatively, the oxygen on the five 
membered ring may be directed in the opposite direction, forming hydrogen bonds 
with Trpl2l, possibly forcing the dimedone-dimethyl group deeper into the 
207 
hydrophobic pocket, with the interaction stabilised via solvent mediated hydrogen 
bonds involving the oxygen at position 9 on the dimedone ring. 
Figure F7- I. Cartoon representation of hCypA, showing residues described in 
the text which are potentially involved in hydrogen bonding and hydrophobic 
interactions with dirnedone derivatives. 
The hydrophobic qualities of a potential ligand are a major contributor to binding 
affinity and increasing the hydrophobic qualities of a ligand may lead to an increase 
in binding affinity (the free energy change on binding per A2 of buried hydrophobic 
surface has been reported to be -16.2 ±2 cal/mol.A 2 ) (200). An improvement in 
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dissociation constants for enzyme ligand binding has been reported for many drug 
leads after the addition of hydrophobic groups (5, 201-203). The Kd values for the 
natural inhibitors FK506 and Rapamycin for FKBPI2 are 0.4nM and 0.2nM 
respectively (85), there are five hydrophobic protein-ligand interactions in the 
FKBP12-FK506 complex, and eight in the FKBPI2-Rapamycin complex, both have 
two direct protein-ligand hydrogen bonds (205). 
Whilst the hydrophobicity of the dimedone derivates may contribute to their high 
affinity for hCypA (the tighter binding of ligand KM 184 is likely to be due to the 
new hydrophobic side chain on the dimedone group packing against the hydrophobic 
patch around Phe60 and Leu122), their poor solubility (which complicated the 
crystal soaking and the ITC experiments) is a problem which will require to be 
addressed. It is also important to remember that an increase in hydrophobicity may 
have an effect on the overall cellular potency of a ligand. This quality relates to the in 
vivo activity of a potential drug lead, and is affected by such things as membrane 
permeability, solubility, and stability in physiological medium (203). Some options 
have been described in the literature for overcoming this problem, involving the 
addition of polar groups, such as nitro- or chioro- groups (203,204). 
Whilst hydrophobic interactions are recognised as a major force driving protein 
ligand binding (206.207) other factors, such as hydrogen bonding, electrostatic 
interactions, van der waals interactions, and the formation of salt bridges, also make 
a significant contribution (194,200). Of the compounds tested here, KM198 (Kd 
=15.85tM by mass spectrometry) has a carboxyl group attached to the dimedone 
ring which is likely to contribute to hydrogen bonded interactions. The potential 
offered by ligand CD278 for hydrogen bonded interactions involving the amine and 
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nitro groups, and the extra oxygen atom, together with the possible extra 
hydrophobic packing are all likely to contribute to the low Kd of 17.83tM. 
Prior knowledge of the ligand/substrate binding site is important in the design of 
ligands with high affinity. The elucidation of the crystal structure of tryrosine kinase 
Src with citrate bound at the SH2 domain identified interactions which had not 
previously been observed in other complex crystal structures, allowing the design of 
inhibitors with additional groups which optimised ligand binding and increased 
affinity (208). The cyclin dependent kinases (CDKs) are major drug targets in the 
development of anti-cancer therapies, and studies identified potential inhibitors of 
these CDK2 using knowledge of the conformation of ATP at the binding site as an 
initial model (209). There are many published structures of CDK ligands based 
around purine bases (210,211) and pyrirnidine bases (203,204,212) which have been 
designed around a known structure, optimising contacts and interactions thereby 
increasing affinity. A structure-activity based approach has also been utilised in the 
development of ligands for FKBP (213), whereby the complex structures of small 
molecules bound to FKBP with micromolar affinities were solved. The micromolar 
Kd of these small molecules was increased to a nanomolar Kd by the careful analysis 
of the interactions made by each small molecule and tethering selected molecules 
together to optimise binding. Other studies based around the knowledge of the 
contacts made by GPI-1046 (described in chapter 1) and of FK506 at the active site 
of FKBPI2 have led to the design of further ligand libraries with high affinity for this 
protein (96). 
This structure based activity approach has been used in the development of these 
dimedone based ligands for hCypA. The initial identification of dimedone as a 
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potential ligand for hCypA, the characterisation of the /iCypA-dimedone structure 
allowed the development of a range of ligands where dimedone was bound via an 
ester bond to a valine residue. Further characterisation and kinetic analysis led to the 
development of these new ligands where dimedone was incorporated into a range of 
molecules via an amide bond. Analysis of these structures has identified potential 
groups which may increase the affinity of these molecules for /zCypA, such as the 
addition of aliphatic chains to optimise hydrophobic packing, and possible hydrogen 
bond donors/acceptors which further stabilise the enzyme-ligand complex. 
Interestingly, exposure of the nematode C. elegans to ligand KM 184 has shown a 
marked reduction in larval numbers, with an 1050 of 190±6O1iM, comparable to that 
seen for CsA (1050 = 28±13 tM), as well as reduced fecundity and growth possibly 
related to a cuticle shedding defect. This is shown in appendix A2: 1. This is likely to 
be attributable to the inhibition of the PPiase activity of cCyp3 (described in chapter 
1), and its associated role in modulating correct protein folding. 
7:2 Future Work 
There is much potential for future work stemming from the work done here. The 
disappointing results obtained by soaking dimedone derivatives into crystals of 
hCypA led to co-crystallisation being attempted. This was shown to be a viable 
option, and it should be possible to characterise the structure of hCypA with other 
representatives of the dimedone-derivative ligand library using this technique. 
As described, knowledge of the interactions made on enzyme-ligand binding and 
complex formation is essential for their optimisation in the design of new ligands. 
With the assumption that the likely conformation of ligand KM19 at the binding site 
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of hCypA being possibility one having been made, potential contacts made by 
KMI84, KM198, Krn135 and CD278 on binding hCypA have been identified. The 
design of dimedone-derived ligands incorporating some of the features which may be 
contributing to these contacts should be undertaken. It should be possible to optimise 
the hydrophobic packing contacts described for ligand KM 184, together with the 
hydrogen bonded contacts described for ligand KM 198. It may also be possible to 
replace the valine with a phenyl group, as seen for ligand KM 135, although this may 
cause even more complications regarding solubility. Further, the new complex 
structure of Val-Pro shows the exposure of the hydrophobic valine side chain, 
indicating the importance of the contacts made at the proline residue. The closeness 
in conformation and orientation of the proline residue here to that seen for the 
hCypA-HAGPIA complex may allow the design of a new range of small molecule 
inhibitors of hCypA. 
The complex structures of hCypA with the small molecules TMSO, PROP and DAP 
bound at the active site offer the potential for database mining. It may be possible to 
develop new hCypA ligand libraries, based around these small molecules. 
It has also been shown how, by utilising the N-terminal hexa-his tag, it has been 
possible to tether hCypA to a sensor chip in a conformation which optimises access 
to the active site. This allowed the precise measurement of ligand binding constants 
by surface plasmon resonance. The N-terminal of hFKBP12 does not appear to be in 
close proximity to the binding site, therefore it may be possible to utilise this 
technique for studies involving hFKBPI2, as N-terminal hexa-his tagged constructs 
have been synthesised. Further, the competition assay performed could be developed, 
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and competitive binding of ligands could be studied using either rapamycin or 
FK506. 
7:3 Conclusions and Summary 
Vectors have been synthesised for the expression of native and hexa-his tagged 
hCypA and hFKBP12. Human hexa-histidine tagged cyclophilin A has been 
crystallised, and crystal soaking experiments have allowed the characterisation of the 
structures of hCypA in complex with the dipeptides Val-Pro, Thr-Pro; and the small 
molecules tetramethylene sulphoxide, 5-diethylamino-2-pentanone, and 3-acetyl- 1-
propanol. The binding of hCypA with the dipeptide Val-Pro has also been measured 
crystal lographically, and the Kcryst value obtained was in accord with the 1050 
value obtained by biophysical means, confirming the fidelity of Kcryst values 
obtained from a measure of relative occupancy of ligand in the crystal structure. 
Additionally, hCypA has been co-crystallised with dimedone-derivative KM 19, 
demonstrating the viability of co-crystallisation of hCypA with compounds from this 
ligand library. This has allowed the identification of possible binding contacts which 
are made, the development of a structure activity relationship, and the optimisation 
of these to further broaden the range of ligands in the library of dimedone-derived 
inhibitors. 
The emergence of hCypA as playing a major role in the infectivity and progression 
of HIV- 1 has led to it being the focus of much research as a potential target for anti-
HIV therapies. Work carried out and described here has identified the potential for 
surface plasmon resonance to be used as a fast and effective means of screening 
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small molecule inhibitors and measuring their relative affinities for /iCypA. By 
tethering the enzyme to the chip using an N-terminal hexa-his tag, the position of the 
active site is optimised, allowing the efficient and precise measurement of ligand 
dissociation constants in a relatively high-throughput manner. Additionally, it has 
shown how the design of a competitive binding assay can increase the range of 
molecules which can be analysed by allowing the binding constants of molecules of 
low molecular weight to be measured (214). The dissociation constants obtained for 
the ligands tested here were in accord with those obtained by other biophysical 
means, such as fluorescence spectroscopy and mass spectrometry. The synthesised 
clones for the expression of hFKBP 12 with an N-terminal hexa-his tag means that 
this system could also he used to screen potential neurotrophic ligands. 
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CELL 0.95372 41.721 52.563 89.437 90.00 90.00 90.00 
ZERR 	4 0.042 0.053 0.089 0.00 0.00 0.00 
REM Space group P 21 21 21 
LATT -1 
SYMM 112-X, -Y, 112+Z 
SVMM-X 1 1/2+Y, 112-Z 
SYMM 112+X, 112-Y 1 -Z 
SFAC OH NO S 
UNIT 3224 6644 876 1436 32 
DEFS 0.01 0.01 0.04 
COLS 50 l 
SHEL1O 
FMAP 2 
PLAN 200 2.3 
LIST 6 
WPDB 2 
Figure A-I The header of the sheix instruction tile, showing title, cell 
dimensions, space group. The circled ' - I' is added as data was previously 
processed using scala. and instructs the program to refine separately data which 




2.504 C1 C 
DFt00 1. 	0.05 C 0XT 
D3G 2002 2.401 CA 0 
- 41 
0.100000 
SWAT 	. 	 2.5585 
PER v96 
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437 data 
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Figure A2. A section of sheix instruction tile showing (cicled, in red)- DFIX/ DANG 
extra restraints imposed for the dipeptide bond lengths and angles; the second free 
variable 0.5; and part I. the start of the protein chain not being refined for occupancy. 
If 
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Figure. A3. A section of sheix instruction file showing the two possible conformations of arginine55 
in part 2 (shown in red). The coordinates of the atoms are fixed by adding 10, and he occupancy, 
normally 11 for the first free variable, is either +21 or -21 to direct it towards the second free variable. 
III 
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2 1 3.351101 10.336019 10.014110 21.00000 
C 1 10. 011302 10.201505 10. 015002 21.00005 
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0 	1 	9.111115 10AM251 10.031105 -21.00000 	0.52513 
LU! 4052 )U)K 
0 	4 10.091677 10.312149 10.010214 -21.00000 	0.31101 
115! 1112 3WX 
0 	1 	1.391671 10.211313 10.543114 -21.10100 	0.25110 
PUT 1 
001 	




o 	i 	0.211101 	0.121132 	0.001103 	11.00000 	0.25003 
Figure A4: section from shelx instruction file, again showing parts I & 2. Part 2 in red 
shows the occupancy refinement of the dipeptide Val-Pro against solvent molecules 6. 15, 
51. 92 and 112, renumbered from 4000. therefore 4006. 4015, 4051. 4092, 4112 (all other 
waters are renumbered from 3000). Coordinates fixed by addition of 10, and occupancies 
either +21 or -21 for free variable. 
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Figure A2-1 : Treatment of C elegans in liquid culture with KM184 causes a phenotype 
characterized by reduced fecundity and growth likely related to a cuticle shedding defect, similar to 
that caused by CsA. Representative light-micrographs of worms grown in the absence or presence of 
either KM 184 (3(X) riM) or CsA (50 p.M) are shown in panels (A), (B) and (C), respectively. In (B) 
and (C). the cuticle shedding defect, absent in (A), is highlighted by red arrows. (D) Dose response 
curves for KM 184 (open circles) and CsA (closed triangles) after 48 hrs exposure. Each data point is 
the mean from three separate measurements. The EC () values for KM 184 and CsA are 190±60LM and 
28±13 iM, respectively. Larvae numbers are plotted against the concentration of KM 184 or CsA in 
&M. 
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